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Abstract 
It has been repeatedly proven that cell therapies can address many current unmet 
clinical treatment needs and also improve on current treatment options for various 
diseases, from neurological disorders to bone repair (Rosset et al. 2014; Corey et al. 
2017). Though the potential of cell therapies has been demonstrated at a relatively 
small scale, the realisation of bringing cell based treatments to a larger market is 
hindered by the complexity of the product along with safety concerned and high 
production cost. Safety concerns can be informed with more in-depth analytical 
analysis of the product, however this in turn increase the costs involved in producing 
a cell therapy (Davie et al. 2012). Consequently the cost of analytical techniques also 
needs to be reduced, to address this need the area of microfluidic based bioanalytics 
holds much promise (Titmarsh et al. 2014). 
The culturing of human mesenchymal stem cells (hMSC) was used as a proof of 
concept model to demonstrate where improved bioanalytical and bioassay methods 
could be utilised in the production of cell therapies. Cells from four donors were 
cultured under three different oxygen environments and the conditioned medium 
assessed for pro-angiogenic capabilities using a tube formation bioassay and a 
proportion of the cytokine secretome profile measured using Luminex technology.  
Thorough secretome analysis it was shown that predicting cytokine levels based 
solely on the donor was not possible as the handling of the cells also had an influence 
on the secretome profile. The donor expression profiles did not behave in the same 
manner across all oxygen environments, for example in some donors IL-8 levels 
increased per cell at lower oxygen where as other donors showed a decrease per cell. 
While the tube formation assay showed some differences between donors in pro-
angiogenic capabilities it also highlights the challenges with interpreting large data 
sets.  
The feasibility of using a microcapillary film (MCF) based enzyme-linked 
immunosorbent assay (ELISA) to detected two relevant cytokines, IL-8 and 
hepatocyte growth factor (HGF) was investigated. Following on from this work the 
development of a combined MCF ELISA assay with hMSC cell culture to produce a 
fully closed cell screening system was initiated. It was shown that it was feasible to 
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measure IL-8 and HGF using the MCF ELISA platform but further work would need 
to be done to make the system more compatible with the manufacturing environment. 
In order to adapt the MCF to also be an hMSC culture platform the first challenge was 
to functionalise the Fluorinated Ethylene Propylene (FEP) surface of the MCF. It was 
concluded that a poly (vinyl- alcohol) (PVA) and gelatin mixture produced a 
homogenous coating to which a consistent level of hMSC would attach. This work 
was carried out on a flat surface; therefore steps were taken to adapt this knowledge 
into the MCF, while there was evidence of hMSCs present inside the MCF more work 
will need to be done to bring this concept to an established platform. 
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1 Introduction 
1.1 Introduction 
There is an ever increasing demand for new clinical treatment options resulting in the 
healthcare industry needing to continually develop safe, effective and affordable 
therapies (FDA 2004). Manufacturers, scientists and engineers are looking to 
regenerative medicine to provide more permanent solutions to these challenges, and 
reduce the reliance of healthcare systems on long term or lifetime drug treatment 
regimes. Regenerative medicine includes tissue engineering, gene therapy, stem cell 
treatments, and cellular products, all of which are of great clinical importance and 
hold much promise for the future of healthcare (Halme & Kessler 2006; Trounson et 
al. 2011). Within this work, cell therapies, in particular human mesenchymal stem cell 
(hMSC) therapies, and the challenges of bringing them to the healthcare market are 
examined from the perspective of satisfying regulatory requirements, ensuring 
product quality and product safety during the expansion phase for the production of 
cell therapies. Cell based assays and bioanalytical technologies are particularly 
important in the development of cell therapies and overcoming challenges unique to 
this field. Treatments predominantly involve administering live cells into a patient, 
thus it is essential that the identity, quality and function of the cells is fully established 
before delivery (Bravery et al. 2013; Carlos Polanco et al. 2013). From a cost-
effective manufacturing perspective, the function of the cells needs to be determined 
not only in early upstream isolation and culture, but continuously monitored 
throughout every processing stage up to delivery. There are also treatments using cell 
therapy products (CTP) whereby a mixed or single population of cell type(s) produce 
a complex cocktail of biomolecules which can be used as the therapy (Ranganath et 
al. 2012). Being able to characterise the product that will be administered to a patient 
is a critical parameter in therapeutic safety, that requires the use of bioassays and 
bioanalytical techniques (Gronthos 2003; Ocampo et al. 2007). 
Bioanalytics refers to the methods used to quantify drugs, drug metabolites and 
biomarkers (Food and Drug Administration 2013). The field utilizes a number of 
different platforms including chromatography, mass spectrometry, enzyme mediated 
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assays, genetic analysis and electrophoretic techniques. In contrast, bioassays are 
methods used to analyse the effect of a product, drug or cell therapy on a population 
of cultured cells (Ma et al. 2015). Combining methods within the two fields would 
create powerful tools that enable safe, efficacious cell therapies to be brought to the 
market and would help reduce the cost and risk associated with cell therapies and 
scalable production (Scheper et al. 1999; Brindley et al. 2011). 
The work presented here identifies some of the challenges facing the regenerative 
medicine industry in taking hMSC therapies to the clinic and develops methods to 
begin addressing these. For example, there are many conditions for which hMSCs are 
being used as a treatment; these range from autoimmune disease to restoring 
neurological functions and re-establishing blood supplies in damaged or implanted 
tissues. Therefor there is a need to establish if every population of cells identified as 
hMSCs can effectively treat such a range of pathophysiologies. While improvements 
in process control can counteract some of these issues of cell expansion the 
manufacturing environment may need to adapt a more responsive approach to the 
hMSC behaviour during culture. To provide increased flexibility and responsiveness 
within the manufacturing of hMSC, more rapid and at line or online bioanalytics and 
bioassays need to be developed. In the first instance it must be established where 
these methods are required, what and where the changes in hMSC functionality are, 
including protein secretion, and what are the parameters the culture needs to meet. 
Once these parameters have been established, the field of microfluidics can meet the 
need of more rapid bioanalytical methods. Microfluidics reduces the scale at which 
standard bioanalytical testing is carried out, this not only reduces the time and cost of 
product analysis but has also been shown to improve sensitivity in some devices 
(Xiong et al. 2014). 
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2 Literature Review  
2.1 Regenerative medicine  
With the increasing demands placed on healthcare attributed to the rising and aging 
population classic pharmaceutical and surgical treatment approaches have a limit 
(World Health Organization 2015). Chronic conditions such as diabetes require a 
lifetime of medication, which is costly to a healthcare system as well as the disease 
having wider socio-economic implications such as loss of work days due to associated 
illnesses (Jonsson 1998; Tunceli et al. 2005; Dall et al 2008). There are also many 
conditions for which there are limited or no existing treatment which amounts to a 
lower quality of life or end of life for the patient. Fortunately, with the expanding 
field of regenerative medicine, scientists and clinicians are exploring and developing 
new treatment options with long-term efficacy as an alternative to a lifetime of 
medication (Fodor et al. 2003; George 2011). There is a lot of different terminology 
used for these treatments, though regulatory bodies refer to them as human cell-based 
medicinal products (European Medicines Agency 2008). Regenerative medicine 
comprises of tissue engineering, gene therapy, cell therapy and stem-cell based 
therapy (Kellathur & Lou 2012; Pfeifer & Verma 2003; Mason et al. 2011). The main 
objective of these treatments is to use the cells to restore normal function to the 
affected organ or tissue  minimising or completely omitting the long term reliance on 
medication and improving the quality of life (Mason & Dunnill 2008). The concept of 
restoring bodily function is not new. Transplanting living cells from either within the 
same patient (e.g. skin grafts) or from a donor into a recipient (e.g. bone marrow 
transplants, blood infusion, organ transplants) are common practice in the healthcare 
field. The main challenge with donor transplants is that the demand for donated tissue 
is greater than the supply (Kirouac & Zandstra 2008) with many patients dying while 
on the waiting list (Dutkowski et al. 2015). There are also genetic diseases which can 
only be managed as opposed to cured, even with tissue replacement and long-term 
medication the only way to completely cure is to target the underlying cause using 
gene therapy. 
Gene therapies comprise of recombinant nucleic acids being administered to a human 
in order to have a therapeutic effect. This can include inserting a new nucleic acid 
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sequence, deleting, repairing or replacing a nucleic acid sequence, the cells can be 
modified in vivo or ex vivo and the transplanted into the patient (Wirth et al. 2013). 
The currently used application of gene therapy is the treatment of individuals with 
genetic disease such as Huntington’s disease (Wild & Tabrizi 2014) and muscular 
dystrophies (Bengtsson et al. 2016). Based on data from The Journal of Gene 
Medicine’s, Gene Therapy Clinical Trials Worldwide website 
(http://www.wiley.co.uk/genmed/clinical) 1178 gene therapy clinical trials have been 
granted approval worldwide in the past 10 years (2006- August 2016) and the total 
number of gene therapy clinical trials that have been granted approval worldwide is 
2409. Of 2409 approved trials 91 to phase III (i.e. 3.9% of the total), only 3 to phase 
IV and a mere 0.1% have been marketed. In comparison  the Food and Drug 
Administration (FDA) approved 108 novel drugs between 2014-2016 alone 
(FDA 2014; FDA 2015; FDA 2016). A challenge of gene therapies is the delivering 
of the recombinant sequence to the cells, there are the standard efficacy issues which 
are recognised in the molecular biology area but there are also important safety 
concerns. Many gene therapies use viral vectors as a delivery mechanism which is 
preferable as viruses are more efficient at delivering the nucleic acids; there are 
concerns about being able to control the viral vector. Incidences such as patients 
suffering from Leukaemia following treatment with a retroviral vector, although the 
treatment was successful (Yi et al. 2005). 
While gene therapies can treat disease with genetic defects they cannot help where 
whole organs or tissues need to be replaced. This is the remit of tissue engineering 
and cell therapies. Tissue engineering focusing on growing whole tissues in vitro 
which may be formed of more than one cell type and require a structure similar or the 
same to the tissue it is replacing. There is also a demand for tissue engineering to 
provide human models for research use with the long-term goal to replace or reduce 
the use of animals in drug testing. By having a tissue model which is made from 
human cells the model is also more relevant to the end user of the drug or treatment 
which has historically been a criticism of using animal models in the development of 
treatments for humans (Holmes et al. 2009). Animal models have different physiology 
and genetic to humans, therefore data collected based on animal models may not 
always be applicable to humans. In addition to the relevance of animal models there 
are also the ethical concerns as studies may induce pain and suffering to the animal 
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subjects, and the premature termination of life (Levy 2012). With the great potential 
of regenerative medicine there is still no routine treatment using stem cells 
(Badylak & Rosenthal 2017), the barriers to market include cost, safety concerns and 
feasibility of  treating large patient numbers. 
2.2 Cell Therapies 
The use of human cells to replace or repair damaged or diseased tissue provides 
treatment options for conditions ranging from cancers (Jorgensen et al. 2003; 
Lipowska-Bhalla et al. 2012), neurodegenerative diseases (Lindvall et al. 2004; Oh & 
Choo 2006) and autoimmune diseases (Jorgensen et al. 2003; Corcione et al. 2006; 
Gieseke et al. 2010) to full organ replacement (Sharma et al. 2010). As the field has 
advanced it has become clear that a multidisciplinary approach is required. The 
complexity of the treatments, controlling and understanding the interactions of the 
cell therapy in vivo coupled with providing a robust supply chain meets this need 
(Badylak & Rosenthal 2017). For example, cells are not only used as physical 
replacements of damaged tissue but their mode of action (MOA) may instead be to 
control and enhance innate biological processes to treat disease. This takes advantage 
of a normal behaviour for a cell type (e.g. secretion of particular proteins) and applies 
the behaviour to a different tissue of disease. Human mesenchymal stem cells 
(hMSCs) are a prime example as they have been shown to not only be used in whole 
cell replacements therapies but also to invoke or regulate a number of biological 
processes discussed in Section2.6.1. 
Broadly, cell therapies can be split into autologous or allogenic treatments and can 
represent various stages of cell linage commitment (Jones et al. 2012). Human 
embryonic stem cells (hESC) and induced pluripotent stem cells (iPSC) have 
unlimited self-renewal capacity and are pluripotent meaning they have the capacity to 
differentiate down any of the linage pathways (Takahashi et al. 2007). Multipotent 
stem cells have a more limited differentiation and self-renewal capacity compared to 
pluripotent stem cells. Multipotent stem cells include human hematopoietic stem cells 
(hHSC) and hMSCs. Any cell type found in the human body can, at least 
theoretically, be used for an autologous cell therapy. Due to the source and nature of 
hESC, treatments using from this cell type will always be allogenic.  
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Autologous therapies have a minimal risk of invoking an  immune reactions to the 
treatment as the treatment uses the patients’ own cells as the starting product thus it 
should not be required for the patient to take immune suppression medication 
(Bang et al. 2005). The use of autologous treatments can be limit due to the diseased 
state of the patient, for example if a patient has bladder disease healthy cell must be 
available to extract and there is also a risk of the disease reoccurring by using a cell 
population from a tissue which has already been diseased (Atala et al. 2006). Thus, all 
treatment options need to be explored including careful consideration of the tissue 
source and cell type for autologous therapies. The tissue source and cell type are not 
mutually exclusive for example hMSCs have been extracted from bone marrow, 
dental pulp and adipose tissue (Barry & Murphy 2004; Collart-Dutilleul et al. 2014). 
The removal of patients’ teeth to extract hMSCs is not ideal as adult teeth do not self-
renew, however it may not be in the best interest of the patient to undergo a bone 
marrow aspirate procedure. These factors need to be considered when developing 
sustainable cell therapy treatments.  
The use of undifferentiated cells provides a greater number of treatment options but 
gives rise to more functional and safety concerns compared to treatments using 
differentiated cells. These concerns are mostly related to the use of iPS and hESC but 
some issues are also applicable to multipotent stem cells. Tumorgenesis is a major 
hurdle for pluripotent cell therapies, resulting in the use of undifferentiated iPS or 
hESC directly as a treatment unsafe (Lee et al. 2013). Subsequently pluripotent, and 
in some cases multipotent stem cells, need to be directed down a differentiation 
pathway ex vivo to produce the cell type required for the intended treatment. Stem cell 
differentiation in vitro can be achieved by using biochemical signalling and some 
work has suggested mechanical stimulation can also instigate differentiation 
(Toma et al. 2001; Reilly 2010). From a treatment perspective, the cells administered 
need to be characterised to be able to quantify how much of the cell population are the 
intended cell type required for the treatment.  
A branch of cell therapies which is gaining momentum within the field is the 
development of cell therapy products (CTP). CTP use the protein molecules or 
exosomes produced by cells as a treatment as opposed to treating a patient with whole 
cells (WC), this overcomes some of the previously mentioned issues in terms of 
safety and characterisation of WCs. One of the mechanisms by which cell therapies 
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are shown to work is though stimulating the body’s innate signalling cascades to heal 
and regrow damaged tissue. The MOA of the molecules produced by the cells may 
invoke different responses depending on which tissue type the CTP is administered to. 
For example, hMSCs are being used to regulate immune responses in patients with 
graft versus host diseases (GVHD) and for tissue ischemia (Yañez et al. 2006; Russo 
et al. 2014). The possibility of invoking the same in vivo response by culturing the 
cell in vitro and administering the enriched culture medium negates the WC safety 
issue, however this treatment may need to be administered multiple times if the MOA 
in not self-sustained. The CTP would also need to be screened for adverse effects as 
with any standard pharmaceutical drug but would provide a more complex cocktail of 
molecules which would simplify a treatment as opposed to artificially making the 
same molecule cocktail. Characterisation of a cell therapy medicinal product 
including WC and CTP a regulatory requirement is part of the regulatory frame work 
governing the use of cell therapies in the clinic (Pellegrini et al. 2014). 
The area of regenerative medicine and cell therapies holds much promise, but the 
question needs to be asked as to what the barriers are in bringing these treatments into 
the main stream healthcare systems around the world. In each branch of regenerative 
medicine there are some common challenges. Most importantly safety, which is the 
reason for the development of detailed regulatory frameworks (Pearce et al. 2014). 
Many of the cell based treatments developed have been established on a small scale; 
therefore in order to meet the demand of these treatments there is the challenge of 
scaling up these treatments with a robust, reliable and cost effective manufacturing 
process while meeting the requirements of a fit for human use product (Hambor J.E 
2012). There is a clear requirement for the standardisation of these processes. The 
FDA gave their perspective on this, highlighting the amount of diversity seen between 
clinical trial application for MSC therapies. Most notably the diversity in cell source, 
culturing methods and lack of continuity in bioactivity characterisation (Mendicino et 
al. 2014). The concept of personalised medicine also needs to be taken into 
consideration when discussing standardisation of cell therapies. Personalised 
medicine is a term used to decided tailoring a treatment or therapy to the patient needs 
as opposed to solely the disease (Vogenberg et al. 2010). However classic 
pharmaceuticals and biologics are still manufactured to a specific standard, but the 
combination of products, dosage and dosing regimens can be tailored to a specific 
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patient. Cell therapies are more complex and therefore the process of standardising 
them may need to be more adaptive, by which the patients physiological state dictates 
the standards a cell therapy needs to meet. In order to overcome these barriers there is 
a key need to have the infrastructure to support these challenges and to take a more 
multidisciplinary approach to achieve progress. In the United Kingdom (UK) for 
example the government funded Cell and Gene Therapy Catapult was formed to help 
support the commercialisation of cell and gene therapies (Gardner & Webster 2017). 
The Cell and Gene Therapy Catapult is therefore able to provide not only support to 
researchers and companies in the area of regenerative medicine but is also able to 
facilitate harmonisation within the field. 
2.3 Cell therapy manufacturing 
The principal objectives of cell therapies and CTP are to deliver improved and long 
term treatments which are safe, well defined and efficacious in a timely manner, 
ensuring they have been fully tested for quality, quantity and potency (Goldring et al. 
2011; Rayment & Williams 2010; Carmen et al. 2012). These tasks are even more 
challenging when dealing with such a complex material as live human cells and 
defining CTP. With demands of up to 109 cells/dose there are challenges in 
maintaining quality and quantity of the cell product in scale up environment (Ratcliffe 
et al. 2011; Simaria et al. 2014). As briefly mentioned, within cell therapies the 
starting material can be a matured cell source such as chondrocytes used in cartilage 
regeneration (Bhosale et al. 2007), or stem cells which have to potential to be directed 
into certain cell types depending on the type of stem cell and multi-lineage potential 
(Pittenger 1999; Baharvand et al. 2008; Yu et al. 2012). As the treatment options can 
potentially be autologous or allogenic, the different combinations of autologous or 
allogenic and differentiated or undifferentiated cells present, independently, some 
unique challenges.  
2.3.1 Autologous vs allogeneic cell therapies 
From an immune system perspective, autologous cells have an advantage over 
allogenic cells; however, this limits the source of starting material and makes the 
material more precious, as cells can only be obtained from the patient who is 
receiving the end product. In turn it becomes even more paramount to have an 
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efficient and reliable scale up/scale out process as there is minimal room for error 
because of the finite and usually minimal amount of starting material. For example a 
10ml bone marrow aspirate was required for an hMSC treatment for osteonecrosis, 
from this aspirate and after a two week culture period 2 × 106 hMSCs were harvested 
(Zhao et al. 2012). This issue can also be further compounded if the starting material 
has limited self-renewal capacity as it therefore needs to be determined if it is possible 
to achieve the cell numbers required for a treatment from the starting material. 
hMSCs are known to have a limited renewal capacity for example it has been shown 
that hMSCs from the bone marrow enter senescence after 7 passages tough this varies 
depending on tissue source and patient age (Lu et al. 2006). Other studies demand 
higher cell numbers which require a stable supply of cells such as a hMSC treatment 
for Crohn's disease which required 1–2×106 cells/kg body weight and each patient 
(10 patients in total) required two infusions 7 days apart (Duijvestein et al. 2010). 
Determining renewal capacity of a cell type or population is also an issue for other 
cell types, there is some debate regarding the extent of the self-renewal capacity of 
hematopoietic stem cells as much variation has been seen within this cell type (Eaves 
2015). This presents some challenges as growth characterisation is a regulatory 
requirement (British Standards Institution 2011) .Pluripotent stem cells such as hESC 
(Oh & Choo 2006), have the potential to differentiate into multiple cell types and a 
greater self-renewal capacity so consequently they are of great interest from a 
manufacturing perspective as from one starting product, in theory, multiple end 
products can be manufactured (Unger et al. 2008). In practice this manufacturing 
pathway and the route to market is exceptionally complicated in fact the first trial 
involving hESC was halted due to strategic issues as opposed to concerns regarding 
product safety (Whiting et al. 2015).  
From a classic manufacturing perceptive all parts of the process need to be controlled 
and any process variation accounted for, however due to the inherent biological 
variation of cells and stem cells a new set of challenges arises particularly in terms of 
defining input material and end product (Ratcliffe et al. 2011). Good manufacturing 
practice (GMP) needs to be adhered to when producing a product that will be 
administered to a patient. This increases the overall cost of a product but is designed 
to ensure product safety and quality (Unger et al. 2008). Autologous cell therapies 
require segregated manufacturing processes for patient specific treatments, at no stage 
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can cells for multiple sources mix or use the same equipment without sterilisation in 
between as per GMP requirements. While from an immunogenicity perspective 
autologous cells have less risk, the cost of manufacturing an autologous treatment is 
greater per unit and there is no room for error in the process which brings into 
question how sustainable they are on an open market. 
2.3.2 Regulatory considerations 
As with all healthcare products manufacturing and over all approval of cell therapies, 
also referred to as human cell based medicinal products, is governed by a regulatory 
framework, which is recognised, along with development costs, as being the major 
barriers to market (Plagnol et al. 2009). The European Medicines Agency (EMA) 
which sets, in conjunction with individual countries’ regulatory bodies, the regulatory 
requirements for cell therapies within Europe refers to all therapies involving cells as 
somatic cell therapy medicinal products and falls under the advanced therapy 
medicinal products (ATMPs) remit (Maciulaitis et al. 2012). The FDA, which is the 
regulatory body in the United States, has the Centre for Biologics Evaluation and 
Research (CBER) which regulates cellular therapy products and like the EMA is also 
includes gene therapy medicines, tissue engineered medicines and devices that are 
transplanted into the body with cells (Center for Biologics Evaluation and Research 
1998). The regulatory framework needs to account for the extra safety concerns which 
are not normally present with classic chemical or biological pharmaceuticals. In 
particular with pluripotent stem cells, including the risk of tumour formation in vivo 
(Abad et al. 2013), and in the case of iPS cells the use of viruses to alter the genes 
carries a risk of uncontrolled genetic modifications leading to cancers (Reisman & 
Adams 2014). There has been criticism toward the regulatory bodies, most notably 
the FDA for not providing stricter regulatory definitions on cell therapies, in 
particular the ambiguity in the regulation of autologous treatments. The use of human 
cells as a treatment is placed into a 361 category or a 351 category. Products in the 
351 are more closely regulated by the FDA as the cells are manipulated to a greater 
degree, such as ex vivo mixing of cell populations, administration on a scaffold or 
containing different genetic material to the recipient (Preti 2005; Knoepfler 2015). 
The 361 products include autologous cells that are being used for the same or similar 
physiological function and have only been minimally manipulated, which under 
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current FDA guidelines, requires minimal vetting and are not subject to the same 
regulatory approvals as a 351 product (Knoepfler 2015; Fox 2008).  
Minimal manipulation includes processes such as separating CD34+ hematopoietic 
progenitor cells from peripheral blood progenitor cells and cryopreservation of cells 
or tissues (Preti 2005). The indistinctness within the 361 FDA regulations has led to 
the opening of clinics which offer patients cell therapies and making unfounded 
claims (Turner 2015), some on these unregulated clinics have resulted in patients 
becoming blind from one such cell based treatment (Ledford 2016). This 
demonstrates the need for not only tighter regulation on all cell-based therapies but 
also a better understanding of even minimally manipulated autologous cells which are 
considered “safe”. The impact of unsafe treatments on the reputation of cell therapies 
also needs to be considered as bad press can negatively impact research funding and 
companies willing to invest into the area if it is thought patients are less likely to 
adopt the treatments. The complexities of cell-based therapies are considered to be the 
reason behind this apparent lack of specificity in the regulatory frame work. As the 
field is continually evolving and more knowledge about stem cell and cell behaviour 
is coming to light it can be a challenge for regulatory bodies to sustain the formation 
of new guidelines at the same rate (Fox 2008). It is important to establish the impact 
of ex vivo manipulations on a cell population including the harvesting of the cells, 
storage of the cells (where needed), culture conditions of the cells and the 
administration methods of WC or CTP.  
Within a manufacturing setting there needs to be a defined process. The starting 
material and the end product need to be defined as per quality parameters, from a 
safety point of view the end product and its behaviour in vivo is the most critical. 
From a manufacturing aspect, in terms of efficiency and therefore cost, a defined 
process is required. Determining that the starting material will form the required end 
product and being able to monitor the process are highly important (Carpenter et al. 
2009).The term critical quality attributes (CQA) of a product refers to a physical, 
chemical, biological, or microbiological property or characteristic, and needs to be 
within an appropriate limit, range, or distribution to ensure the desired product quality 
(Ich 2009). CQA are determined by the MOA of a product which is the pathways 
through which a product achieves its intended therapeutic effect (Food and Drug 
Administration, HHS 2005). The EMA states within regulation (EC) No 1394/2007 
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“When products are based on viable cells or tissues, the pharmacological, 
immunological or metabolic action should be considered as the principal mode of 
action”. 
One of the challenges when manufacturing CTP and WC is ensuring that the product 
will still invoke the MOA and maintain CQA, this includes identity, purity, potency 
and safety of the product (Carmen et al. 2012). As previously discussed pluripotent 
stem cells can differentiate into multiple cell types, therefore identifying the cell types 
present in the manufacturing process of pluripotent stem cells is one of the first 
challenges due to the heterogeneity of the population. If in the regulatory approval, it 
is stated that only differentiated cells will be administered to a patient then analysis 
needs to be carried out to determine the homogeneity of the population. For example, 
current clinical trials using hESC derived retinal pigment epithelium (RPE) cells for 
the treatment of acute wet age related macular degeneration in the first instance 
determine successful hESC differentiation and maturation based on pigmental 
changes and a cluster formation with cobblestone morphology. Though the cells may 
look like RPE cells subsequent testing including karyotyping, staining for hRPE 
markers, functional analysis included phagocytosis says, fluorescence-activated cell 
sorting (FACS), genetic analysis, FACS labelling for undifferentiated hESCs and 
testing for pathogen contamination is required. In this particular instance >99 % of the 
cell population fulfilled the RPE identification criteria and >90 % viable cells were 
transplanted into the patient (Song et al. 2015). It can be argued that it only takes a 
few cells to be unintentionally transplanted and a tumour may form. The advantage 
with this treatment is that the retina can be easily visually monitored, and any adverse 
effects seen and treated.  
CTPs differ in terms of safety as the cells themselves are not being administered, 
however the potency and purity of the product needs to be assessed and from a 
manufacturing perspective continuous monitoring of any adverse effects during 
manufacturing is paramount (Food and Drug Administration 2008; Unger et al. 2008). 
Within the cell therapy manufacturing space there is a constant demand in very stage 
of the process for product monitoring and analysing. The FDA among other 
stakeholders identified that the more widely adopted offline process measurements 
used in pharmaceutical manufacturing were impacting production quality and 
efficiencies (Read et al. 2010). Within the pharmaceutical industry, the FDA 
   33  
 
promoted the concept of process analytical technology (PAT) in 2004 in order to 
encourage innovation for the development of at-line, in-line and on-line measurement 
systems. The measurements could be physical, biological or chemical but the overall 
aim is for the measurements to improve process control and optimisation (FDA 2004). 
One of the key elements in manufacturing is reducing the sample to result window, 
particularly in processes that involve an active biological environment (Scheper et al. 
1999), which is highly applicable to in stem cell manufacturing where cells can 
intentionally or unintentionally differentiate or de-differentiate. It is also important as 
cell culture environments as factors such as temperature, oxygen concentration, pH 
and growth medium are consistently shown to impact on cell growth and behaviour 
(Chen et al. 2014; Kagawa et al. 2016; Heathman et al. 2016).  
2.3.3 Manufacturing scale 
Some clinician-led autologous treatments currently in clinical trials are manufactured 
at a smaller scale and use a scale out approach as opposed to scale up. This method is 
not seen as being financially viable for the larger biopharmaceutical industry, and 
may not meet the market demand (Hourd et al. 2014). In order to produce the number 
of cells required for a treatment and quality testing, bioreactor systems are commonly 
used in the scale up of cell manufacturing. Bioreactors types include stirred tank 
reactors (Kirouac & Zandstra 2008; Rafiq et al. 2013), roller bottles, packed bed 
reactors (Palomares & Ramírez 2009; Brandwein et al. 2012). Bioreactors are also 
being used to replicate 3D in vivo environments for tissue engineering such bone 
constructs on scaffolds (Viateau et al. 2014). There are added challenges in the scale 
up of adherent cells such as hMSC to achieve the required level of cell growth. 
Though work is being carried out to successfully culture viable adherent cells in 
aggregates (Bartosh et al. 2010), most hMSC cultures require the cells to be attached 
to a functional surface. The use of microcarriers in stirred tank bioreactors provides a 
greater surface area per volume unit compared to the standard monolayer culture 
methods such a stacked T-flasks (Rafiq et al. 2013). The surface to which the cells are 
adhered, the seeding and harvesting methods and the forces the cells are exposed to 
during culture have also been shown to impact on cell viability (Curran et al. 2005; 
Heathman et al. 2016). Given the number of variables that can occur during the scale 
up processes, online system monitoring is of paramount importance to insure the 
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product will meet the quality standards required and to have as much continuous 
information as possible regarding the culture environment the cells are exposed to. 
Within the bioreactor system it is standard to have sensors constantly monitoring 
temperature, carbon dioxide levels, dissolved oxygen concentration and pH. Factors 
which as previously mentioned impact cell behaviour. However, given the 
complexities of cells simply measuring these parameters is not sufficient to determine 
how the cells are behaving and coping within the culture environment. Other 
measurements are usually taken which includes cell viability, cell surface marker 
analysis using flow cytometry, genetic profiling and protein analysis, however these 
methods are often carried out offline (Astori et al. 2010; Pal et al. 2012). Allogenic 
therapies are seen as more sustainable on terms to reaching a bigger market with and 
off the shelf product as opposed to a personalised autologous treatment.  
2.4 Bioanalytics for Cell Therapy Manufacturing 
Whether it is meeting regulatory requirements for release criteria or forming part of 
the manufacturing process, culturing cells for human use requires extensive testing 
and monitoring. The tests used need to need justified and related to the MOA and 
CQA of the cell-based treatment. It is possible to perform basic monitoring of gases 
and some metabolites online, but these measurements do not give an entire over view 
of the cells behaviour. Offline monitoring of product potency in the form of 
bioanalytical testing is therefore necessary but there is an need for test that reduce the 
time gap between sampling and date output of bioanalytical test (Scheper et al. 1999). 
The complex challenges of cell therapy manufacturing alone and the high level of 
testing required to meet regulatory standards drives the need for bioanalytics within 
the cell therapy manufacturing and processing environments (Lim et al. 2007). 
Bioanalytics specific to hMSC are discussed further in section 2.6. 
The uses of bioanalytical methods are fundamental in the discovery and 
manufacturing processes of drug and biologics. Bioanalytics, also referred to as 
bioanalysis, originated due to the need to measure drug levels in biological fluids as 
part of the evolving science of toxicology. The emerging field of pharmacokinetics in 
the 1930s coupled with new drug development fuelled the need for high specificity 
analysis methods (Hill 2009). The field utilizes a number of different platforms 
including chromatography, mass spectrometry, enzyme mediated assays and 
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electrophoretic techniques. There is some debate regarding the use of the term 
bioanalytics/bioanalysis when referring to the determination of purity and identity of a 
product. Ritter (2011) argues that the term bioanalytics is often used wrongly as an 
overarching term for all analytics including bioassays. 
In this work bioassays refer to the testing of the biological response to a treatment at a 
cellular level and are often used to determine the potency of a product i.e. the effect of 
a product on the cell population. Bioanalytics refers to the measurement of a discreet 
molecule or compound such as a protein or metabolites. Bioanalytical methods are 
used across many areas of research and manufacturing including drug development, 
biotherapeutics, biomaterial development, quality system monitoring and diagnostics 
(Romanyshyn et al. 2000; Whitmire et al. 2011; Zhang et al. 2016). Classic small 
molecule and even biotherapeutics (proteins including antibodies) are relatively 
simple to characterise as opposed to cell therapies. In general, the manufacturing 
processes are well defined, robust and reliable and it is proven in the development 
phase that certain manufacturing parameters will consistently produce an intended 
product (Li et al. 2010). This results in more straight-forward monitoring of the 
product, quality checks and batch release criteria. Bioanalytical methods used include 
immunoassays, flow cytometry, genetic analysis, electrophoreses, spectrometry 
methods and chromatographic methods which detect protein expression, 
characterisation of proteins, mRNA expression profiles, cell surface markers and the 
presence of metabolites  (Findlay et al. 2000; Romanyshyn et al. 2000; Harkness et al. 
2008; Carlos Polanco et al. 2013). Flow cytometry is of particular interest in the cell 
therapy field as it is a common method for characterising and sorting (FACS) cell 
types based on cell surface markers also known as cluster of differentiation (CD) 
markers (Kiel et al. 2005; Rasini et al. 2013). Immunoassays also are able to provide 
information on the proteins a cell population is secreting in vitro, proteins such as 
cytokines are the major conduit through which cells communicate with the 
microenvironment and with each other (Turner et al. 2014). Immunoassays are 
capable of extracting a molecule of interest from a complex matrix (Ohno et al. 2008) 
they amplify the signal from these molecules through a number of mechanisms which 
result in a detectable signal that is proportional to the quantity of the molecule 
(Wild 2013). 
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A limitation of flow cytometry and immunoassay methods is that prior knowledge is 
needed to be able to screen for specific CD markers or proteins. Flow cytometry 
utilises CD markers using fluorescently conjugated CD marker specific antibodies. As 
with most antibody related analytical test there is the risk of nonspecific binding, 
while this can be reduced through the use of blocking buffers background 
fluorescence is an artefact which needs to be compensated for during data analysis 
(Andersen et al. 2016). Different cell types also express on or more of the same CD 
markers; therefore, a panel of CD markers specific to a cell type must be screened for. 
Due to this issue negative testing is also required to prove the absence of a cell type in 
a population, for instance to separate undifferentiated hESC from a differentiated cell 
type (Pruszak et al. 2007). There are new markers and cell types regularly being 
identified consequently field is continuously re-evaluating the CD marker panels, 
expression levels and the impact on the function of the cell population 
(Diaz-Romero et al. 2005; Carlos Polanco et al. 2013) 
Again, this is a disadvantage of manufacturing such a complex product which carry 
out 100s or processes within the cell unit while communicating and reacting to the 
culture environment, it is not possible to gain a full picture of cell behaviour based on 
a minimal number of analytical tests. Thus, a wider panel of bioanalytical tests need 
to be carried out and at multiple stages in the manufacturing process (Figure:1). 
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Figure:1 Summary of a cell therapy manufacturing process. The green text boxes refer 
to information that need to be determined and the pink text boxes process 
requirements which need to be satisfied. 
Figure:1 shows a simplified summary of the manufacturing process and identifies in 
the pink text boxes some of the areas where bioanalytics and in some case bioassays 
are required. In basic terms the starting material needs to be characterised, screened 
for infectious agents and the cell behaviour assessed prior to committing to an 
expensive and time-consuming scale up process. The methods used and the criteria 
the cells will need to meet will depend on the cell source and the treatment type. This 
is decided during the process development period. The scale up/scale out system 
needs to be monitored during the culture period. For instance, if unexpected events 
occur such as an accelerated growth rate, feeding regimes may have to be altered to 
avoid batch loss. Post expansion the cells need to be harvested and unwanted 
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contaminants such as cell debris or microcarriers removed and the final product tested 
when purified. The final product also needs to be tested for potency and to test for 
adverse effects such as impurities which could invoke an immune response. How to 
supply the product to the patient is also a factor which could impact product quality. 
Cryopreservation is a favoured method to preserve cells but there is evidence that 
there is a negative impact on cell quality (Xu et al. 2012; Coopman & Medcalf 2014). 
The number of tests required for one product run adds to the cost of the overall 
manufacturing process and requires samples of the product for testing. With 
destructive testing methods used, more tests mean more of the product is lost in 
quality control, reducing that available for treatment. This is particularly challenging 
for autologous treatment. There is also the  additional time delays from the time the 
samples are taken to obtaining the results, many of the methods used at the research 
level in cell therapy are not optimal for large scale manufacturing (Scheper et al. 
1999; Vojinović et al. 2006). As cell behaviour is difficult to predict during culture it 
is even more paramount, compared to classic pharmaceutical manufacturing, to be 
able to have continues feedback of the system and to reduce the test to result time 
frame would enable a more flexible and proactive approach to cell therapy 
manufacturing. Cost coupled with regulatory hurdles are some of the biggest barriers 
to a cell therapy reaching the market (Plagnol et al. 2009). It is unlikely regulatory 
requirements will ease for cell therapies, the product needs to be deemed safe and 
effective, and as there are so many elements where a cell therapy can fail to meet 
these requirements a panel of bioassays and bioanalytical tests will be required to 
determine with product quality.  
2.5  Microfluidic-based Bioanalytics  
With such extensive demands on bioanalytics within the cell therapy industry the area 
of microfluidic bioanalytics aims to satisfy these demands. Microfluidics is based on 
fluid handling and manipulation between 10-9 to 10-18 litre scale (Whitesides 2006). 
Microfluidic based platforms can help to address some of the hurdles encountered in 
cell manufacturing and at the fundamental research level, firstly by minimising 
quantities of reagents and cells used, thereby reducing costs. Secondly by reducing 
the scale of an assay it may be possible to improve assay sensitivity due to the unique 
microenvironment (Pihl et al. 2005). Finally, the speed of the assay is often quick 
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compared to standard bioanalytical assays. For example, many core analytical tests 
such as flow cytometry require many manual handling steps and long incubation 
steps. Due to the scale and geometries in microfluidic devices it is possible to carry 
out multiple steps in one system and reduce incubation times. All these factors allow 
the biomanufacturing field to have continuous process monitoring capabilities (Karle 
et al. 2016). 
A number of assays have already been translated from macro to micro scale and 
exploited the benefits of micro scale assays. The majority of microfluidic platforms 
are ‘lab-on-a-chip’ style devices; these allow for a high level of control with low 
reagent and sample volume requirements (Whitesides 2006). 
Barbulovic-Nad et al. (2008) used a planar array of electrodes in combination with 
droplets of reagents to increase the sensitivity of a live/dead cytotoxicity assay 
(calcein AM and ethidium homodimer-1) by 〜20 fold compared to the standard 
microtiter plate. Reverse transcription polymerase chain reaction (RT-PCR) assays 
are also a focus of scaling down the reaction size with the aim of achieving rapid and 
reliable results for the point of care (POC) diagnostics market. Verdoy et al. (2012) 
developed salmonella POC detection chip that incorporated the time-consuming 
sample preparation steps and reduced the analytical test time to 35mins; this is 
considerably quicker compared to the well plate assay which, depending on reagents 
requires 1.5-2hrs. Chang et al. (2006) combined microfluidic PCR chips with digital 
technology, utilising electro-wetting-on-dielectric (EWOD) and moving reagent 
droplets along micro channels via hydrophilic/hydrophobic generated tension 
gradients. The authors focused on amplification of Dengue II virus and report a 
reduction in consumable costs and amplification time compared to larger scale assays 
(Chang et al. 2006). Lab-on-a-chip devices have been able to analyse microscopically 
down to the single cell level. Cells which are culture in micro wells under separate 
conditions can be stimulated with biochemicals and the response analysed, this 
platform accommodates a high number of cells in the same device with low reagent 
costs (Gupta et al. 2010). Being able to identify a single rogue or undifferentiated 
cells within a population is important for treatments using iPS or hESC, as previously 
mentioned these cells can results in tumour formations (Abad et al. 2013). Some 
organ-on-a-chip concept use chambers on a microfluidic chip which contain the cell 
populations that form a tissue or organ. The chambers are continuously perfused, and, 
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using finely controlled channels between the chambers, the aim is to be able to mimic 
the in vivo physiological functions of the organ or tissue in vitro 
(Bhatia & Ingber 2014). Through using organ-on-a-chip platform tissue responses to 
pharmaceuticals, integration of stem cell derived tissues within the platform can be 
analysed as well as being able to test the cellular products such as protein production 
after exposure to specific conditions. These platforms can also help identify the 
impact of single rogue or undifferentiated cells within a system. There are application 
for this technology within drug research, particularly as organs-on-chips could be a 
realistic replacement of animal testing, or at least be able to reduce the use of animals 
in line with government and ethical body initiatives (Huh et al. 2012). In the remit of 
personalised medicine organs-on-a-chip would be highly functional in terms of using 
a patient’s own cells and being able to analyse drug responses. Similar work to this 
has been carried out in microarray formats, however these are not able to replicate the 
fluidic dynamics of the in vivo system which lab-on-a-chip devices can 
(Xu et al. 2011). 
Cells being cultured inside microfluidic devices and be analysed using a number of 
techniques for example in-cell Westerns. In-cell Westerns adapt standard 
immunohistochemistry staining of proteins inside cells coupled with a laser scanner 
detection method. The short distance between the cells inside a microfluidic device 
and the lasers reduces the level of environmental interface which improves the 
sensitivity of the method and enables successful quantitation of the proteins. 
(Paguirigan et al. 2010). It has also been shown that it is possible to carry out 
analytics at the nanolitre scale using electrode array for cell based assays 
(Barbulovic-Nad et al. 2008). Toriello et al. (2008) developed an integrated single cell 
gene expression analysis which is able to capture a single cell and amplify the mRNA 
using pumps that operate at the nanolitre scale. The amplified product is then analyses 
using microcapillary electrophoreses that is integrated into the same system (Toriello 
et al. 2008) Microfluidic applications for analysing cell products are also another 
focus within the field, with a demand for POC and easy to use tests are of particular 
interest (Myers & Lee 2008). Developments so far include paper-based microfluidics, 
where micro-channels are patterned onto the paper using a wax printing and cutting 
method. This platform has been used for immunoassay bioanalytics but is struggling 
to compete with the level of sensitivity achieved by conventional bench top 
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immunoassays (Martinez 2011). Novo et al. (2014) integrated a photodiode based 
optical detection system with a microcapillary system that could carry out sequential 
fluid flow function in order to carry out a chemiluminescence ELISA spot assay. The 
whole system could be contained in a 5.5cm x 15.2cm x 3.3cm box, and the assay 
could be carried out in 15mins achieving a LOD of ~2nM. 
There are some challenges when using microfluidic devices to perform 
measurements, assays or culturing live cells such as maintaining the optimal 
environment. Bubble formation in microfluidics is a common issue (Gao et al. 2012; 
Young & Beebe 2010), and though the issue is often debated within the cell culture 
field, bubbles are thought to harm cells when they burst due to hydrodynamic shock 
damaging the cells (Hu et al. 2011). The cells produced during the manufacturing 
process need to be consistent or at the very least any variation introduced due to the 
manufacturing processes needs to be accounted for in terms of safety and 
functionality  
A challenge in using optical detection of absorbance in microfluidic devices is the 
reduction in the light path length which in turn reduces the sensitivity (Mogensen & 
Kutter 2009). This is based on the Beer-Lambert law where by absorbance is directly 
proportional to the light path length (Strafford 1936; Vila-Planas et al. 2011), the 
shorter the light path the more sensitive the value is to issue such as poor mixing and 
contaminants.  
2.6 Bioanalytics and hMSCs 
2.6.1 Clinical applications using hMSCs  
While there are many cell types being used in clinical trials, hMSCs are of great 
interest for cell therapy applications due to their multilineage potential (Figure 2) 
ability to be expanded in vitro and the minimally invasive techniques used to obtain 
aspirates of them from within bone marrow (Caplan & Bruder 2001). Dental pulp, 
adipose tissue, Wharton’s jelly and umbilical cords have also been used as sources of 
hMSCs (Yañez et al. 2006; Collart-Dutilleul et al. 2014; Chen et al. 2015). There is 
also evidence that hMSCs are an immunoprivileged or immunoevasive cell type 
whereby they do not express antigen stimulating surface markers which trigger an 
immune response leading to issuers of immunogenicity and immunotoxicity (Caplan 
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& Bruder 2001; Goldring et al. 2011; Shin et al. 2017). A minimal criteria for 
defining hMSCs is that they are paslstic adherant, can differiantate down the adipo- 
cytes, chondrocytes and osteoblasts lineages and express CD105, CD73 and CD90, 
but lack the expression of CD45, CD34, CD14, CD79a and HLA-DR (Dominici et al. 
2006; Rasini et al. 2013). 
 
Figure 2 Bone marrow derived hMSCs differentiation pathways. Cells types which 
hMSCs have been shown to differentiate to under specific biochemical (in vitro) and 
physiological (in vivo) conditions (Uccelli et al. 2008). 
The paracrine properties of hMSCs are becoming of increasing interest, these 
properties are not included with it characterisation criteria of hMSCs. The paracrine 
properties of hMSCs have been used for treatments such as graft-versus-host disease 
(GVHD). In autoimmune diseases hMSCs are shown to supresses the immune system 
through multiple pathways including direct cell to cell contact with T-cells and 
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secretion of cytokines which among other mechanisms seem to supress dendritic cell 
migration and expression of CCR7 on T-lymphocytes which results in dendritic cells 
from maturing. Maturation and migration of dendritic cells is a key mechanism in 
acute GVHD (Li et al. 2008). The challenge as with many biological processes is that 
though a cause and effect can be seen. In the example of GVHD treatment with 
hMSC in vitro and in vivo has been shown to dampen the immune response, all the 
exact molecular mechanisms remain elusive. Some signalling pathways have been 
extensively studied and are widely accepted such as cytokines hepatocyte growth 
factor (HGF) and transforming growth factor beta (TGF-β) have been shown to be 
involved in signalling to supress T-cell proliferation. These cytokines are also 
expressed by hMSCs and therefore are considered to be some of the mechanisms by 
which hMSCs regulate immune responses (Dorronsoro et al. 2013). Other conditions 
which use hMSCs as a treatment include ischemic stroke (Bang et al. 2005), cardiac 
tissue recovery after damage (Windmolders et al. 2014) and neurodegenerative 
diseases (Kim et al. 2013). 
Though a wide variety of hMSC-based treatments are being investigated at the 
laboratory bench level not all have advanced as far as clinical trials. In the United 
States of America, as of March 2017, 704 were registered in that were either 
completed or on going. The most treated clinical conditions include 82 trials for using 
hMSCs to heal wounds and injuries, digestive system diseases, most notably liver 
conditions for which there are 73 trials registered and there are 43 trials registered for 
diabetes mellitus (ClinicalTrials.gov 2017). Translating laboratory research into the 
clinical has been highlighted as a particular problem in the UK and Europe (Plagnol et 
al. 2009) In 2015 there were 58 registered clinical trials that are using hMSCs within 
the European Union (European Medicines Agency 2015) based on data from 2017 
this figure now stands at 74 (European Medicines Agency 2017). These values 
indicate that, as noted by Plagnol et al. (2009), the European  industry, including the 
UK, is lagging behind the United States in terms of bringing hMSC treatments to 
fruition. As mentioned in Sections 2.1 and 2.2 there are many hurdles to bring a cell 
therapy to the clinical trial stage and to the wider market. 
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2.6.2 Utilising hMSC conditioned medium 
Many of the clinical trials use the cells to either replace tissue or modulate biological 
process. However, the use of condition medium as a form of CTP for a treatment 
option are also being investigated (Kwon et al. 2014a). Using medium in which 
hMSC have been cultured and expressed CTPs such as complex paracrine factors and 
exosomes which invoke behaviours in vivo including immunomodulation, negate the 
issue of administering a live cell product to a patient (Baraniak & McDevitt 2010; 
Anderson et al. 2016). With the use of hMSCs in clinical trials and the cell type 
becoming a realistic and established treatment option the demand is increase for cost 
effective, rapid and sensitive assays which can qualify the product for the healthcare 
market. There is also the additional challenge that hMSCs are used for multiple 
clinical conditions which exploit different properties of hMSCs. As mentioned 
previously of particular importance are assays that characterise cells, measuring the 
products ability to carry out the intended mode of action, measurements of adverse 
effects and potency assays, there for the analytics need to be aligned with the specifics 
mode of treatment, while also ensuring no adverse effects occur. For example when 
using hMSCs to supress T-cell and B-cell activity in an autoimmune system disorder 
such as GVHD (Ma et al. 1998; Gieseke et al. 2010), hMSCs properties such as 
promotion of angiogenesis would be an adverse side effect. Consequently, it is 
difficult to justify the commonly used hMSC characterisation criteria which is 
routinely cited as the focus of so many treatments are the utilisation of discrete 
aspects of hMSC behaviour. Functionality of an hMSC population for a specific 
treatment cannot be determined based on the existing characterisation criteria. Cell 
characterisation in general revolves around the quantification of cell types that are 
present in a population based on CD surface markers which the cells display. A 
minimal criteria for hMSC characterisation was defined by ISCT (Dominici et al. 
2006), following on from this paper a working proposal was published highlighting 
the need for characterising the immunoregulatory function of hMSC (Krampera et al. 
2013). To distinguish between other cell types hMSCs must be plastic adherent when 
cultured under standard conditions and differentiate down the adipocyte, chondrocyte 
and osteocyte linages. They must also be positive for CD90, CD73 and CD105; and 
the hMSCs must also lack the expression on haematopoietic stem cell markers in 
order to be deemed hMSCs (Dominici et al. 2006; Chan et al. 2013; Rasini et al. 
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2013). However, given the range of treatment applications the hMSCs are being 
harnessed for the question of how relevant the characterisation criteria really are 
needs to be asked. 
2.6.3 Clinical need for improved product characterisation 
Clinical trial NCT00447460 is an example of a clinical trial using hMSCs which were 
characterised based on the ISCT guidelines. The trial involved 18 patients being 
treated for GVHD with hMSC donated by family members or by a haploid match. 
Originally there were 28 patients in the trial, 4 responded to standard medication prior 
to treatment, the hMSC for 1 patient failed to expand and 5 died before they could 
receive the treatment. This alone demonstrates the need for a faster pipeline of cell 
therapies, patient death while waiting for the product to be manufactured is 
unacceptable but at this stage unavoidable. Of the 18 patients treated with an hMSC 
infusion 10 had refractory or relapsed acute graft-versus-host disease GVHD and 8 
had chronic GVHD. Only 1 patient from each group had a complete response to the 
treatment 3 chromic patients and 6 refractory or relapsed acute had a partial response 
and the rest had no response (Pérez-Simon et al. 2011). Besides the hMSC used in this 
trial being characterised according to the ISCT guidelines a tissue match between 
donor and recipient was also carried out but no further testing. The hMSCs were not 
tested to see if they had the ability to invoke the level of immune suppression required 
to modulate GVHD. The cells were administered into patients whose tissue was being 
damaged by the grafts immune response, hMSC survival and function within a 
pathophysiological environment (e.g. pro-inflammatory) was not assessed. When 
trials using hMSCs are not as successful as intended it can harm funding and licensing 
for subsequent trials, therefore more needs to be carried out in determining the 
hMSCs from a selected donor are suitable for the patient and the disease requiring 
treatment. 
The current release criteria require a minimum of 70% cell viability, viability does not 
automatically equate to functionality. The issue of limited release criteria and lack of 
functional testing at the point of release caused the death of four paediatric bone 
marrow recipients at Great Ormond Street hospital in 2013. Prior to transplantation 
the cell viability was deemed acceptable but after an investigation into the deaths it 
was determined that the cells transplanted where not functional and could not mature 
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once administered to the patient (Morgenstern et al. 2017) The cryopreservation 
processes was thought to have not been effective though the same process had been 
used for ten years, this not only demonstrates the urgent need for more in-depth 
testing post thaw and prior to transplant but also that process monitoring (in this 
instance cryopreservation) needs to be continuous (Morgenstern et al. 2016). For 
these reasons, surrogate potency assays have become more of a focus within cell 
therapies. Potency assays provide a quantitative measure of a cell or cells biological 
activity which is biologically relevant to the end therapeutic need. Potency assay are 
more in the remit of bioassays as opposed to bioanalytics in terms of a product or cell 
population us applied to cells and the effect of the product on the cells is measured 
(Bravery et al. 2013). Potency assays in vitro are not a new concept, they have been 
used to test microbial responses to antibiotics (Jones et al. 2008) and for testing drug 
toxicity on hepatocytes (Xu et al. 2008). However, as previously mentioned in 
Section 2.5 these models are often not fully representative of the spatial interactions 
which occur in vivo though this is being addresses using lab-on-a-chip and other 
methods (Vernetti et al. 2017).  
For hMSC potency assays the cells or conditioned medium need to be applied to 
assays which represent the intended mode of action and/or assays to screen for 
adverse effects as per regulatory guideline (Food and Drug Administration 2008). 
However this is further complicated as not all mode of actions are defined or can be 
assessed within one test and regulatory bodies do not state defined release criteria for 
this assays (Galipeau et al. 2016). There are some angiogenesis assays which have 
been reported and are applicable to hMSC functional analysis, this is discussed further 
in Section 2.8. Potency assays are not just important to determine the potency of the 
cells from a particular donor but also to ascertain the impact of manufacturing 
processes such as cryopreservation, cell culture conditions and even the 
administration method on the product potency (Spellman et al. 2011). This raises the 
same issue as other bioanalytical measurements, in that potency assays could also 
cause a bottleneck in the manufacturing process due to the time taken for them to be 
carried out. 
2.6.3.1 Cytokine detection 
As many of the mechanisms through which hMSCs exert their immuno-suppressive 
and pro-angiogenic (see section 2.8) MOA is through the secretion of cytokines 
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measuring cytokine levels and relating the values back to the potency of the hMSCs 
on a biological process would be a powerful tool. The most common based method 
for specific protein identification and measurement is the enzyme-linked 
immunosorbent assay (ELISA). The ELISA was developed as a safer and more stable 
replacement of radioimmunoassays, the technique was first published by 2 
independent research groups in 1971 (Engvall & Perlmann 1971; Van Weemen & 
Schuurs 1971). ELISAs use protein specific antibodies to capture a target protein then 
amplify the protein directly or indirectly using colorimetric or fluorescent methods so 
a signal can be detected (Andreasson et al. 2015). ELISA technology has rapidly 
advanced since 1971 but many of the assays still utilise horseradish peroxidase (HRP) 
as the substrate converting enzyme to produce a measurable colour was used in the 
first papers published. There are different configurations of the ELISA assay (Figure 
3) and the type of assay which is used depends on the application and the available 
reagents. ELISAs are completely reliant on the antibodies available and the quality of 
the antibodies. For instance, if there is only one antibody available for a specific 
antigen then a competitive ELISA must be used. Factors such as the purity of the 
sample and anticipated concentration of target antigen also influence the type of 
ELISA most suitable (Cox et al. 2004; Moises & Schäferling 2009). 
 
Figure 3: Summary of ELISA assay types (Moises & Schäferling 2009), these are 
most of the basic principles of ELISA assay but the platform in which they are carried 
out can vary depending on the test need including using a fluorophore detection 
system for multiplex ELISAs. 
While antibody technology and substrate sensitivity has improved, challenges remain 
in terms of reducing the cost of the assays. As a panel of ELISA would be needed to 
be carried out to determine the multiple cytokine levels though which hMSCs invoke 
many of their paracrine effect, cost per assay becomes an influential factor. Cost of 
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reagents, length of time per assay and requirements for technically trained operators 
are issue which need to be addressed. Methods used to address these issues include 
multiplexing assays. The Luminex platform (Pham et al. 2014) is one of the most 
popular immunoassay multiplex platforms, however as discussed in Chapter 4 there 
are still some limitations. Therefore, researchers are looking towards the field of 
microfluidics to find methods which will ideally improve all aspects of ELISA. 
2.6.3.2 Microfluidic ELISA  
ELISA are a focus of the microfluidic field, whereby the aim is to reduce the total 
assay time and costs with equal to or improved sensitivity and/or specify through 
reducing the scale. Standard ELISAs, such as the commonly used sandwich ELISA, 
have been translated into a variety of lab-on-a-chip formats while improving the 
detection methods. Detection methods in ELISA are mostly image based, detecting 
colour intensity changes in either illuminances, absorbance or fluorescence. 
Therefore, the sensitivity of the detection equipment is very important as it needs to 
be able to accurately distinguish between concentrations with only a few femtograms 
or picograms difference. Many of the lab-on-a-chip devices are fabricated from 
polydimethylsiloxane (PDMS), a soft polymer in which micro-wells and channels can 
be moulded and has excellent optical clarity allowing for sensitive optical detection 
(Schneider et al. 2009). An important parameter used to determine the performance of 
an ELISA platform if the limit of detection (LOD), the LOD is the lowest amount of 
analyte that can be detected and distinguished from background noise (Findlay et al. 
2000).  
Devices developed to date include a femtomolar scale micro well-patterned PDMS 
chip (Figure 4) designed by Wang et al (2013) (Wang, Zhang, Dreher & Zeng 2013) 
which contains over 100 wells per chamber and has an integrated-on chip pump 
system which allows for programmable, controlled fluid handling and excellent 
mixing. The chip is able to detect insulin-like growth factor 1 receptor (IGF-1R) with 
a limit of detection (LOD) of 0.0035pg/ml and a detection range 
of 0.1pg/ml  to 1000pg/ml, the LOD was calculated from the value of blank signal 
plus three standard deviations. This assay was compared to 6 commercially available 
kits; the most sensitive of the commercial platforms had a LOD of 6 pg/ml the highest 
LOD was 250pg/ml showing this platform is much more sensitive. While the 
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detection range is smaller for the microfluidic chip compared to the commercial kits 
which can detect up to 6000pg/ml-20000pg/ml it is not a draw back as samples can be 
diluted. This chip is also more focused on the detection of low abundance proteins, 
within the cell therapy manufacturing field this would be more applicable for 
contaminates such as virus capsid proteins. At the laboratory research level being able 
to detect protein which using standard kits would not be identified may give greater 
insight into signalling mechanisms. 
 
Figure 4: Micro well patterned PDMS chip developed by Wang et al. (2013). Micro 
wells and micro channels were formed in PDMS on top of a glass slide. The chambers 
are opened for carrying out the assay and closed during detection which forces liquid 
into the wells and allow for a concentrated and focused image of the well to be taken.  
While the data presented on the femtomolar scale micro well-patterned PDMS chip 
holds a lot of promise, the authors did not comment on the failure rate of the device 
and the potential to mass manufacture such an intricate system to a high quality while 
still providing a cost-effective assay to the market. These questions are important to 
consider when looking at the commercial market. 
Ellinas et al. (2017) used a sandwich ELISA carried out on magnetic beads in a 
microfluidic device approach. The use of magnetic beads as the solid phase for 
capture antibody immobilisation is the principle of the Luminex MAGPIX platform 
(Baker et al. 2012), but this is carried out in a 96 well plate format which still requires 
higher reagent volumes and longer incubation times compared to what has been seen 
in microfluidic platforms. The micro-bead platform used a 3-way valve mechanism to 
deliver wash buffer or reagents to an inlet port which was in turn connected to the 
bead containing chamber. This simplifies the fluid handling compared to pipetting 
and aspirating reagents in to microtiter plate wells. Washing, fluid addition and 
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removal from the chamber were carried out when a magnet was applied to the 
chamber to prevent any loss of magnetic beads and there for the ELISA reaction. One 
of the negatives for this assay platform is the detection technology, 3 methods were 
investigated including using an epifluorescence microscope and a custom-made 
spectrophotometer based biosensor (Ellinas et al. 2017). These pieces of kit are bulky 
and are not fully integrate able with the microfluidic chip.  
While many of the microfluidic devices achieve a more rapid and, in terms or reagent 
use, are more cost-effective ELISA tests compared to the standard micro well plate 
test the devices themselves are intricate and are not straight forward to manufacture. 
Many also require the use of external pumping system and bulky detection equipment 
which can increase the cost and prevent or complicate the integration into a 
manufacturing process. From a manufacturing industry perspective, the ELISA must 
be fit for purpose and fully validated with the intended use in mind, Figure 5 gives an 
overview of factors which need to be considered and processes which need to be 
undertaken to achieve this. One of the key aspects of assay validation is the 
robustness, repeatability and influence on operator effects. The microfluidic assay 
must be easy to use and reliable. Assay failure could be detrimental to a batch run 
when only a small amount of sample is available, and/or there is a short time frame in 
which the measurements can be carried out. 
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Figure 5: Flow chart out lining the development, optimization and validation of 
immune  
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2.7 The microcapillary film 
The microcapillary film (MCF) is a recently developed microfluidic platform with 
hollow capillaries embedded within it, invented by Hallmark et al. (2005). The MCF 
(Figure 6) is produced using a melt extruded method which is not only low cost, but it 
allows flexibility in terms of the number of embedded capillaries and the diameter of 
the capillaries. As a result, many applications for the MCF have been developed 
including a plastic microcapillary flow disc (MFD) reactor. The MFD has been 
utilised for a continuous flow reaction system for organic synthesis which is capable 
of withstanding high temperatures and pressures (Hornung. et al. 2007). The MCF can 
be manufactured from several different polymers, including ethylene vinyl alcohol 
(EVOH). EVOH creates capillary walls within the MCF that are porous, creating the 
options to use the MCF for membrane applications such as filtration and membrane 
bioreactors (Bonyadi & Mackley 2012). However, one of the more relevant 
applications for cell therapy manufacturing is the use of the MCF for immunoassays. 
 
Figure 6: Image of the MCF (Hallmark et al. 2005) 
To date ELISA have been developed for prostate serum antigen the cytokines IL-1β, 
IL-6, IL-12p70 and TNFα in fluorinated ethylene propylene (FEP)-based MCF 
(Barbosa et al. 2014; Castanheira et al. 2015). The method of carrying out such an 
MCF ELISA is explained in detail in Chapter 4 but in brief, a long length of MCF is 
coated with capture antibody and then blocked. The MCF is then cut into small strips 
and placed in a multi-syringe aspirator. All subsequent ELISA steps including wash, 
target protein incubation, and detection steps are carried out by aspirating fluids into 
the MCF. Detection is either carried out using a flatbed scanner or a smart phone 
depending on the format of the assay (Barbosa et al. 2014; Castanheira et al. 2015). 
The assays can be completed in less than 15 mins post addition of the sample and thus 
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far have been aimed at the point-of-care and in-field diagnostics market. With the cell 
therapy manufacturing field needing a platform such as the MCF ELISA examining 
the feasibility of its use for relevant cytokine detection is a logical step (Chapter 4). 
There is also value in exploring the possibility of combining cell culture (in this case 
hMSCs) with the technology of the MCF ELISA, to be able to detect cytokines 
production within the same device (Chapter 5). Using the MCF for adherent cell 
culture applications the suitability of the surface needs to be examined, the 
practicability of administering hMSC into the MCF and the methods used to analyse 
the cells inside the MCF. 
2.7.1 Surface Chemistry of Fluorinated Ethylene Propylene 
FEP is a copolymer of hexafluoropropylene and tetrafluoroethylene it has similar 
properties as poly (tetrafluoroethylene) (PTFE) and a refractive index of 1.338 (Sahlin 
et al. 2002). The refractive index of FEP is close to that of water which is 1.3325, 
making FEP an ideal material to manufacture products from which required optical 
interrogation. Fluorocarbon polymers are inert and hydrophobic; this is due to the 
fluorine carbon bond (F-C) resulting in an overall low surface energy (Kozlov et al. 
2003; Griesser et al. 1991; Shoichet & McCarthy 1991). Hydrophobic surfaces, which 
are a benefit for antibody immobilisation due to hydrophobic interactions are, 
however difficult to block effectively resulting in issues with nonspecific binding. 
This is something which needs to be addresses effectively when using the MCF as an 
ELISA platform (Eteshola & Leckband 2001).  
The hydrophobicity of FEP has been determined using contact angle measurements, 
values reported are over 110º (113.8° ± 0.19 (D Li & Neumann 1992), 117° (Coupe & 
Wei Chen 2001) and 115° (Shoichet & McCarthy 1991)). It has been reported that 
surface roughness can increase the hydrophobicity of fluoropolymers and that adding 
roughness can be achieve in many ways including simply stretching a film made from 
the polymer (Ma & Hill 2006). Contact angle measurements are predominantly 
calculated based on Young’s equation (Figure 7), however this equation assumes a 
droplet is being measured on a perfectly smooth ridged surface, on which a maximum 
contact angle of 120° can be measured (Xu & Wang 2010). However, by combining 
chemical composition and surface roughness larger contact angles can be achieve. 
Wenzel and Cassie equation takes into account the roughness of the surface and 
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chemical composition of the surface which is being measured (Figure 7). The 
variation in contact angle of FEP reported in the literature could be due to the 
manufacturing process when making the FEP samples that were tested, irregularities 
in the measurement methods, or calculation of the contact angle. 
 
Figure 7: Young, Wenzel and Cassie models for calculating contact angle based on 
the roughness of the surface (Zhan et al. 2014). 
While for many applications chemical inertness and hydrophobicity are required, for 
cell attachment fluoropolymers are not an optimal surface, this is thought to be due to 
the low surface energy and lack of functional groups (Griesser et al. 1991; Shoichet & 
T. J. McCarthy 1991). There are multiple elements that need to be considered when 
developing a cell culture-based platform made from FEP. The desired properties of 
FEP such as the optical clarity and robustness of the fluoropolymer need to be 
maintained after functionalization. The functionalization process must produce a 
homogenous coating equal or better than current methods used to culture the cell type 
of interest, for hMSCs this is standard tissue culture plastic. It is always desirable for 
the functionalization process to be as inexpensive and as easy to carry out as possible, 
options have been presented that can satisfy these requirements. Once the FEP surface 
has been functionalised it may need to be further optimised in order for cells to adhere 
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and proliferate but any further steps need to comply as much as possible with these 
requirements When modifying FEP for cell attachment the surface energy must be 
increased, essentially reducing the hydrophobicity, but there must be the correct 
functional groups that are optimal for the adhesion of the required cell type(s). The 
extra cellular matrix (ECM) is formed of macromolecules which provided structural 
support to which cells can adhere it also provided functional cues through the cells 
physical interaction with the ECM and spatial relationship to other cells (Liu Tsang et 
al. 2007). Therefore, the ECM plays a critical role in cell function and survival in 
vivo; the requirements for cells to adhere to the ECM in vivo need to be considered 
when culturing hMSC in vitro. 
2.7.2 Current Modification Methods of FEP 
Due to the inertness of FEP, modification of the surface chemistry is most commonly 
achieved either by absorption or using high energy processes to break carbon-fluorine 
bonds and exchange the fluorine atoms with more reactive functional molecules such 
as hydroxyl groups. There are many reasons for the surface of FEP to be modified; 
these include improving wettability, increasing adhesion and biocompatibility 
(Kozlov & McCarthy 2004). For example, Ranieri et al (1995) utilized a 
radiofrequency glow discharge (RFGD) method when modifying FEP for neuronal 
cell attachment. Once the surface was modified with hydroxyl groups, laminin 
derived oligopeptides were introduced to the surface, a region of the peptide reacted 
with the hydroxyl group via a nucleophilic substitution reaction resulting in the 
peptide being immobilized on the FEP surface (Ranieri et al. 1995). This method 
enabled successful neuronal attachment, but it limited by the lack of control over the 
fluorine/hydroxyl group exchange which can result in a heterogeneous surface 
modification. RFGD can also not effectively be applied to FEP surface that difficulty 
to access such as the inside of a microcapillary tube.  
There are a number of polymers which have been investigated to coat fluoropolymers 
and other hydrophobic materials in order to functionalize the surface. Poly-L-Lysine 
(PLL) and Poly-D-Lysine (PLD) are common coatings used to coat tissue culture 
plastic to promote cell attachment and growth (Harnett et al. 2007; Qian & Saltzman 
2004; Mazia 1975; Quirk et al. 2001). PLL promotes cell adhesion through non-
specific electrostatic interactions of the polycation with the negative charges of the 
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cell membrane (Quirk et al. 2001; Harnett et al. 2007). It has also been shown that 
PLL is able to absorb onto FEP under certain conditions (Shoichet & T. J. McCarthy 
1991). Shoichet & McCarthy (1991) showed that PLL could absorb onto the FEP 
surface but only if a high enough molecular weight and when the PLL polymer is 
used at approximately pH11. At pH11, the PLL is thought to form a α-helix this 
structure along with the decrease in interfacial free energy drives the absorption of 
PPL to FEP (Shoichet & McCarthy 1991). 
Poly-vinyl alcohol (PVA) has been shown to be absorbed from aqueous solution on to 
hydrophobic surfaces and successfully reduce the hydrophobicity of the surface 
(Kozlov & McCarthy 2004). PVA is unusual as it is both an atactic and semi 
crystalline polymer, properties which are thought to be why it can be absorbed onto 
hydrophobic surface. PVA contains reactive hydroxyl groups which results in similar 
surface chemistry as (John P. Ranieri et al. 1995) in terms of reactive functional 
groups.  
Exactly how the absorption of PVA onto a hydrophobic surface is driven is still 
unclear but due to PVA having atactic and semi crystalline properties it is thought the 
process at the aqueous/sold interface is hydrophobic interaction driven resulting in 
absorption/crystallization of PVA at the aqueous/solid surface (Kozlov & McCarthy 
2004). Kozlov et al. (2003) have stated that the molecular weight and degree of 
hydrolysis have been shown to have an effect. Kozlov et al. (2003) have shown that a 
higher molarity of PVA solution results in a thicker layer of coating, the outcome of 
which is a greater reduction of contact angle. The absorption capacity of a 
hydrophobic surface has been shown to plateau at 24h hours and no de-absorption of 
the subsequent PVA layer occurred after fourteen days in water (Coupe & Wei Chen 
2001; Kozlov & McCarthy 2004). PVA has been shown to be irreversibly absorbed 
onto FEP after 96hrs (Wei Chen 2003). Though Kozlov et al. (2003) did investigate 
the effect of molecular weight on PVA absorption other studies did not justify the use 
of specific molecular weights for example Wei Chen (2003) only uses PVA with a 
molecular weight of 108,000.  
PVA has been shown to absorb onto FEP but there is also evidence that PVA is not an 
optimal polymer for cell attachment. While FEP is too hydrophobic, PVA is 
considered too hydrophilic for cell attachment (Liu et al. 2009) and has been 
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presented to not support the adhesion and growth of a number of cell types 
(Zajaczkowski et al. 2003). The surface characteristics required for cell adhesion does 
vary depending on cell type (Rosso et al. 2004; Harnett et al. 2007; Trappmann et al. 
2012) but for hMSCs there are no specific studies to show how well hMSCs adhere to 
and expand on PVA. 
PVA is used to make hydrogels and electro spun scaffolds as it is a biocompatible and 
porous polymer that can mimic some of the in vivo architecture of the human body 
(Zajaczkowski et al. 2003; Song et al. 2012). To be able to overcome the inability for 
cells to adhere directly to PVA, studies have either mixed (ECM) mimicking 
macromolecules with the PVA in aqueous solution or functionalised the PVA surface 
with ECM proteins (Liu et al. 2009; Zajaczkowski et al. 2003; Song et al. 2012). 
Gelatin is a commonly used tissue culture coating; it is denatured collagen and is 
there for cheaper and easy to use than the structurally integral collagen (Paguirigan & 
Beebe 2006). 
2.8 Angiogenesis, bioassays and hMSCs 
There are many physiological processes which hMSC can influence with in the body 
through paracrine effects, immunomodulation has been previously discussed. There 
are conditions which require the processes of angiogenesis to be stimulated or 
controlled such as post ischemic injury and there are reports that hMSC may be able 
to accomplish this (Russo et al. 2014). Angiogenesis is the formation of new blood 
vessels that sprouting from existing blood vessels, blood vessels are critical for 
supplying oxygen and nutrients to cells and tissues, as well as removing cellular waste 
(Nakatsu et al. 2003; Ishak et al. 2014). The actual process of angiogenesis is a multi-
step and tightly controlled biological procedure through pro- and anti-angiogenic 
factors that involve the endothelial cells (ECs) which, form the parent vessel, being 
stimulated to sprout and form new vasculature (Nakatsu et al. 2003). Angiogenesis is 
vital for tissue survival, however angiogenesis can also be damaging to tissues when 
not tightly regulated which is part of the pathophysiology of tumour formation (Walsh 
2007). Activating and controlling angiogenesis has several potential therapeutic 
applications ranging from restoring blood supply to damaging tissue in vivo to 
forming new vasculature in tissue engineered products. Angiogenesis is such a critical 
process and though the process and be studied extensively the complexity and 
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involvement of multiple dependant and independent factors mean information in the 
field is continuously being updated (Richarz et al. 2017). 
Fundamentally angiogenesis progresses when the ECs are stimulated and some of the 
ECs lining the blood vessel act as tip cells (TCs), the TCs react to gradients of 
signalling molecules within the microenvironment via filopodial extensions (Herbert 
& Stainier 2011). Filopodials are thin extensions of the plasma membrane which 
contain a high proportion of actin (Mattila & Lappalainen 2008), via filopodial 
sensing migration of the TCs can be guided (Gerhardt et al. 2003). As the TCs 
migrate into the interstitial space they are trailed by other ECs that have been 
stimulated to become stalk cells (SCs), SCs maintain the connection between the 
parent vessel and the sprouting vessel. The process of elongation and migration of the 
TCs and SCs is halted when the TCs make contact with other ECs and the 
mechanisms of anastomosis are initiated (Gerhardt et al. 2003). A summary of this 
process can be seen in Figure 8 which has been minimally adapted from 
Francavilla et al. (2009). 
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Figure 8 The process of EC activity during angiogenesis (Francavilla et al. 2009) 
There are many factors which have been shown to play a role in positively or 
negatively regulating angiogenesis through intracellular communication. These 
include but are not limited to; angiogenin, angiopoietins, fibroblast growth factors 
(FGFs), hepatocyte Growth Factor (HGF), IL-8, platelet derived growth factor 
(PDGF), placental growth factor (PIGF), TGF-β, Vascular endothelial growth factors 
(VEGFs), endostatin, IL-12 and platelet factor 4. Signalling pathways such as the 
Filopodials 
Stalk cells 
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notch signalling pathway also play a role in the regulation of angiogenesis via ligand-
receptor binding. (Rehman & Wang 2006). Ligands and receptors expressed on the 
surface of the cells allow signals to be exchanged between neighbouring cells, this 
signals can be modulated and thus control the fate of the cell 
(Ahmed & Bicknell 2009). 
Direct cell-cell interactions have a function within angiogenesis, however, hMSC are 
thought to primarily have an effect on angiogenesis due to the aforementioned 
secreted factors. VEGFs are part of the PDGF family, the VEGF family of cytokines 
and receptors play a key role in angiogenesis (Shibuya 2009). Five isoforms of 
VEGF, VEGF-A, B, C, D and E, have been identified, VEGF-A has been shown to 
play the key role in the regulation of angiogenesis(Shibuya 2011; Herbert & Stainier 
2011). Many publications when using the term VEGF are referring to VEGF-A 
specifically. VEGF-A binds and activates two tyrosine kinase receptors, VEGFR-1 
[Flt (Fms-like tyrosine kinase)-1] and VEGFR-2 [KDR (kinase insert domain 
receptor) (Shibuya 2009). VEGF-A has been shown to have a higher binding affinity 
to the VEGFR-1 receptor however the strength of the tyrosine kinase activity is 
greater via the VEGFR-2 receptor, triggering of the tyrosine kinase activates 
downstream signal transduction mechanisms that regulates ECs migration and 
proliferation and the initiation of the filopodial formation (Cross & Claesson-Welsh 
2001) VEGF is the main cytokine investigated when developing strategies to target 
angiogenesis in tumour formation and therefore preventing the tumour from growing 
and surviving (Chuang et al. 2014).It was originally thought the VEGF receptors were 
only found on the surface on ECs making VEGF an ideal target to inhibit in order to 
supress tumour growth, however evidence is being found that other stromal cells also 
express these receptors (Duffy et al. 2013). 
The proliferative effect of VEGF-A occurs in SCs, proliferation of the SCs is 
dependent on the concentration of VEGF-A, however TCs also respond to VEGF-A, 
but this response is gradient dependant (Herbert & Stainier 2011). FGFs have been 
shown to have an important role in angiogenesis, within the FGF family 22 ligands 
and 4 receptors have been identified (Presta et al. 2005; Yancopoulos et al. 2000; 
Ornitz et al. 1996). There are a number of mechanisms through which FGFs invoke 
angiogenesis these are primarily by stimulating tyrosine kinase receptors, heparan-
sulfate proteoglycans, and integrins which are present on the surface of the 
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endothelial cells lining blood vessels (Presta et al. 2005). Acidic FGF (aFGF, also 
known as heparin binding growth factor 1 or endothelial cell growth factor) and FGF 
basic (also known as bFGF or heparin binding growth factor 2) are thought to be of 
particular importance for angiogenesis (Chen & Forough 2006; Ornitz & Itoh 2015).  
Both VEGFs and FGFs can stimulate the endothelial cells to secrete molecules such 
as proteases such as metalloproteinases which in turn degrade the surrounding ECM 
(Herron et al. 1986). This then provides a region where the TCs can invade 
(Presta et al. 2005). There is also thought to be cross talk between FGFs and VEGFs, 
although the exact mechanisms are not fully understood (Presta et al. 2005). Work by 
(Murakami et al. 2011) provides strong evidence that the maintenance of the VEGFR-
2 receptor independent on FGF via the activation of transcription factors, as VEGFR-
2 has been shown to be the strong activator of the tyrosine kinase pathways 
deactivation of this receptor results in a reduction of the effect of VEGF-A. Therefore, 
successful initiation and speed of angiogenesis is not solely dependent on the levels of 
VEGF-A but also FGF. In fact too much VEGF-A would result in over 
vascularisation of tissues which is why VEGFR-1 receptors function is so important 
as it is able to act as a sink for excess VEGF-A without producing such a strong 
intracellular signal (Lieu et al. 2011). 
While VEGFs and FGFs play key roles in initiation of angiogenesis, other factors are 
also involved in the recruitment of ECs to the newly forming vessel and the 
maintenance of the vessel. IL-8 is a member of the chemokine family and is a key 
factor in capillary tube organisation (Li et al. 2003). IL-8 binds to CXCR1 and 
CXCR2 receptors which can be found on ECs cells, CXCR1 and CXCR2 are G-
coupled protein receptors (Heidemann et al. 2003a). Li et al. (2003) have shown the 
ECs cultured in IL-8 spiked medium has a higher proliferation rate and that when IL-
8 activity is blocked in a tube formation assay capillary like structures fail to form. It 
should be noted that the tube/branch formation assay used in this work was only 
imaged after 6hrs therefore it cannot be determined if capillaries were formed and 
then degraded due to the absence of IL-8 activity. 
PDGF is another cytokine involved in angiogenesis, however it does not have a direct 
action ECs to form new vessels, instead it up regulates VEGF, and in conjunction 
with VEGF and FGF-basic aid the recruitment of other cell types to mature the newly 
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formed vascular structure (Raica & Cimpean 2010). It has been demonstrated that 
PDGF-AA specifically dominates the VEGF regulation in angiogenesis, making 
PDGF-AA an essential autocrine regulator of VEGF and therefore angiogenesis 
(Shikada et al. 2005). 
HGF, also known as Scatter Factor, is considered to be a potent mitogen. VEGF and 
HGF have been shown to activate distinctly separate signalling pathways but when 
combine both factors create a potent proliferative effect on ECs through the up 
regulation of a number of other growth factors and receptors (Gerritsen et al. 2003; 
Gerritsen 2005).  
2.8.1 Angiogenesis bioassays  
To study angiogenesis at the research level there are a variety of in vivo and in vitro 
bioassays. The in vivo assays involve the uses of animal models which are costly, 
time consuming and subject to ethical regulation, therefore relevant in vitro  bioassays 
are more commonly used (Bischel et al. 2013). Many of the bioassays carried out in 
vitro need to replicate in vivo angiogenesis events involving ECs where factors such 
as ECM need to be considered. In vivo ECs are in contact on the basal (non luminal) 
surface with a thin, highly specialized ECM: the basement membrane. This matrix 
forms a continuous sleeve around the endothelial cells, and maintains the tube-like 
structures of the blood vessels. (Arnaoutova et al. 2009).The branch formation assay 
is one of the most popular surrogate angiogenesis assays used, measures the ECs 
ability to form capillary like structures. When carrying out the branch formation assay 
the ECM needs to be recreated in vitro usually by coating a microtiter plate with 
basement membrane proteins such as matirgel and Geltrex (Kleinman & Martin 
2005). Coating the microtiter plate out manually the surface smoothness can be 
inconsistent which impacts the quality of the image however whether it impacts the 
function of the assay has not been established, but this is something which needs to be 
taken into consideration. In a branch formation assay disintegration of the ECM to 
prepare space for ECs to migrate into doesn’t occur as the cells are in a single cell 
suspension. Post attachment to the ECM it is the motility, elongation of SCs and the 
maintenance of the structure which can be studied using the branch formation 
assay(Arnaoutova et al. 2009).  
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The angiogenesis assay is a useful tool to measure hMSC potency on ECs in vitro. 
While it could be used as a screening tool for hMSC cell donors to determine if the 
cells will function to the required level, it is not the optimal assay to be carried out in 
parallel with the hMSC scale up culture. Many of the measurements are taken 
between 4-8hrs after hMSC conditioned medium has been applied (Donovan et al. 
2001; Lehman et al. 2012). Within this time the expression profile may have change 
in the cell culture which many have a different angiogenic effect.  
2.8.2 hMSC cytokines relevant to angiogenesis  
Many of the cytokines involved in angiogenesis have be shown to be secreted by 
hMSC, hypoxia has also been shown to improve the levels of angiogenic cytokines, it 
is well established in tumour angiogenesis that the process of established a blood 
supply in stimulated by the hypoxic tumour environment (Neufeld & Kessler 2006) 
Five cytokines know to have a functional role in angiogenesis have been proposed to 
be further investigated in this work, in terms of optimal combined potency are; 
vascular endothelial growth factor A (VEGF-A), basic fibroblast growth factor 
(bFGF), hepatocyte growth factor (HGF), platelet-derived growth factor (PDGF-BB) 
and Interleukin 8 (IL-8) /CXCL8 (Heidemann et al. 2003b; Kaga et al. 2012; 
Boomsma & Geenen 2012; Kwon et al. 2014b). IL-6 is also often analysed in 
experiments relating to angiogenesis. It is a multifunctional cytokine involved in 
immune regulation, haematopoiesis and inflammation (Fan et al. 2008). Although it is 
relevant to the angiogenesis work due to its multiple functions it lacks a strong single 
association to angiogenesis when in a multi-tissue environment (Tran & Damaser 
2014).  
Findings from a few studies detailed below are an example of the lack of continuity in 
the area of cytokine induced angiogenesis research. The culture methods vary in 
seeding density, FBS concentration and length of conditioning time, as well as the 
detection methods. Some of these issues have been highlighted by Ranganath et al. 
(2012), hypoxic preconditioning effects are also not well understood as well as being 
able to optimize the effect of hypoxia in terms of optimal cytokine secretion for an 
optimal duration. A number of methods have been used to determine the levels of 
cytokines secreted by hMSCs for angiogenesis applications in a variety of culture 
conditions. The methods used include antibody arrays, gene expression and ELISAs. 
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Kinnaird et al. (2004) conducted a broad-spectrum analysis of the cytokine coding 
genes that are expressed by hMSCs using the Affymetrix GeneChip platform. ELISAs 
were also carried out to determine the secretion levels of VEGF, bFGF, IL-6, PIGF 
and MCP-1. hMSCs were cultured for 72hrs in normoxic (20% oxygen) or hypoxic 
(1% oxygen) conditions, but seeding density was not stated. For the GeneChip array 
8µg of total RNA was used to synthesize cDNA, HGF and PDGF showed no 
significant increase in hypoxic conditions (a >1.5 fold change was considered 
significant). However, VEGF-A gene expression increased 2.47 fold in hypoxic 
conditions compared to normoxic and bFGF showed a 1.62 fold increase, IL-8 results 
were not reported. The ELISAs were carried out using hMSC conditioned medium 
which was collected after 24hrs of culture. After collection the cells were lysed and 
total protein concentration determined, ELISA values were corrected for total cell 
protein. Five cytokines including VEGF, bFGF, and IL-6 were measured using 
sandwich ELISA kits from R&D systems. The reported level of VEGF-A, bFGF, and 
IL-6 secretion for normoxic and hypoxic (1% oxygen) are summarised in Table 1. 
The increase levels of cytokine detected corresponds to the gene expression results 
(IL-6 had a 2.26 fold increase in hypoxic conditions). 
Table 1 Summary of VEGF, bFGF and IL-6 cultured under normoxic and hypoxic 
conditions from work carried out by Kinnaird et al. (2004). 
Cytokine Normoxic 
(pg/ml) 
Hypoxic (1% O2) 
(pg/ml) 
VEGF 375 698 
bFGF 2320 3970 
IL-6 3885 7665 
 
Kagiwada et al. (2008) investigated hMSC VEGF production in vitro and in vivo 
using both ELISA and an Angiogenesis Antibody Array I (RayBiotech, Norcross, 
GA, USA). Results for the array were based on presence/absence of spots or intensity. 
ELISAs were used to determine in vitro VEGF secretion over 9 passages (P2-P10) 
from 3 different donors. Cells we seeded at P2 with a density of 4x105 cells/100mm 
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culture dish, culture medium was collected after 3 days, and the cells we then 
passaged and reseeded at the same density. The procedure was repeated until P10. 
VEGF secretion levels across all passages and donors ranged from 300pg/ml/106cells 
to 850pg/ml/106cells. To measure VEGF production in vivo hMSCs were seeded on to 
hydroxyapatite discs at passage 2 with a density of 2.5x105 cells/disk. The disks were 
implanted into the backs of mice and harvested after two or four week. VEGF 
production was estimated by grinding down the implants and separating the 
supernatant, the supernatants were then used for ELISA assays. The VEGF levels 
after 2 weeks’ implantation were 49.4±3.81 pg/implant and 43.9±6.08 pg/ implant at 
4 weeks. 
Park et al. (2009) cultured hMSCs under standard culture conditions at a density of 
2x103/cm2 cells, cells and medium were collected and the early 3rd passage. The 
culture medium was diluted either 4 or 20-fold and then applied to Human Cytokine 
Arrays VI and VII (Ray Biotech Inc, Norcross, GA), detection was by enhanced 
chemiluminescence captured on X-ray film. Semi- quantification was conducted 
using the average gray-scale of the positive control and negative controls to 
normalise. Expression levels were reported as average intensity: PDGF-BB as 6.5, 
HGF as 21.9, IL-8 as 112.5 and bFGF 10.5. The paper reported array intensities of 
60.3 and 26.9 for VEGFB and VEGFD respectively but did not report finding from 
VEGF-A which is considered the most influential and most studied form of VEGF  in 
angiogenesis (Lehman et al. 2012). The study does not provided fully quantitative 
data  
Kwon et al. (2014) used hMSCs from a number of donors at passage 5 and seeded 
them at 1.6x106 cells in 1 T-175 (density of 9.1x103/cm2), the cells were cultured in 
DMEM completed with 10%FBS. To condition the medium after 24hrs the cells were 
washes with PBS and the medium was replaced with DMEM containing 1% FBS and 
incubated for 72hrs. The conditioned medium was then tested for the presence of 
seven growth factors and cytokines Including VEGF, HGF, IL-6 and PDGF-AA. The 
level of VEGF measured ranges from 336.1 ± 11.1 (pg/ml) to 428.2±30.1 (pg/ml), 
PDGF-AA was 2.5±0.8 (pg/ml) to 3.1±1.1 (pg/ml), HGF 169.7±18.0 (pg/ml) to 
283.5±26.6 and IL-6 28.0±0.7 (pg/ml) to 71.0±2.7 (pg/ml).  
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It is difficult to draw direct comparisons from these studies, each used different 
culture containers, densities and detection methods. It highlights a more wide spread 
issue in the field that it is not always possible to draw conclusions based on work 
from multiple research groups, therefore conclusions can only be specific to a small 
subset of experimental parameters which may not be applicable to commercial 
applications. There is also significant number of cytokines that are produced by 
hMSCs with up to 120 being identified (Park et al. 2009) yet not all will have a 
significant role in angiogenesis. The aforementioned studies look at a number of 
cytokines know to be secreted by hMSCs and play a role in inducing angiogenesis 
however the studies have only chosen a small number of cytokines for example Kwon 
et al. (2014) only looked at PDGF-AA but PDGF-BB and PDGF-AB which have 
been shown to have a role in angiogenesis (Yancopoulos et al. 2000; Boomsma & 
Geenen 2012; Vertelov et al. 2013). It has been determined that IL-8 has an 
angiogenic effect (Petzelbauer et al. 1995; Heidemann et al. 2003b) and is secreted 
hMSCs (Park et al. 2009) but it is not as well reported in the area of hMSC induced 
angiogenesis as VEGF. It is a large undertaken to define the CQA needed in an hMSC 
population to induce the MOA required, the task is complicated as the full 
angiogenesis mechanisms are not completely defined.  
Looking at cytokine detection form the perspective of hMSC manufacturing the 
sample preparation methods and relevance need to be considered. For example in the 
work carried out by Kinnaird et al. (2004) the cells were lysed to determine cytokine 
levels, intracellular cytokine production is not relevant when using CTP or analysing 
how much hMSC produce as the cytokines need to be secreted in order to invoke an 
effect. Extra sample preparation steps also increase the time taken for analysis and 
maybe a hurdle to online or inline product analysis. 
Bioanalytical methods need to improve in order for more cell therapy products to 
satisfy safety and regulatory requirements, successfully bringing much needed 
treatments to the market. The issues which have been mostly spoken about in the cell 
therapies context are also applicable to the wider regenerative medicine field. 
Microfluidics is a promising filed which can address many of the cost and time 
challenges associated with currently used bioanalytical methods. However, as many 
of these devices intricate devices are at the research stage it is yet to be determined if 
the devices can be reliably and cost effectively manufactured. As cytokine expression 
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is a key element of hMSCs regulating biological processes immunoassays are of 
particular importance in the bioanalytics needed for hMSC. Bioassay give a greater 
insight into physiological effects of hMSC, angiogenesis is the main bioassay focus of 
this review. As it is not feasible to run a bioassay inline or online with the cell 
manufacturing process they could be used to determine the cytokine panel and 
respective ranges needed to achieve a specific level of angiogenesis. The cytokines 
could then be measured in parallel to the culture process using rapid microfluidic 
detection methods such as the MCF ELISA, giving close to real time values. Real 
time values enable a more reactive manufacturing process; if the levels of cytokines 
are not being reached the manufacturing process can be ended saving time and 
money. From another perspective if a donor cell population reach the required values 
more rapidly than anticipated the treatment can be administered to the patient sooner. 
2.9 Aims and objectives 
The aim of this work was to examine the culture conditions of hMSCs and the effect 
of the culture environment on the promotion of angiogenesis by using a surrogate in 
vitro bioassay. This work aimed to identify the challenges of studying this therapeutic 
application and proposes the utilisation of microfluidics to overcome these challenges. 
2.9.1 Objectives 
• Determine the impact on the secretome profile of five cytokines when 
culturing hMSCs from four donors at three different atmospheric oxygen 
concentrations and cultured over 3 passages by analysing the conditioned 
culture medium. 
• Improving the amount of data obtained when analysing hMSCs functionality 
in relation to angiogenesis using an in vitro bioassay and assessing the 
challenges of using this assay. 
• Assess the levels of relevant pro-angiogenic cytokines present in the 
conditioned medium used in the bioassay. Determine the relationship between 
these levels and the data obtained from the angiogenesis bioassay. 
• Evaluate the feasibility of using a microcapillary film (MCF) based enzyme-
linked immunosorbent assay (ELISA) for the detection of the cytokines 
previously measured.  
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• Adapt the MCF to facilitate the culturing of hMSCs with a view to develop an 
all in one pre-screening tool for hMSC function or a hMSC based assay.  
• Identify the overarching issues of culturing hMSCs to be used in cell therapies 
through a review of the literature and lessons learnt during the experimental 
studies of hMSC. 
2.9.2 Hypothesis 
Hypothesis 1: The hMSCs secretome profiles of VEGF-A, bFGF, HGF, PDGF-BB 
IL-8 /CXCL8 exhibited the same trends under three different atmospheric oxygen 
concentrations independent of the cell donor. 
Hypothesis 2: Translating a plate-based ELISA assay into an MCF based microfluidic 
platform reduces the time between the addition of sample to result.  
Hypothesis 3: The surface of FEP can be modified to improve the culture of viable 
hMCS. 
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3 Manufacturing of hMSCs for pro-
angiogenic therapies 
3.1 Introduction 
With the use of hMSCs for promoting angiogenesis in diseased tissue and engineered 
tissue further knowledge is required to understand the consistency of hMSC 
behaviour between donor populations. Angiogenesis activity is accelerated in oxygen 
environments below normal physiological levels. A condition which tumour 
formation takes advantage of (Krock et al. 2011), but which is also looking to be 
exploited in the development of new therapies. Most hMSC culturing methods are 
carried out at atmospheric oxygen conditions however this is not truly representative 
of the oxygen levels the cell are exposed to in vivo as dissolved physiological oxygen 
concentration is less than the atmosphere (Rosová et al. 2008). Work has been carried 
out in the area of hMSC preconditioning at lower oxygen levels to improve hMSC 
performance for a variety of treatments including treating ischemia through 
promoting angiogenesis (Mirotsou et al. 2011), however little has been done 
identifying the challenges of bring consistent hMSC treatments to market. This 
Chapter explores the variation between four hMSC lines obtained from four different 
donors over three passages cultured in 3 different oxygen environments atmospheric, 
5% oxygen and 2% oxygen. This study also examines the methods used to determine 
the angiogenic capacity of hMSCs via the application of an angiogenesis bioassay. 
While hMSC are the cell type used many of the lessons learnt are applicable to other 
cell types and bioassay in terms of the methods used to obtain samples for analysis, 
the handling of the samples and the analysis of the data. The donor variation is 
investigated from the point of view of hMSCs promoting angiogenesis via cytokine 
production. There is a plethora of research aiming to ascertain the paracrine effects of 
hMSCs on a number of biological processes including immune regulation, 
neurogenesis and angiogenesis (Doorn et al. 2012; Bang et al. 2005; 
Liang et al. 2014). The mechanisms involved in processes such as angiogenesis are 
complex involving feedback mechanisms, other cell types and signal cascades (as 
mentioned in Chapter 2, Section 2.8), therefore there is yet no single indicator that an 
hMSC line will invoke the required signalling for successful angiogenesis. There is 
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more than likely a combination of factors which need to be measured in order to have 
a truly reliable and predictable profile. 
As discussed in the literature review (Section 2.6.1) there are several hMSC based 
treatments currently in trials being used to treat patients with a variety of conditions 
including those with cardiac tissue damage induced by myocardial infarction where 
the hMSCs ability to stimulate angiogenesis is believed to be a key factor in its MOA. 
However success has varied (Suna Wang et al. 2015) which may be due to a number 
of reasons including that many of the treatments use autologous hMSC and therefore 
the starting material is not consistent in every treatment. The response of the patients’ 
cells in vivo to the cytokine stimulation may vary between patients with some patients 
requiring higher concentrations of some cytokines compared to others. The variation 
of patient response to the same treatment has given rise to the concept of precision 
medicine, where by treatments need to be tailored to the individual not to the majority 
(Collins & Varmus 2015). There is  currently only defining criteria for hMSC cell 
identity (Rasini et al. 2013) but not criteria for a hMSC cell line that will guarantee 
the promotion, to the required level, of angiogenesis in vivo. Consequently, pre-
screening hMSC should be a requirement and data obtained for the individual donors 
regarding the secretome profile of the hMSC line also collected. As well as donor 
variation the impact of cell treatment post thaw and atmospheric culture conditions 
were also investigated. The impact of cold shock during the cryopreservation of cells 
has been shown to effect the growth rate recovery time posy thaw (Xu et al. 2012), 
therefore it is important to determine if this also effects the cells ability to secrete 
cytokines. There is evidence that by reducing the atmospheric oxygen levels during 
hMSC cell culture cell growth and stability increases (Estrada et al. 2012). In cancers 
angiogenesis is stimulated by the hypoxic conditions, hMSC have also been shown to 
increase the production of some cytokines most notably VEGF in hypoxic conditions 
(Potier et al. 2007). Thus culturing of hMSC in lower oxygen environments is not 
only relevant to mimic physiological conditions but the environment may also 
enhance the angiogenic potential of the cells. Post thaw recovery and controlling 
culture conditions are central features of cell therapy manufacturing, therefore any 
improvements or adverse effects of these processes needs to be established, including 
whether those effects are donor specific or a constant affect across all lines. 
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Five cytokines PDGF-AA, FGF-basic, IL-8, VEGF and HGF; that have been shown 
to be involved in angiogenesis and have been previously shown to be produced by 
hMSCs (Boomsma & Geenen 2012; Bronckaers et al. 2014) were screened for in 
hMSC conditioned medium using Luminex technology. Four different hMSC donor 
lines were used to produce conditioned medium. As hypoxia has also been shown to 
increase the levels of proangiogenic cytokines (Potier et al. 2007), therefore all four 
hMSC lines we cultured in 2% oxygen, 5% oxygen environments and compared to 
controls cultured at atmospheric oxygen levels. The 5% atmospheric oxygen 
environment is also considered to be more relevant as a hypoxic chamber was not 
available the cultures were carried out in an oxygen level controlled incubator 
Investigating the effects of hypoxia provides important information on the cell 
behaviour from a manufacturing point of view and a treatment point of view. From a 
manufacturing perspective controlling the oxygen levels could be a low cost method 
of increasing cytokine yield when manufacturing hMSC, however the yield from the 
system as a whole needs to be considered. While reducing oxygen levels in the 
manufacturing system could increase the per cell yield, this gain could be 
counteracted with a reduction in cell growth. Physiological oxygen levels depending 
on the tissue type can range from 1-11% (Carreau et al. 2011), therefore, if hMSCs 
are administered directly as a treatment the secretome profile at lower oxygen levels 
in important. When administering hMSC to a tissue that requires improved 
vasculature the oxygen environment of that tissue is below normal physiological 
oxygen levels as the tissue is usually ischemic (Suna Wang et al. 2015; Anderson et 
al. 2016)hence differences in branch formation and cytokine secretions across a range 
of oxygen concentrations needs to be investigated. 
Conditioned medium samples were run on an in vitro HUVEC based branch 
formation assay (also called tube formation assay) to determine the angiogenic effects 
of the conditioned medium (Arnaoutova et al. 2009). The branch formation assay 
allows many of the processes of angiogenesis to be studied as a whole as opposed to 
individual steps these processes include cell adhesion, migration, alignment which 
result in overall branch formation followed by degradation of the branches which is 
an indicator of protease activity. The branches form capillary like network and are 
therefore an indicator on how well the conditioned medium/lines will perform in vivo, 
all though true in Vivo performance is only truly known when live animal studies 
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have been conducted. The branch formation assay has been used is tandem with in 
Vivo animal studies and is considered to be a realistic representation of in Vivo 
activity (Donovan et al. 2001; Lehman et al. 2012). 
This Chapter aims to determine the PDGF-AA, FGF-basic, IL-8, VEGF and HGF 
secretome profile in four hMSC lines (M2, M3 M6 and Rooster); in standard culture 
conditions compared to 2% and 5% oxygen culture conditions. Fresh medium was 
added to the cells on day 3 of culture and conditioned for 48hrs. Using conditioned 
medium from hMSCs is a cost effective method of delivering paracrine factors to a 
patient. This approach negates the regulatory and safety hurdles of delivering live 
cells to a patient and has a simpler route to market compared to live cells, as biologics 
are a common pharmaceutical treatment. Therefore the experimental protocol was 
designed to reflect a realistic treatment option, but insight into live hMSC treatments 
was also gained. The age of the cells is also being investigated to determine if potency 
changes as the passage number increases and impact of post thaw recovery. The 
impact of lower oxygen levels on the secretome profile and variation at lower 
atmospheric oxygen levels across all three passages compared to standard oxygen 
conditions is also examined. 
3.2 Materials and Methods 
3.2.1 Materials  
Low glucose Dulbecco's Modified Eagle Medium (DMEM), phosphate buffer saline 
(PBS) Bone marrow derived human Mesenchymal stem cells (hMSCs), ultra 
glutamine 200mM were purchased form Lonza (Slough, UK). Fetal Bovine Serum 
(FBS), Trypsin 0.25% (1X) Solution with 0.1% EDTA, human Umbilical Vein 
Endothelial cells (HUVECs), Medium 200PRF, Low Serum Growth Supplement, 
Geltrex lactose dehydrogenase elevating virus -free reduced growth factor basement 
Membrane Matrix, Trypsin/Neutralising Solution and Suramin, hexasodium salt 
StemPro osteogenesis, adipogenesis and chondrogenesis differentiation medium kits 
were procured from ThermoFisher Scientific (Paisley, UK). NucleoCounter® 
NC-3000 and Via1-Cassett were obtained from Chemometec (Allerod, Denmark). A 
Galaxy 107R CO2 incubator with oxygen sensor was purchased from Eppendorf UK 
Limited (Stevenage, UK). Silver nitrate solution (2.5% solution) naphtol AS-MX 
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phosphate alkaline solution, Fast Violet B salt grade III, Oil Red O powder, Alcian 
blue powder; fixation buffer (4% para-formaldehyde), 0.1 N Hydrochloric Acid 
(HCl), and 99% isopropanol were brought from Sigma (Dorset, UK). Luminex assay 
kits (LXSAHM-05) with analytes: CXCL8/IL-8 (BR18) FGF basic (BR47) HGF 
(BR66) PDGF-AA (BR56) VEGF (BR26) purchased from Bio-Techne, (Abingdon, 
UK). Biostation CT was manufactured by Nikon Instruments Europe and Nikon CL 
Quant software (Amsterdam, Netherlands). CD73 (PE-Cy7), CD90 (APC), CD105 
(PE) and HLA-DR (FITC) antibody conjugates were purchased from BD Biosciences 
(UK). 
3.2.2 Cell Culture 
Human mesenchymal stem cells were cultured in low glucose DMEM supplemented 
with ultra-glutamine 2nM and 10% v/v fetal bovine serum (FBS). Cells were seeded 
in T25 flasks at a density of 5000 cells/cm2 and cultured in 5mls medium for five days 
with a medium change on day three. Cell cultured was carried out at 37°C, 5% carbon 
dioxide with 95% humidity and either 2%, 5% or atmospheric oxygen levels. At 
separate times two vials for each line were thawed, each vials was divided between 8 
T25 flasks, 4 flasks from one vial were cultured at 5% oxygen and the other 4 flasks 
from the same vials cultured under atmospheric oxygen as the control condition. This 
process was repeated for the second vial and the experimental condition was 2% 
oxygen.  
Cell passage was undertaken on day five; all medium was aspirated and placed in a 
sterile centrifuge branch then frozen for later use. The flask gently washed with PBS 
added at a volume 0.2ml/cm2 then aspirated. Cells were detached using trypsin 0.25% 
(1X) solution with 0.1% EDTA at a volume of 0.04ml/cm2, the cells were incubated 
with the trypsin solution at 37°C for 3-5mins; detachment was checked visually using 
an inverted light microscope. The trypsin was inactivated by quenching with the cell 
culture medium. The cell suspension was aspirated into a centrifuge branch; 0.5ml 
removed to an eppendorf branch for cell counting. The centrifuge branch was 
centrifuged at 220g for 5 minutes, the supernatant aspirated away and the cell pellet 
re-suspended in the culture medium. Cells were seeded on a new surface at a density 
of 5x103/cm2 with a culture medium volume of 0.2ml/cm2. 
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Cells from four donors were cultured in this work labelled M2, M3, M6 and Rooster, 
these were internal cell donor labels. 
3.2.3 Branch formation assay  
Geltrex was treated as per manufactures instructions, 95µl was used per well to coat 
wells in a 24 well plate, then placed in an incubator for 30mins at 37ºC. The 
previously collected hMSC medium was thawed in a water bath at 37 ºC. Containers 
were inverted for mixing and 1ml of conditioned hMSC medium was added to each 
well and placed in incubator at 37ºC. HUVEC cells were seeded in a T75 at a density 
of 2.5x103/cm2, cultured in M-200 supplemented with LSGS till 80% confluent under 
standard conditions of 37°C, 5% carbon dioxide with 95% humidity and atmospheric 
oxygen levels. Medium was changed after 24hrs then every 48hrs till 80% confluence 
was reached. Passage was carried out by aspirating medium then washing cells with 
PBS. 0.01% EDTA at a volume of 0.047ml/cm2 was added and the cells incubated at 
room temperature for 3mins, detachment was checked visually using an inverted light 
microscope. Trypsin was quenched with 3mls trypsin neutralizer solution the flask 
was further washed with 3mls trypsin neutralizer solution. A 0.5ml sample was taken 
for cell counting and the cell suspension was centrifuged at 200g for 7 minutes. 
Liquid was aspirated from the cell pellet and the pellet was resuspended to a 
concentration of 5.5x105/ml, 100µl of cell suspension was added to each well 
containing conditioned medium in the 24 well plates. Positive controls used 1ml fresh 
DMEM and negative controls were 1ml fresh DMEM with 10µl Suramin.  The plate 
was then put into the Biostation CT and a 7 mmx7 mm area at 4x magnification of 
each well was imaged using a phase contrast setting every 20 minutes for 24 hours. 
Branch length and node formation was determined by image analysis using 
Nikon CL Quant software. The software processing and data out puts are summarised 
in Table 2. The image processing recipe which was custom developed for the CL 
Quant software. The software provides 5 data out puts, in this work the count which is 
the number of branches (referred to as lines by the software) between two nodes were 
used in the data analysis. The mean branch length of the branches between two nodes 
was also used. Though total branch length would also have been informative image 
quality issue arose in the lower oxygen concentrations. Debris within the wells 
resulted in poor image quality and there for the software was falsely reporting nodes 
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and extra branch length. By using branches which were connected to two nodes the 
data was more reliable. The optimisation of this assay including seeding density and 
optimal surface coating was carried out in conjunction with Alexander Chan (Chan 
2016). 
 
Table 2: Branch formation assay image processing methodology in Nikon CL Quant 
software.  
Mask Output data 
 
 
Mask0: Tubes 
connecting to one 
node point or two 
node points 
Count(Mask4) 
Mask1: Node points Mean of Ph-Mask 
4 Line length 
Mask2: Node points 
connecting to more 
than 3 “Mask4” tubes 
Number of 
nodes(Mask1) 
Mask3: Closed tube Total of Ph-Mask 
0 Line length 
Mask4: Tubes 
connecting to two 
node points 
Total of Ph-Mask 
4 line length 
Mask5: Tubes 
connecting to one 
node point 
Mask6: Tubes 
connecting to no node 
point 
 
3.2.4  Luminex analysis  
A multiplex five cytokine panel analysis was carried out as per manufactures 
instruction. 50µl of sample was added per well, and each well was analysed for 
PDGF-AA, FGF-basic, IL-8, VEGF and HGF quantities. 
   76  
 
3.2.5  Differentiation assays 
Differentiation assays were carried out using StemPro kits purchased from 
ThermoFisher Scientific (Paisley, UK). The kits contained a basal medium (adipocyte 
differentiation basal medium and osteocyte/chondrocyte differentiation basal 
medium) which was completed with either an adipogenesis supplement, osteogenesis 
supplement or chondrogenesis supplement. The manufacturer does not provide further 
details regarding specific molecular components found in the medium or supplements. 
3.2.5.1  Adipogenesis  
The hMSCs were seeded in a 12 well plate at a density of 2.5x103cells/cm2, with 2mls 
completed DMEM. After 24hrs the DMEM was aspirated and 2mls adipogenesis 
differentiation medium was added to each well. Cells were culture for 21 days with 
differentiation media changes every 3 days. After 21days cultures were fixed by 
washing 3 times with PBS, 1ml fixation buffer was added to each well and incubated 
for 30mins at room temperature. The wells were then washed three times with PBS. 
Cells were stained by adding 1ml of a 1.8mg/ml working solution of Oil Red O to 
each well and incubated at room temperature for 5mins. Oil Red O is a fat-soluble dye 
which statins lipids present in adipocytes (Nunnari et al. 1989). Wells were then 
washed with deionised water until the water ran clear imaged under a light 
microscope. 
3.2.5.2 Osteogenesis  
Cells were seeded in a 12 well plate at a density of 2.5x103cells/cm2, with 2mls 
completed DMEM. After 24hrs the DMEM was aspirated and 2mls osteogenesis 
differentiation medium was added to each well. Cells were culture for 21 days with 
differentiation media changes every 3 days. After 21days cultures were stained for 
alkaline phosphatase using a 4% v/v solution of naphtol AS-MX phosphate alkaline 
solution in Fast Violet B salts, alkaline phosphates is indicative to osteoblasts 
(Addison et al. 2007). Sliver nitrate staining was used to show the presence of 
insoluble calcium phosphate salts which is indictive of bone tissue 
(Schmitt et al. 2008). Cell cultures were fixed by washing 3 times with PBS, 1ml 
fixation buffer was added to each well and incubated for 30mins at room temperature. 
The wells were then washed 3 times with PBS. Cells were stained first with 1ml of a 
4% v/v solution of naphtol AS-MX phosphate alkaline solution in Fast Violet B salts 
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solution, the plate was incubated in the dark for 45mins and then washed 3 times with 
deionised water. 1ml of 2.5% silver nitrate solution was added to each well and 
incubated at room temperature under UV for 30mins. The cells were washed in 
deionised water 3 times then imaged under a light microscope. 
3.2.5.3 Chondrogenesis 
Post cell count and centrifugation cells were resuspended at 1 x107 cells/ml. 5 x 5µL 
droplets of concentrated cell suspension were pipetted per well of a 12 well plate in 
order to form micro masses. The plate was then placed in the incubator at 37°C, 5% 
carbon dioxide with 95% humidity for 1-2hrs. Without disturbing the micro-masses 
1ml of warmed chondrogenesis differentiation medium was added to each well. Cells 
were cultured for 21 days with differentiation media changes every 3 days. The 
cultures were then stained for the presence of glycosaminoglycans using alcian blue, 
glycosaminoglycans are indicative though not exclusive to cartilage 
(Mallinger et al. 1986). Micro-masses were then fixed by washing 3 times with PBS; 
1 ml fixation buffer was added to each well and incubated for 30mins at room 
temperature. Micro-masses were stained with a filtered solution of 1%wt/vol of alcian 
blue (powder) in 0.1N HCl, 2 mls was added to each well and incubated at room 
temperature for 1hr. The solution was aspirated, and the micro masses washed with 
0.1N HCl solution 3 times with 1 mL/well and then 2 times with deionised water. The 
micro masses were then imaged under a light microscope. 
3.2.6 Flow cytometry analysis 
In a 96 conical clear well plate hMSCs were seeded at a density of 2x105 cells/well, 
the plate was centrifuged for 5 min at 250g to obtain cell pellets in wells. The 
supernatant was aspirated and each pellet resuspended in 200 µl staining buffer, the 
plate was briefly vortexed and centrifuged for 5 min at 250g and the supernatant 
aspirated. 0.5µl of anti-human fluorescently tagged CD73, CD90, CD105 and 
HLA-DR antibodies (see Table 3 for details) were added directly to cell pellets, the 
cell pellets were then resuspended and an additional 50 µl staining buffer was added 
to each well. The cells were incubated with the antibodies for 30 minutes in the dark 
at room temperature. The plate was then centrifuged at 250g for 5 min and the 
supernatant aspirated. The antibody cell pellet was washed x2 with 200 µl of staining 
buffer, then resuspended in 200 µl of staining buffer. Cells were analysed using a 4-
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colour panel on the FACS Jazz. This protocol is based on a paper published by Chan 
et al. (2013). 
 
Table 3: Detail of antibody-fluorophore conjugates and respective emissions spectra 
used in flow cytometry analysis of hMSCs. 
CD Antibody Fluorophore conjugate Excitation max Emission max 
CD73 PE-Cy7 496 nm 785 nm 
CD90 APC 650 nm 660 nm 
CD105 PE 496 nm 578 nm 
HLA-DR FITC 494 nm  520 nm 
 
3.2.7 Statistical analysis 
Evaluation of cytokine data and branch formation assay data was carried out using 
GraphPad Prism 7 purchased from GraphPad Software (California, US). 
3.3 Results and Discussion 
3.3.1 Characterisation of hMSC lines 
The minimum criteria for characterising hMSC according to Rasini et al. (2013) is 
based on the ability for the cells to adhere to tissue culture plastic, the ability for the 
cells to differentiate down the adipocyte, osteocyte and chondrocyte linages and to 
display certain phenotypic markers while being negative for surface markers 
associated with other cells. In this work CD90, CD73 and CD105 are used as positive 
phenotypic markers and HLA-DR negative (Chan et al. 2013). The four donor cell 
populations used in this work were first characterised after growth in standard control 
conditions at passage P2 and P3.  
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A                                                               B 
 
C                                                                 D 
 
Figure 9 Histology of differentiated lines taken in phase contrast. A) Chondrocytes 
stained with alcian blue, scale bar 500µm B) Osteocytes stained with Fast Violet B 
Salt with 4 % (v/v) naphthol AS-MX phosphate alkaline solution, scale bar 100µm C) 
Adipocytes, M2 and M3 stained with Oil Red O, M6 and Rooster lines are imaged in 
phase contrast unstained, scale bar 100µm. Yellow circles highlight the lipid 
vacuoles. Each image is representative of 3 wells (n=3) D) Control hMSC lines 
plastic adherence at P2 imaged on day 6 under standard cell culture conditions. 
Imaged in phase contrast with 100µm, scale bar. Images representative of n=3. 
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Table 4 Flow cytometry analysis of M2, M3, M6 and Rooster donors. All four cell 
lines were positive for CD105 (PE) and CD90 (APC) and negative for HLA-DR 
(FITC). Over all there were some equipment issues which affected the quality of the 
results subsequently the results for CD73 (PE-Cy5) are unclear. This is discussed 
further in the chapter.  
 
M2, M3, M6 and Rooster lines demonstrate tissue culture plastic adhere (Figure 9D), 
the cell cultures in vitro display the fibroblast spindle like morphology that is 
commonly referred to the literature as the typical morphological traits of hMSCs 
(Gebhardt et al. 2003; Ullah et al. 2013). After 6 days in culture the rooster line 
achieves full confluence compared to M2, M3 and M6 lines, giving an early 
indication that there may be a difference in growth rates between lines. The four lines 
are all able to differentiate down the adipocyte, chondrocyte and osteocyte lineages 
(Figure 9). All four lines formed microspheres and stained positive for alcian blue 
(Figure 9 A) which confirms the presence of cartilage proteoglycans 
(Ullah et al. 2012). Alkaline phosphatase staining (red) was positive in all lines when 
under osteogenic differentiation conditions (Figure 9 B). The M6 line produced more 
areas that stained positive for mineralisation (black) compared to the M2, M3 and 
Rooster lines. M2, M3, M6 and Rooster lines all show under phase contrast lipid 
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vesicle formation, the M2 and M3 cultures were stained with Oil Red O which has 
been taken up by the lipid vesicles (Figure 9 C). One of the challenges of histological 
analysis of hMSC differentiation is the method is difficult to accurately quantify. 
Consequently, while one donor line maybe more efficient at differentiation it can only 
be determined whether or not the cells are capable of differentiating and are therefore 
the starting material can be classified as hMSCs.  
Some of the data presented in Table 4 is not very clear; this was due to issues with the 
voltage while the measurement was taken however all four cell lines were positive for 
CD90, CD73 and CD105 and HLA-DR negative. Due to the voltage issues it was not 
possible to fullly quantify the population percentage which displayed the 
aforementioned markers. The cell lines analysed in the work have been used by other 
researchers from the same facility. Some of this work has been published which 
further supports the premise that these cell populations are hMSCs (Chan et al. 2013; 
Rafiq et al. 2013; Heathman et al. 2016; Rafiq et al. 2018). 
While the M2, M3 M6 and Rooster donors meet the minimal criteria 
(Dominici et al. 2006) for hMSC identification, it is not possible to assume that all 
four donors are completely identical. Some differences have already been shown in 
levels of confluence achieved in the same culture period (Figure 9 D), and level of 
mineralisation when differentiated down the osteogenic lineage (Figure 9 B). 
Variation of the population doubling times (PDT) between lines and passage numbers 
can be seen in Figure 6. The Rooster line had the fastest PDT at passage 2 (~0.5 days) 
this concurs with evidence (Figure 9 D) that the line is fast growing over 5 days 
compared to M2, M3 and M6. At P2 M2, M3 and M6 have a PDT of less than 2 days 
in all culture conditions, in the M6 line a PDT of 〜2 days is maintained across all 
three passages. The PDT of P3 2% oxygen significantly increases (P<0.05) in the M2 
and M3 lines with PDT in excess of 6 days. In the M3 line at P4 the atmospheric 
oxygen control for the 5% oxygen PDT also significantly increases compared to P3. 
Differences can also be seen between the controls in M2 and M3 at P4, in the M2 line 
(Figure 10A) PDT for the 2% control remains below 2 days, however in the 5% 
control the PDT increase to over 2 days. PDT is important from a manufacturing 
perspective as higher yields can be achieved in a shorter time therefore decreasing 
costs (Davie, et al 2012). When considering the possible reasons for this variation 
between the controls three main factors need to be considered, the control cells were 
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thawed from separate vials, at separate times therefore did the thawing processes 
cause cell damage and thus an increase in PDT. The M2 and M3 lines were cultured 
at the same time in the same incubator; during P4 the incubator environment could 
have been compromised resulting in a decreased growth rate. The cells were also 
passaged at the same time, if there was an issue with the NucleoCounter the potential 
errors in counting would result in inconsistent seeding density, seeding density has 
been shown to be an influence in cell growth rate (Thomas et al. 2007).  
When examining the in vitro growth rates of other cell types such as hESC and iPSC, 
high growth rates are not automatically assumed to be a positive attribute. 
Enhancement of hESC and iPSC proliferation rates in vitro has been shown to be 
linked to changes in the cells karyotype and an indication of tumorigenicity, this is 
thought to be more of a safety issue in pluripotent stem cells but multipotent stem 
cells such as hMSCs are also susceptible (Knoepfler 2009). From a manufacturing 
standpoint the rate of cell proliferation must also be balanced with consistency 
between batches. 
 
Figure 10: Population doubling times in days of M2 (A), M3(B), M6 (C) and Rooster 
(D) lines cultured in 2% or 5% atmospheric oxygen compared to a control cultured in 
20% atmospheric oxygen. Mean values and standard deviation of n=4 are shown 
Two-way ANOVA was performed, significant differences (P = ≤ 0.05) were seen 
indicated by *. 
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3.3.2 Secretome profile of hMSC lines 
A number of factors are being investigated when looking at the secretome profile of 
the four hMSC lines, firstly the difference between each line for each of the five 
cytokines (PDGF, FGF-B, IL-8, VEGF and HGF), secondly does the oxygen level 
affect the cytokine production, and thirdly does the passage number and therefore the 
age of the cells affect cytokine production. 
 
Figure 11: PDGF secretome profile of M2 (A), M3(B), M6 (C) and Rooster (D) lines 
cultured in 2% or 5% atmospheric oxygen compared to a control cultured in 20% 
atmospheric oxygen. Samples were collected after 48hr of conditioning with the 
hMSCs which were on day 5 of culturing. Expression quantities calculated per cell 
based on the per ml value divided by the cell number at the end of the passage, n=4 
and standard deviated is shown  
Across all four lines and all three passages PDGF expression does not exceed more 
than 0.3fg/cell (Figure 11). It is difficult to draw direct quantitative comparisons from 
the literature however PDGF expression has been reported as being lower compared 
to other cytokines in the same sample, Kwon et al. (2014) reported PDGF production 
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between 2.5pg/ml-3.1pg/ml, no per cell values were given but cells we cultured at a 
higher density of 1.6x106 in T175 flasks. 
From a cryopreservation recovery aspect, the M2 and M3 show an increase in PDGF 
production after the first passage in all four experimental conditions. The M6 and 
Rooster lines show PDGF production at P2 across all four conditions, but in both 
incidences the 5% oxygen and respective control does not produce PDGF within the 
detectable range at P3 and P4. The greatest amount produced was in the M3 cells line, 
in all culture conditions and passages PDGF was detected P4 20% Oxygen (5% 
oxygen control) had the highest amount with 0.2275 ±0.0737 fg/cell. The same 
culture condition also had a significantly higher PDT in Figure 10, however P4 2% 
oxygen had a higher PDT so a direct relationship between longer PDT and increase 
PDGF production cannot be theorised. The M2 line produced the PDGF in all 
condition apart from P2 2% oxygen, however in the P3 and P4 conditions PDGF is 
detected and increases further in P4 producing the highest amount 
(0.0675 ±0.02 fg/cell) for the M2 conditions. Interestingly some differences between 
the 20% oxygen control conditions can be seen, particularly in the M6 and Rooster 
lines where no PDGF was detected in the 5% oxygen control but was detected in the 
2% oxygen control. PDGF-AA has been reported to have a proliferative effect (Doorn 
et al. 2012), it has also been shown to regulate VEGF expression at an autocrine level 
(Shikada et al. 2005). However the minimal concentration of PDGF required to 
induce a biological response has not been determined, it is also not the sole cytokine 
to have a proliferative effect FGFs have also should to hold similar properties (Doorn 
et al. 2012). 
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Figure 12: FGF basic secretome profile of M2 (A), M3(B), M6 (C) and Rooster (D) 
lines cultured in 2% or 5% atmospheric oxygen compared to a control cultured in 
20% atmospheric oxygen. Samples were collected after 48hr of conditioning with the 
hMSCs which were on day 5 of culturing. Expression quantities calculated per cell 
based on the per ml value divided by the cell number at the end of the passage, n=4 
standard deviated is shown 
In Figure 12 the production of FGF-basic cytokine is at a larger scale compared to 
PDGF which was detected at the 10ths of a femtogram level (Figure 11). The 
secretome profile of M6 and Rooster lines are similar as PDGF, FGF is detected in P2 
across all four culture conditions, but in P3 and P4 the levels are not detectable for the 
5% oxygen and the respective control. In the M2 line 5% oxygen, 20% oxygen 
(5% oxygen control) conditions FGF-basic is produced at all three passages, levels at 
P2 and P3 are similar for each condition but at P4 the level rises to over 1fg/cell for 
the FGF-basic in the control condition compared to the lower oxygen condition at 5% 
oxygen (Figure 12). Interestingly at P4 the 2% oxygen culture condition has a 
0.95±1.12 fg/cell FGF-basic production. This behaviour is also seen in the M3 line, 
no FGF-basic is detected at P2 and P3 in the 2% oxygen culture condition and the 
20% control, but at P4 in both the 2% oxygen and the corresponding 20% oxygen 
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control FGF-basic levels of 2.027±1.581 fg/cell and 0.485±0.1 fg/cell respectively are 
shown. The disparity between the controls in the M2 and M3 in both PDGF and FGF-
basic could be attributed to the fact they were cultured at different times or from 
separate vials, damage in thawing, drop in culture temperature or changes in CO2 
levels (Xu et al. 2012). The profiles of the M6 and Rooster line FGF-basic production 
follow a similar pattern as the PDGF production with the exception that in the Rooster 
line 5% oxygen at P3 is producing FGF-basic but not PDGF (Figure 11). At 5% 
oxygen in the P3 passage all four lines produce FGF-basic and in the corresponding 
control the values are either similar (M2) or greater (M6 and Rooster), only in M3 P3 
is the control value higher 2.84±0.84 fg/cell compared to 0.90±0.28 fg/cell, but both 
the control and experimental condition have higher standard deviations. The situation 
changes in M2 P3 where the 5% oxygen condition produces more FGF-basic 
(0.43±0.02 fg/cell) compared to the 20% control (1.33±0.22 fg/cell). By P4 in the M2 
and M3 lines the 20% oxygen control is producing more FGF-basic compared to the 
corresponding 5% oxygen samples. Overall for the M6 and Rooster lines the 
2% oxygen condition produces either similar amount or greater amounts of FGF-basic 
compared to the control which would indicate that when cultured in 2% atmospheric 
oxygen FGF-basic expression can be upregulated, the difference is most notable at 
P3. The 2% condition also shows a delayed recovery and FGF-basic expression at P4 
in the M2 and M3 lines, this delay maybe not be a consistent trait of the lines in 2% 
oxygen due to the disparity between the 20% oxygen controls however it is interesting 
that FGF basic secretion recovers better in the 2% oxygen condition compared to the 
respective control. 
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Figure 13: IL-8 secretome profile of M2 (A), M3(B), M6 (C) and Rooster (D) lines 
cultured in 2% or 5% atmospheric oxygen compared to a control cultured in 20% 
atmospheric oxygen. Samples were collected after 48hr of conditioning with the 
hMSCs which were on day 5 of culturing. Expression quantities calculated per cell 
based on the per ml value divided by the cell number at the end of the passage, n=4 
standard deviated is shown. 
IL-8 is produced by every cell hMSC line, in all oxygen culture conditions across all 
three passages (Figure 13), the per cell quantities are higher than PDGF and in some 
conditions higher that FGF-basic with levels in M6 and Roster around 5 fg/cell. The 
disparity between the 20% controls seen with the PDGF and FGF-basic cytokines can 
still be seen within the M2 and M3 conditions though all controls in are producing 
IL-8. In the M2 and M3 line IL-8 production does not exceed 2.5 fg/cell; in the 2% p4 
condition IL-8 production is the lowest at 0.25±0.08 fg/cell in the M2 line and 
0.21±0.12 fg/cell in the M3 line. The highest amount of IL-8 produced was in the M6 
line in 5% oxygen at P4 with a value of 7.75 fg/cell and a large standard deviation of 
±8.17 fg/cell. At P3 IL-8 production was similar between the 5% condition and the 
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parallel control. In the M6 P2 and P4 the 20% control was less than the 5% condition. 
In the Rooster line the parallel control for the 5% oxygen condition produced the 
highest amount of IL-8 across all three passages. Differences can be seen between the 
two 20% oxygen controls at P2 and P3; but at P4 the 2% oxygen control has a value 
of 4.190±1.151fg/cell and the 5% oxygen control a value of 4.273±0.684fg/cell. 
Overall based on the data in Figure 13 the 5% oxygen condition stimulates the 
expression of IL-8 more than at 2% in M2, M3 and M6 cell lines. 
 
Figure 14: VEGF secretome profile of M2 (A), M3(B), M6 (C) and Rooster (D) lines 
cultured in 2% or 5% atmospheric oxygen compared to a control cultured in 20% 
atmospheric oxygen. Samples were collected after 48hr of conditioning with the 
hMSCs which were on day 5 of culturing. Expression quantities calculated per cell 
based on the per ml value divided by the cell number at the end of the passage, n=4 
standard deviated is shown. 
VEGF is produced by every cell hMSC line, in all oxygen culture conditions across 
all three passages. In the M2, M3 and M6 lines the highest amounts of VEGF are 
produced in the 5% oxygen environments based on the mean values. The M6 line 
produced the most overall P2 9.23±0.76 fg/cell, P3 11.65±2.83 fg/cell and P4 
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9.73±0.75 fg/cell. The ability for VEGF production to be induced by hypoxia is 
mention in numerous papers (Jin et al. 2002; Yancopoulos et al. 2000) so it is 
therefore not surprising that in most of the 2% and 5% conditions more VEGF in 
detected compared to the equivalent controls. The M3 P4 2% condition is the only 
condition where more VEGF is detected in the control compared to the lower oxygen 
environment. In the M2 and M6 P4 conditions for 2% oxygen similar levels of VEGF 
are produced by the control and experimental condition. In the majority of conditions 
for the M6 and Rooster cells lines fg/cell values between 5 and 10 have been detected 
compared to the M2 and M3 conditions where few conditions exceed the 5fg/cell 
production level. 
 
Figure 15: HGF secretome profile of M2 (A), M3(B), M6 (C) and Rooster (D) lines 
cultured in 2% or 5% atmospheric oxygen compared to a control cultured in 20% 
atmospheric oxygen. Samples were collected after 48hr of conditioning with the 
hMSCs which were on day 5 of culturing. Expression quantities calculated per cell 
based on the per ml value divided by the cell number at the end of the passage, n=4 
standard deviated is shown. 
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Figure 16: M2 HGF secretome fold difference compared to P2 20% oxygen control. 
n=4 standard deviated is shown. 
The rooster line produces the greatest amount of HGF with a peak value of 
18.17±2.69 fg/cell at P4 20% oxygen (5% oxygen control). A positive increase in the 
amount of HGF produced can be seen going from P2 through to P4 in all four 
conditions of the Rooster line (Figure 15). At P2 the 5% oxygen condition produces 
the most HGF but in P3 and P4 the corresponding 20% oxygen control produces the 
most HGF (P3= 10.36±1.02 fg/cell and P4 18.17±2.69 fg/cell). As seen previously 
there is variation between the 20% controls with the P3 and P4 2% oxygen control 
producing 0.83±0.06 fg/cell and 3.44±0.84 fg/cell respectively. Much lower levels of 
HGF are produced by the M6 and M3 lines, in the M3 line only a small amount of 
HGF is produced in the 2% P4 condition. In the M6 line only at P3 5% is HGF 
produced, but HGF is detected though all passages at 2%.Based on the graph in 
Figure 15 it seems that only at P4 in 5% oxygen HGF is produced, however as shown 
in Figure 16 small quantities of HGF is produced in the 5% oxygen condition and the 
parallel control across all three passages. No HGF was detected in the 2% condition 
and the parallel control. When examining the fold difference of the M2 line HGF 
production in relation to the P2 20% control value the control decreases with 
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increasing passage number. The 5% oxygen condition fluctuates initially having 〜
0.5 fold more than the P2 control but in P3 the amount of HGF is lower than the P2 
20% oxygen control. At P4 the HGF level recovers to be over 1 fold greater than P2 
20% oxygen control. This could indicate that the cells have recovered from 
cryopreservation and are now responding to the environmental stimulus. 
 
Figure 17: fold difference of M2 VEGF secreatome comparing expression levels to 
the respective P2 20% oxygen control.  
The data from Figure 11 to Figure 15 shows that there is not one line that consistently 
produces the most or the least of every cytokine analysed, showing that just because 
one cytokine is produced in a high amount by a specific line the line will not produce 
all cytokines to high quantities. For example, Rooster cells produced more HGF 
(Figure 15) than the M2 cells but under certain conditions M2 cells are capable of 
producing more PGDF than the Roosters (Figure 11) One of the issues to be further 
investigated is the variation in cytokine levels between the two 20% oxygen controls. 
For example, in Figure 14 the M2 line the 5% oxygen control is producing more 
VEGF that the 2% oxygen control. When examined further (Figure 17) it can be seen 
that the differences are not proportional within the conditions, the two controls were 
thawed from different vials which suggests there could be some variation introduced 
by the handling of the cells. This is seen again in the HGF secretome profile (Figure 
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15) as no HGF is detected in the 2% oxygen control, interestingly despite the 
variation in controls the 2% P4 oxygen condition produces the most PDGF in the M2 
line, which suggests that this line is capable of being primed using lower oxygen 
concentrations on increase PDGF. The differences between secretome profiles 
indicates that for treatments that utilises hMSCs for their paracrine properties a ‘one 
cell donor source fits all’ approach may not produce the desired effect. Consequently, 
further investigation into the physiological behaviour of the hMSC line secretome 
profile needs to be investigated. 
Protein degradation needs to be discussed; the conditioned medium samples were 
treated consistently in terms of the number of freeze thaw cycles they were subjected 
to. However, if the rates at which each cell line produces the cytokines varies, the 
cytokines for some cell lines may be exposed to the culture conditions for longer, and 
therefore potential factors which may cause protein degradation. For example hMSCs 
have been shown to produce proteases (Hematti & Keating 2013), the production 
degradation profile of hMSCs has not been extensively investigated in terms of hoe 
long secreted proteins retain integrity while in cell culture. It also needs to be noted 
that the pH of the cell culture conditions was not tightly monitored, the standard 
DMEM buffer systems was in each cell culture system but no adjustments were made 
for the lower oxygen conditions. Subsequently proteins with a structure that is 
influenced by pH may have be adversely affected in these culture conditions. In this 
incidence it was not feasible to run the conditioned medium samples on the Luminex 
plate immediately necessitating the need for freezing the sample. Due to the sample 
numbers and the volume of medium in which the cells were being cultured it was not 
cost effective to take samples at shorter time points in order to investigate protein 
degradation and establish a secretion degradation profile. This highlights a limitation 
of the Luminex assay when being used in a manufacturing setting, specifically in 
terms of the cost as one plate is £525 on which 41 samples can be run in duplicate and 
in terms of time scale, either 41 samples need to be ready to be run at the same time 
or samples are put through a freeze thaw cycle, which my compromise sample 
integrity. 
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3.3.3 Branch formation assay in vitro 
Using an in vitro branch formation assay the pro-angiogenic in vitro effect of the 
hMSC conditioned medium analysed in Section 3.3.2 can be determined. The branch 
formation assay or tube formation assay as it is also called has been used by multiple 
research groups to determine angiogenic properties of various solutions on endothelia 
cells (Arnaoutova et al. 2009). Normally the assay is imaged at discreet time points 
however in this methodology the assays were imaged every 15-20mins. The region 
selected for imaging is also, in previous studies, subject to operator bias, using the 
Biostation the area and position imaged in the wells were predefined and automated. 
By using a more extensive imaging procedure with multiple time points the graphs 
created have tightly packed error bars horizontality which results in difficult to read 
graphs. Therefore, examples of graphs containing the respective error bars can be 
seen in Appendix 1. The graphs display the average branch length between two nodes, 
also known as branch junctions. During the assay branches are constantly being 
formed and reformed into longer branches, this creates an irregular graph as the 
images are so frequent small changes are plotted. The branch formation assay 
analyses images and calculates the total length of branch of nodes, the number and the 
average branch length between two nodes (Section 3.2.3). The decision was made to 
only plot the average branch length as the software will include debris or scratches in 
the total branch length, by only including branches between two nodes the false 
measurements are not included. 
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Figure 18: M2 Average branch length for the 2% oxygen Vs 20% controls (A) and the 
5% oxygen vs 20% control (B), over 3 passages. n=4 
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In the M2 2% oxygen condition displayed in Figure 18 the condition with the longest 
average branch length that increases over time is the P4 20% control. The P4 2% 
oxygen condition produced the shortest average branch length; at no time point did 
the mean average branch length exceed 200µm. Of particular interest the difference 
between the 20% controls, at the beginning of the assay the 5% control has a lower 
average tube length (under 150um) compared to the 2% oxygen control. This 
disparity could be linked to the differences seen in the M2 cytokine expression 
profiles (Figure 11-Figure 15). 
Previous luminex data show cytokine production based on a per cell value, however 
as shown in Figure 10 the number of cells per flask varied due to different PDT 
therefore the amount of cytokines the branch formation assay contained varies. Table 
1 shows the cytokine levels the HUVEC cells are exposed to during the assay notably 
there is a higher amount of VEGF and IL-8 in the control compared to the 2% 
condition. 
 
Table 5 Cytokine expression profile mean values and standard deviation in pg of M2 
P4 2% oxygen and M2 P4 20% oxygen, corresponding to average branch length 
profile Figure 18 A. n=4 
Cytokine M2 P4 2% SD 
M2 P4 20% 
(control) 
SD 
PDGF 0.89 0.022 0.52 0.006 
FGF-basic 0.31 1.128 Below LOD  
Il-8 1.07 0.079 49.26 0.147 
VEGF 0.75 0.484 142.43 0.358 
HGF Below LOD  Below LOD  
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Figure 19: M3 Average branch length for the 5% oxygen Vs 20% controls (A) and the 
2% oxygen Vs 20% control (B), over 3 passages. n=3 
   97  
 
 
Figure 20: M6 Average branch length for the 5% oxygen vs 20% controls (A) and the 
2% oxygen vs 20% control (B), over 3 passages. n=3 
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Figure 21: Rooster Average branch length for the 5% oxygen vs 20% controls (A) and 
the 2% oxygen Vs 20% control (B), over 3 passages. n=3 
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The average branch length in Figure 21 A and B show there is little distinction 
between the experimental conditions, in both data sets only the P2 20% oxygen 
control is more distinct from the other data sets. In Figure 21A the longest average 
branch length is in the P2 20% control which reaches the 300-400µm length with two 
time point exceeding 450µm length: the shorter average branch length can be seen in 
the P2 5% oxygen control. Table 6 shows the average cytokine levels in each well of 
the angiogenesis assay. The values in this context would initially indicate that longer 
average tube length is not directly relates to VEGF concentrations as in the 20% 
condition there is less VEGF compared to the 5% condition. Just based on the data in 
Table 6 it would indicate that higher levels of PDGF, IL-8 and HGF or lower levels of 
FGF-basic and VEGF are important for longer average branch length. However this is 
just a snap shot of the data and the standard deviations are also indicating sources of 
variation, therefore this data would need to be analysed in greater detail, in terms of 
assaying for a wider panel of cytokines. 
Table 6: Cytokine expression profile mean values and standard deviation in pg/ml of 
Rooster P2 5% oxygen and Rooster P2 20% oxygen, corresponding to average branch 
length profile Figure 21 A. n=4 
Cytokine Rooster P2 
5% 
SD Rooster P2 20% 
(control) 
SD 
PDGF 2.52 2.91 3.61 0.58 
FGF-basic 156.53 66.60 92.49 12.11 
Il-8 245.89 11.86 291.94 7.72 
VEGF 776.81 38.83 596.18 16.54 
HGF 1182.47 44.39 1244.40 83.27 
 
The data form the Rooster P2 20% (oxygen control) and the corresponding P2 5% 
culture conditions was further analysed to the individual replicate level in order to 
further understand the variation in the data. 
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Based on the data in Figure 21, in both A and B, the P2 Rooster 20% control results in 
the longest average branch length; in A after 314min the average branch length in 
over 250nm for the rest of the duration of the assay with a spike at 1314mins of over 
600 nm. In B the average branch length does not exceed 259nm until after 614mins, 
the average branch lengths between 250nm-350nm are then maintained for the 
duration of the assay. Examining Figure 21 A further the P2 5% oxygen conditions 
results in the shortest branch length as it reduces after 814 compared to the other 
conditions. Table 6 displays the mean cytokine values which the assays contain. For 
both the 20% and 5% conditions PDGF quantities are low in comparison to the four 
other cytokines. In the 20% oxygen condition there is 46.05pg more Il-8 and 61.93pg 
more HGF however there is actually 64.04 pg less FGF-basic and 180.63pg less 
VEGF in the better performing 20% condition which is interesting as VEGF is 
considered to be a key cytokine for angiogenesis (Rosano et al. 2012; Neufeld & 
Kessler 2006). The data presented in Figure 21 and Table 6 are an average of four 
repeats, the standard deviations of cytokine expression (Table 6) are large which 
indicates that each individual replicate contained a varying quantity of all five 
cytokines. The data is deconstructed further to the individual replicates data.  
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Figure 22: Rooster P2 20% oxygen (5% oxygen control), A, B, C and D are 
individual repeats, the mean of which is in Figure 21 A. The average branch length 
(µm) and corresponding number of branches are displayed for each repeat on the 
same graph. It should be noted the graph scale for replicate B is higher in order to 
accommodate all the data points. 
Figure 22 and Table 7 are a breakdown of the individual replicates (A, B, C and D) 
shown in Figure 21 A and Table 6 for the P2 20% oxygen condition. The number of 
branches decreases over the duration of the branch formation assay as shown in 
Figure 22, degradation of the branches is expected due to protease activity 
(Lehman et al. 2012). Repeats A and B have a higher number of shorter branches in 
the early phase of the assay (between 200-300 minutes), examining the cytokine 
levels in these repeats the only commonality is they have a lower FGF-basic 
concentration with 82pg in the assay (Table 7), though this is not conclusive evidence 
that low FGF-basic levels produce shorter branches in the early phase. The spike seen 
at 1314min in Figure 21A P2 20% oxygen control can be attributed to replicate B; this 
data point demonstrates the need for detailed data analysis.  
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Table 7: Corresponding cytokine values for each repeat of Rooster P2 20% oxygen 
(5% oxygen control) (Figure 22) 
Cytokine A B C D 
PDGF 3.53 3.84 4.8 3.61 
FGF-basic 82 82 102.97 102.97 
Il-8 805.13 1115.39 1244.95 874 
VEGF 930.56 1140.59 1355.19 1006.25 
HGF 115.39 142.88 191.75 128.18 
 
Replicate C has the highest levels of all 5 cytokines, while C maintains an average 
branch length between 200nm and 400nm throughout the duration of the assay it does 
not reach the above 400nm that are seen in replicate B. Replicate B produces the 
longest average branch length during the assay run time yet there is no reason for this 
which can be conclusively related to the cytokine levels.  
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Figure 23: Rooster P2 5% oxygen, A, B, C and D are individual repeats, the mean of 
which is in Figure 21. The average branch length (µm) and corresponding number of 
branches are displayed for each repeat on the same graph. 
Table 8: Corresponding cytokine values for each repeat of Rooster P2 5% oxygen 
(Figure 23). 
Cytokine A B C D 
PDGF 5 5.08 Below LOD Below LOD 
FGF-basic 
106.08 93.06 202.43 224.55 
Il-8 1016.64 952.73 495.4 538.17 
VEGF 1932.1 1864.61 980.72 1066.03 
HGF 97.2 85.75 609.51 693.07 
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3.4 Conclusions 
This Chapter looks at several aspects of using hMSCs as a cell therapy ranging from 
methods used in determining the fundamental biological effect of hMSC on 
angiogenesis to identifying key areas for improvement during the processing of a 
hMSC treatment. Cells from four donors were cultured in lower than atmospheric 
oxygen conditions over three passages. Due to the complex nature of cells, in this 
case hMSCs, there are always some common challenges relating to the impact of 
culture methodology and environmental conditions. The standard 20% oxygen 
culturing condition controls showed variation in population doubling times and 
secretome profile (Section 3.3.1and Section 3.3.2). This is therefore indicating that 
despite the cells being from the same donor and cryopreserved at the same time the 
recovery processing steps of the vials are also important. This highlights that without 
tight controls and a rigours cell recovery methodology it cannot be assumed that all 
cells from the same donor and at the same passage will behave the same. Further 
work into vial to vial variation would need to be conducted. Alternatively, in a 
manufacturing setting, early indications in the upstream processing that a batch/vial of 
cells would not meet defined criteria would mean the run could be halted sooner 
resulting in time and money being saved. 
The Rooster line under standard culturing conditions showed the shortest population 
doubling time and produces the highest amount of HGF. PDGF and FGF-basic. In 
Figure 11 A and Figure 12 A the production of PGDF and FGF-basic was greatest at 
P4 2% compared to the P4 20% control. While the issue of variation between controls 
has been discussed, the question arises does the M2 line produce more PDGF and 
FGF-basic at lower 2% or does the production of this recover quicker post thaw at this 
oxygen level? This would need to be investigated with further repeats but based on 
Figure 22 and Table 7 FGF-basic may potentially have an impact on initial rate of 
branch formation. Reducing the lag time between dosage and response of treated 
tissue is important in conditions where rapid restoration of the bloody supply is 
critical in order to retain organ/tissue function. 
Though no direct trend between cytokine levels and average branch length can be 
deduced, it needs to be acknowledged that only 5 cytokines have been analysed in this 
work. The complex control of angiogenesis involves physical stimulus and many 
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more cytokines such as angiogenin, angiopoietin and placental growth factor 
(Bronckaers et al. 2014). While a strong relationship between a single cytokine and 
average branch length cannot be determined, the cytokine data may be applicable for 
other hMSC paracrine actions. IL-8 is known to have a pro migratory effect on 
epithelia cells, and its role in wound healing is being investigated 
(Guo & Dipietro 2010). 
Overall this data presents the case that not all hMSC lines will have the same effect 
on angiogenesis and do not exhibit the same cytokine secretome profiles in standard 
culture conditions or in lower oxygen culturing conditions. Therefore hypothesis 1 
that the hMSCs secretome profiles of VEGF-A, bFGF, HGF, PDGF-BB 
IL-8 /CXCL8 exhibited the same trends under three different atmospheric oxygen 
concentrations independent of the cell donor (Chapter 2, Section 3.2) must be 
rejected. It cannot be assumed that a high amount of VEGF will automatically mean a 
longer branch formation which in this instance is the presumed surrogate for average 
capillary length. Based on the data presented in Figure 18, Figure 21, Figure 22 and 
Figure 23 there appears to be no obvious link between cytokine secretome profiles, 
which were analysed, and average branch length. This is reflective of the complexity 
of angiogenesis that one single cytokine is most likely to not be the single biomarker 
for a good level of angiogenesis. In this instance the cytokine panel should be 
expanded to include other angiogenesis related cytokines, however given the number 
of variables which need to be controlled when conducting protein analysis, this would 
be an extensive and expensive undertaking. 
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4 Miniaturised ELISA tool for rapid 
cytokine quantitation of hMSC 
manufacturing 
4.1 Introduction 
With the increasing cost and complex nature of a cell therapy treatments there is a 
need for low cost and rapid bioanalytical technologies (Konstantinidis et al. 2013). 
The demand for affordable, high throughput, accurate, sensitive and rapid 
bioanalytical tests is increasing not just in the cell therapy market but also in point of 
care, precision medicine and drug monitoring trials (Heinzelmann 2016). As 
examined in Chapter 2 a bioanalytical method must be relevant to the product in 
terms of identity and/or potency. Alternatively, the method can be used to detect any 
adverse effect which compromises the safety and/or integrity of the product. For 
example given that cells are usually cultured at 37°C and temperature increases lead 
to protein degradation (Chi et al. 2003). During the manufacturing hMSCs for their 
paracrine properties rapid analysis of the secretome is important in order to ensure the 
require expression profile is being achieved (Chapter 3). Therefore, reducing the 
sample to result time is critical when dealing with a dynamic environment such as 
stirred-tank bioreactors when scaling up cell production. 
ELISA-based technologies, including direct ELISAs, sandwich ELISAs and ELISA 
spot arrays are common methods for protein detection and quantification. There are 
many platforms which use the fundamental principle of an ELISA assay and in this 
work three of the platforms were used; the Luminex assay, the standard 96 well plate 
assay and a novel microfluidic based platform. Current 96 well plate formats are time 
intensive, some methods having incubations time totalling 3hrs after the addition of 
the sample. While magnetic Luminex screening assays can analyse multiple analytes 
simultaneously there are still 3.5hrs of incubations post sample addition. Microfludic 
ELISA platforms being developed to address many of the limitations of well plate 
platforms as discussed in Chapter 2. Previous work carried out by Barbosa et 
al. (2014) used a microfluidic based platform to produce a rapid yet sensitive method 
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to quantify prostate serum antigen levels. This method used a microcapillary film 
(MCF), which contained 10 parallel capillaries each with a 〜200µm diameter Figure 
24. Each MCF is then connected to a syringe via a multi-syringe aspirator (MSA) 
which is able to hold up to 8 syringes in parallel. This device enables 8 samples to be 
analysed at the same time and in each strip of MCF there are 10 replicates. Using the 
MCF device time intensive wash steps are removed as fluid handling is simplified by 
aspirating waste fluid into the syringe from the side of the MCF connected to the 
device while concurrently aspirating in new reagents of wash buffer from the 
unconnected end of the MCF. Due to the high surface area to volume ratio of the 
MCF incubation times can also be reduced in the ELISA assay as the time for 
antibody diffusion and adsorption of antibodies and substrates is faster than in the 
well plate. Further work on cytokine detection has been carried out by Castanheira et 
al. (2015), whereby in a singleplex format human IL-12 could be detected to 
concentrations as low as 2pg/ml. Multiplexed ELISA assays using the MCF platform 
have also been demonstrated, overall the assay times for cytokine detection have been 
shown to be as fast as 17mins post sample addition (Castanheira et al. 2015). 
 
Figure 24: Images of the MCF containing 10 capillaries with a 〜200µm diameter A) 
cross sectional image B) Image of an empty MCF from above. 
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The MCF ELISA platform was patented in 2011 (Edwards et al. 2011) and entered 
the commercial arena as part of the company Capillary Film Technology Ltd (CFT). 
The work on the MCF platform and the commercial focus on CFT has been around 
the point of care market. This is reflected in the choice of equipment, flatbed scanners 
and smart phone cameras, used for detection which are low cost and easy to use 
(Barbosa et al. 2014; Castanheira et al. 2015; Barbosa et al. 2015). While the benefit 
of rapid ELISA tests for point of care diagnostics is clear, there is also the scope for 
the platform to be utilised within the protein and cell therapy manufacturing sector. In 
Chapter 3 the cost and time constraints, in terms of the potential number of analytes 
needed to be quantified, and the constant monitoring of cell cultures was discussed. 
There are also the additional complexities of biological variation between cell sources 
and cell behaviour during culture in terms of different growth rates and the need for 
cytokine production rates to be effectively modelled thus there is a clear requirement 
for faster analytics which could be fulfilled by the MCF ELISA platform. A 
simplified version of the cell therapy manufacturing process for hMSCs (though the 
process is currently similar for most adherent cell types) can be seen in Figure 25, the 
role of the MCF would vary depending on the end product requirements. For 
example, if a whole cell product was required then the initial selection of cells to enter 
the expansion phase would be important. Being able to have near real-time feedback 
in the cell culture environment reduces the risk of batch failure and consequently 
increased costs as well as market supply issues. Though this work is looking at the 
application of hMSC to promote angiogenesis the application of the MCF ELISA can 
work in any therapeutic area where cytokine expression is a critical parameter. If the 
multiple cellular products, which in this case is the cytokine production for hMSCs, 
needs to be monitored at various stages of the production process then there would be 
multiple roles for the MCF platform. 
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Figure 25 Manufacturing of hMSCs. A simplified schematic indicating the stages 
where the MCF ELISA platform could be utilised 
The aim of this work was to determine the feasibility of using the MCF ELISA 
platform for the detection of IL-8 and HGF cytokines while ensuring the reliability, 
robustness and time efficiency required for the manufacturing environment. In the 
case of the IL-8 assay the limits of detection and coefficient of variation will be 
compared to a commercially available 96 well plate kit and the magnetic Luminex 
screening assay used in Chapter 3. Pre-validated commercially available antibody 
pairs with protocols for making up the standards were used to translate into the MCF 
ELISA platform. 
4.2 Materials and Methods 
4.2.1 Materials 
Human IL-8 ELISA Ready-SET-Go, human IL-8 recombinant protein was purchased 
from eBioscience, (Hartfield,UK). Human Il-8 cytoset, high sensitivity strep-HRP 
was obtained from ThermoFisher Scientific, (Paisley, UK). Human HGF monoclonal 
antibody (clone24516), human HGF biotinylated affinity purified polyclonal with 
analytes: CXCL8/IL-8 (BR18) FGF basic (BR47) HGF (BR66) PDGF-AA (BR56) 
VEGF (BR26) were purchased from Bio-Techne, (Abingdon, UK). Fetal bovine 
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serum [Origin: E.U. Approved (South American)] were from Invitrogen Gibco now 
ThermoFisher Scientific, (Paisley, UK). The Bio-Plex MAGPIX System, and Bio-
Plex Manager software were purchased from Bio-Rad Laboratories Ltd (Watford, 
Hertfordshire, UK). Micro capillary film (MCF), 10 capillaries each with a 〜200µm 
diameter (Figure 24) was produced by Lamina Dielectrics Ltd (Billingshurts, West 
Sussex, UK). MAGPIX multiplex reader was purchased from Bio-Rad Laboratories 
Ltd, (Hertfordshire, UK). Phosphate buffered saline (PBS) was obtained from Lonza 
(Slough, UK). SIGMAFAST o-phenylenediamine dihydrochloride (OPD), urea 
hydrogen peroxide/buffer tablet and Tween-20 were purchased from Sigma (Dorset, 
UK). HP Scanjet G4050 Photo Scanner with built-in transparent materials adaptor 
was purchased from Amazon (Slough, UK). Chip vortexer with plate holder platform 
was obtained from Agilent Technologies LDA UK Limited (Stockport, UK). 
4.2.2 96 well plate ELISA 
The 96 well plate ELISA was carried out as per manufactures instructions, the coating 
was reconstituted to 1µg/ml; 100µl was added to each well of a 96 well flat-bottomed 
plate which was then incubated over night at 4°C. Coating antibody was aspirated and 
the wells washed 4 times with 400µl wash buffer. 300µl of blocking buffer (provided 
as part of the IL-8 cytoset, individual components not specified) was added to each 
well and incubated for 1hr at room temperature, assay buffer was then aspirated and 
100µl of sample or known standard added to designated wells. 50µl of 0.04µg/ml 
detection antibody was added to each well and the plate was incubated at room 
temperature on a chip vortexer with a plate holder platform set at 700 rpm for 2hrs. 
After incubation the liquid was aspirated, and the plate washed 5 times with 300µl 
wash buffer, then 100µl of streptavidin diluted to 1/2500 was added to each well and 
incubated for 30mins at room temperature on a chip vortexer with a plate holder 
platform set at 700 rpm. The liquid was aspirated, and the plate washed 5 times with 
300µl wash buffer, 100µl of tetramethylbenzidine (TMB) substrate (provided as part 
of the IL-8 cytoset) and incubated for 30mins at room temperature on a chip vortexer 
with a plate holder platform set at 700 rpm. 100µl of stop solution was added to each 
well and absorbance was measured at 450nm within 30mins of the stop solution being 
added. 
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4.2.3 Luminex Assay 
Standards were reconstituted as per manufacturer’s instructions; 6 standards were 
made in a 3-fold dilution series. Microparticles were mixed and diluted in 5ml of 
RD2-1 diluent; 50µl of mixture was added to each well flowed by 50µl of sample or 
standard which was added to designated wells. The plate was then covered with a foil 
plate sealer and incubated for 2hrs at room temperature on a horizontal orbital shaker 
set at 800rpm. Using a magnetic plate holder removal of reagents and wash buffer 
was done by securing the plate in the magnetic plate holder, after resting in the holder 
for 1min liquid was removed by inverting the plate. Post sample incubation the plate 
was washed 3 times and 50µl of diluted biotin antibody cocktail was added to each 
well. The plate was covered with a foil plate sealer and incubated for 1hr at room 
temperature on a horizontal orbital shaker set at 800rpm. The plate was washed 
3 times and 50µl of dilute streptavidin-PE was added to each well the plate was 
covered with a foil plate sealer and incubated for 30mins at room temperature on a 
horizontal orbital shaker set at 800rpm. Post-incubation the plate was washed 3 times 
with wash buffer; particles were resuspended in 100µl of wash buffer and placed on 
the shaker for 2mins.The plate was then immediately read using a MAGPIX multiplex 
reader and the data analysed using Bio-Plex Manager Software. 
4.2.4 MCF ELISA 
The MCF ELISA was carried out by following the SOP- Microcapillary film 
operational procedure – Multi-Syringe Device: Singleplex Sandwich ELISA Standard 
Curve produced by Capillary Film Technology (Appendix 2). A solution of coating 
antibody was prepared to the required concentration using PBS as the diluent. The 
coating antibody solution was aspirated into a 30cm long piece of MCF (Figure 24) 
by using a 2cm long piece of tubing to interface one end to the MCF with a 5ml 
syringe, liquid was taken up by releasing the syringe ensuring all capillaries were 
filled. 
The piece of MCF was placed inside a sealable plastic bag which contained a tissue 
moistened with water and then incubated inside the humid environment for 2hrs. Post 
incubation blocking solution was then aspirated into the MCF; the MCF was placed 
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back in the moist environment and incubated for 2hrs. Post-incubation the MCF was 
washed with wash buffer using the same aspirating technique. 
 
Figure 26: MCF strips, each 3cm in length in the rubber connector strip (Capillary 
Film Technology 2014). 
The MCF was cut into 3cm strips and, using PBS with 0.01% tween as lubricant 8 
strips were inserted into a rubber connector strip which forms part of the MSA 
(Figure 26). The rubber strips were then inserted into a plastic holder which was then 
connected to syringes and the MSA (Figure 27). 
 
Figure 27: MCF strips in the rubber connector strip inserted into the MSA (Capillary 
Film Technology 2014). 
The MCF strips were filled with PBS until all capillaries were full and no air bubbles 
could be seen. 150µl of standards or sample were pipetted into wells of a custom 
designed plate which can hold the MSA while the MCF strips are dipped into the 
wells. The knob on the MSA was rotated 6 times (Figure 28), which aspirated 78µl of 
solution from each well.  
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Figure 28: Turning of the MSA knob while the MCF strips are inserted into reagent 
wells (Capillary Film Technology 2014). 
The standards or samples were incubated for 30mins at room temperature. 150µl of 
wash buffer was added to the next row of corresponding wells and the solution was 
aspirated into the MCF post incubation. Biotinylated antibody solution was made to 
the required concentration, 140µl was added to each well and aspirated into the MCF; 
this was incubated for 10min at room temperature and then washed once. A solution 
of streptavidin was made to a concentration 1µg/ml and added to each well, and 
incubated for 10mins at room temperature, post incubation the MCF was washed 
3 times. A solution of 4mg/ml OPD was made and 150µl added to each well, this was 
aspirated and the MSA placed on a flatbed scanner for measurements. Image analysis 
was conducted on the scanned images using imageJ software. The RGB images 
(Figure 29C) were split into the red, green and blue channels, only the blue channel 
(Figure 29B) was used for the analysis. A 6mm2 area was selected and overlaid 
successively on each of the 8 strips. A grayscale profile (Figure 29C) for each strip 
was produced and the peak heights measured, each peak corresponds to one capillary. 
 
Figure 29: Image processing steps conducted in ImageJ. Converted substrate can be 
seen in all 10 capillaries (A), the image is split into the red, green and blue channels. 
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Only the blue channel is used for analyses (B). A grey scale profile in produced by the 
software (C) from which the peak heights are measured, and the absorbance 
calculated. 
The absorbance is proportional to the concentration of analyte the greater the amount 
of analyte, the greater about of substrate is converted, producing a higher 
concentration of colour which in turn causes more light from the flatbed scanner to be 
absorbed. From the peak high was absorbance determined by: 
 
"𝐴𝑏𝑠" =  −log (𝐼/𝐼o) 
 
(Equation 1) 
Where I is the absorbed light and Io the transmitted light. 
A standard response curve using known concentrations was developed from which 
unknown sample concentrations can be calculated.  
4.2.5 Model fitting 
With all three ELISA platforms used in this work a standard curve also referred to as 
a calibration curve is required from which the unknown sample values can be 
calculated. In both the Lumiex and standard 96-well plate ELISA methods a serial 
dilution of known standards are run on every plate. With the MCF ELISA known 
standards are used in the development and validation processes, when running 
samples known concentrations are inserted into runs, as due to the capacity of the 
MSA it is not possible to formulate a full standard curve on every run. In order to 
insure the accuracy of the standard curve an appropriate mathematical curve fit model 
must be used (Herman et al. 2008). In this work the 4 parameter logistic regression 
model (4PL) was used for the 96 well plate and the MCF platforms, the 5 parameter 
logistic regression model (5PL) was used for the Luminex assay. The 4PL model was 
calculated using Microsoft Excel software, the 5PL model was fitted within the 
Lumiex software. The 4PL model, as with all regression models, aims to achieve the 
smallest weighted sum of squared errors (SSE) through adjusting the 4 parameters on 
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the curve(Gottschalk & Dunn 2005). The 4 parameters are the minimum response 
(A), the maximum response (D), the inflection of the curve (C) and the degree of the 
slope (B), the equation is (Findlay & Dillard 2007): 
𝑌 = (
𝐴 − 𝐷
1 + ((
𝑋
𝐶)
𝐵
)
) + 𝐷 
(Equation 2) 
The 5PL model includes the same parameters in the 4PL model but takes into account 
the asymmetry of data by adding a fifth parameter (G) which controls the degree of 
asymmetry of the curve and for asymmetric data sets results in a better curve fit 
(Gottschalk & Dunn 2005), the calculation is (Findlay & Dillard 2007): 
𝑌 =
(
 
 
 𝐴 − 𝐷
((1 + (
𝑋
𝐶)
𝐵
))
𝐺
)
 
 
 
+ 𝐷 
(Equation 3) 
Assessing the quality of the curve fit is also required, in this work the SSE value 
which is referred to as residual variance has been used in the 5PL model. The SSE 
calculates how far away the actual data points are to the curve of best fit, therefore 
calculating the quality of the standard curve. The smaller the SSE value the better the 
fit. If the curve fitting model is a poor fit to the true data, this cannot be compensated 
for; if the model is deemed a poor fit then the choice of model must be re-examined 
(Wild 2013).  
4.3 Work flow of ELISA Methods 
The three ELISA platforms used in this work have a number of advantages and 
disadvantages between the platforms in terms of cost, capacity, work flow and time. 
There are also the technical limitations to consider in terms of test accuracy, 
reliability and sensitivity. The ELISA platform selected needs to be fit for purpose; 
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the requirements of a research laboratory may be different to a manufacturing facility, 
therefore the role the ELISA platform needs to fulfil must be considered. Across all 
three platforms the reagent requirements are similar (Figure 30). The 3 platforms used 
the sandwich assay method which requires a capture and detection antibody. It is 
widely reported that antibody behaviour, in terms of binding affinity and cross 
reactivity, can be influenced by the preparation method of the antibodies, the surface 
to which the capture antibody is immobilised and the buffer reagents used (Butler et 
al. 1992; Dmitriev et al. 2013; Tarakanova et al. 2015; Cohn et al. 2015). The 
structure of an antibody is critical to its performance, therefore any factors such as 
pH, which change the structure of the antibody, in particular the binding site, or 
conformational changes which occur while the antibody is immobilised on a solid 
surface, could result in loss of function (Butler et al. 1992; Tarakanova et al. 2015). 
In this work the antibody pairs (capture antibody and detection antibody) were 
sourced from a commercial company whom had validated the compatibility of the 
antibody pairs and optimised the reagent conditions in terms of buffer pH and 
concentration required for the 96 well plate formats.  
 
Figure 30: Key reagents of ELISA assays, the utilisation of these reagent varries 
between the ELISA platform. The 96 well plate ELISA (Figure 31) and the MCF 
ELISA (Figure 33) utilise a colourimetric based format where by a substrated is 
converted using streptavidin HPR,  which results in colour formation. The formation 
of colour is directly proptional to the concentration of analyte. The Luminex platform 
(Figure 32) uses a fluorescent detection method in this incidence streptavidin 
conjugated to PE. 
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The commonly used 96 well plate ELISA platform consists of 6 incubation steps 
including capture antibody immobilisation, blocking reagents, detection reagents, and 
samples, with repeated wash steps in between (Figure 30 and Figure 31). From a 
liquid handling perspective, the assay is straightforward and requires basic skills to 
carry out; it is a series of pipetting steps and washing steps, but the time required to 
carry out the steps is considerable. In addition to the long incubation times outlined in 
Figure 31 when running the plate manually the repeated reagent pipetting and 
washing increases length of time it takes to perform the assay. There is scope to 
utilise automatic liquid handling robots in order to reduce the labour intensiveness of 
the manual pipetting (Kong et al. 2012) however this does not overcome the 
incubation time requirements. Post-sample addition 4hrs of incubations are required 
in this example, though incubation times are also influenced by antibody 
performance, in this instance incubation times were determined by the manufacturers 
protocol. In the 96-well plate colorimetric format it is only possible to detect one 
analyte per well which limits the throughput of the assay, and in situations where 
samples are precious and require multiple analytes to be measured it is not an optimal 
system. A multiwell plate reader is used to determine absorption levels in each well; 
the run time on a plate reader is relatively short 〜5mins however from the absorption 
values need to be converted into concentrations. This is done by creating a standard 
curve using serial dilutions of known concentrations of analyte. The standard curve 
also needs to be fitted to a regression model to calculate fit and confidence in the 
values. 
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Figure 31: Flow diagram of the 96 well plate ELISA format. Images are 
representative of 1 well of a 96 well plate, image components are explained in Figure 
30. This work flow requires a minimum of 17hrs of incubations and 9 washes. One 
analyte can be detected per well using this format. 
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The Luminex platform addresses some of the limitations of the 96 well ELISA 
platform. The capture antibodies are immobilized on colour coded beads which can to 
distinguished from one another within the same well allowing multiple analytes can 
be measured in one well. This reduces the amount of sample required for analysis, 
and is consequently more time efficient. In the context of this work for the amount of 
data the Luminex has produced in 1 plate 5 standard 96-well ELISA plates would 
have been needed. Over all incubation times in a Luminex plate are also reduced from 
〜17hrs to 〜3.5hrs (Figure 31 and Figure 32), this is attributed to the beads being 
pre-coated with the capture antibody, and no blocking step being required. While it is 
possible to buy pre-coated 96-well plates these cost more and do not have the added 
benefit of multiplexing which the Luminex platform has. Though the costs can vary in 
terms of reagents and labour verses the amount of data obtainable per plate the 
Luminex platform is considered to be overall more cost effective (Wild 2013). From a 
manufacturing of a cell therapy perspective the Luminex platform is not perfectly 
compatible. As discussed in chapter 2 section 2.8 reducing the sample to result time is 
critical in such a dynamic growth environment, once the sample has been added to the 
Luminex plate there is still 3.5hr or incubations on top of which there are also 9 wash 
steps in total, and the plate can take more than 20mins to run on the machine (run 
time is dependent on the number of analytes being detected per well). Though, as with 
the standard 96-well plate format there is the scope to investigate the use of automatic 
liquid handling machines in tandem with the Luminex platform. The current 3.5hrs 
incubation times could still be seen as a time delay from obtaining results. Measuring 
all the wells on the plate takes more time that the plate reader used in the 96 well pate 
formats. For a 5-cytokine panel, the run time is 〜1hr, however there is the added 
advantage that all the analysis is carried out in the Bio-Plex Manager Software 
including the 5PL model fitting. The Luminex plate has the capacity to analyse 41 
samples per plate when allowing for each sample to be run in duplicate. Wells on the 
96 well plate also need to be allocated for analyte standards and a matrix normalising 
control which is required for every plate run.  
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Figure 32: Flow diagram of the Luminex assay format. Images are representative of 1 
well of a 96 well plate image components are explained in Figure 30. This platform 
requires 3.5hrs incubation and 9 wash steps, in this instance 5 analytes can be 
quantified per well.  
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The MCF ELISA format addresses the issue of long incubation times, post addition of 
the sample incubation times can total 50min or less (Barbosa et al. 2014), and due to 
the use of the MSA washing is carried out by rotating a knob 6 times as opposed to 
pipetting and aspirating which also reduces the time needed to carry out the washing 
steps.  
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Figure 33: Flow diagram of the MCF ELISA formant. Images are representative of 10 
capillaries image components are explained in Figure 30. The MCF ELISA requires 
3.5hrs in incubation steps (excluding OPD incubation time) and 6 wash steps, post 
sample addition an image can be obtained within 32mins; however the image requires 
further analysis using imageJ software in order to calculate the absorption. One 
analyte can be detected per strip  
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4.4 Results and Discussion 
4.4.1 Magnetic Luminex Screen Assay- IL-8 standard curve 
The most important steps when developing an immunoassay is the validation and 
calibration. Every commercial kits require standards with a known concentration to be 
run on every plate in order to formulate a calibration curve from which unknown 
concentrations can be calculated.  In this work the Luminex platform comprises of 
magnetic beads pre-coated with antibodies specific for one of the target analytes 
(Figure 32). Each well on the 96 well plate contained 50µl mixture of magnetic beads 
for all 5 target analytes, fresh culture medium was used as the control sample against 
which the results were normalised. 
  
 
Figure 34: Standard curve for IL-8 analyte produced using Bio-Plex Manage Software. 
Values were formulated from standards in a five panel magnetic Luminex screening assay 
and calculated within the Bio-Plex Manage Software. A 1 in 3 serial dilution was carried 
out 5 times resulting in standard concentrations of 1140pg/ml 380pg/ml, 126.67pg/ml, 
42.22pg/ml, 14.07 pg/ml and 4.69 pg/ml. The standards were carried out in duplicate and 
then fitted to the 5PL model. From the standard curve the Bio-Plex Manager Software 
calculated the upper limit of quantitation (ULOQ) at 1141.801pg/ml and a lower limit of 
quantitation (LLOQ) which was 4.68pg/ml. A residual variance value of 0.0944was  
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calculated deeming the curve a good fit 
The Luminex assay has an upper limit of detection/quantitation (ULOQ) of 
1144.619pg/ml and a lower limit of 4.649pg/ml for IL-8. Previously reported values 
hMSC IL-8 secretion lie within these limits, based on the data produced in chapter 3. 
However, given the disparity of hMSCs culturing methods discussed in chapter 2 
section 1.8.2 dilutions of sample maybe required. For example Potier et al. (2007) 
reported 780±390 pg/ml IL-8 secreted by hMSCs cultured in hypoxic condtions and 
440±230 pg/ml in normoxic conditions, accounting for the standard deviation of the 
quantities produced in the hypoxic conditions exceeds the ULOQ for this Luminex 
assay. 
4.4.2 96 well plate based IL-8 ELISA standard curve 
 
 
Figure 35: IL-8 Standard curve produced from a standard 96 well plate ELISA 
following manufacturers’ instructions. Results were fitted to the 4PL model. Standard 
concentrations were 800pg/ml, 400pg/ml, 200pg/ml, 100pg/ml, 50pg/ml, 25pg/ml, 
12.5pg/ml and 0pg/ml. r2= 0.99973, LOD=0.698088pg/ml, CV 0pg/ml 24.96% (n=3) 
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4.4.3 MCF IL-8 ELISA 
Sensitivity of an ELISA assay can be determined by how much signal is produced 
when no analyte is present in the assay, the lowest concentration detectable should not 
fall within 3 standard deviations of the mean of the absorbance value when no analyte 
is present (Wild 2013). One of the parameters that can help improve the sensitivity of 
an ELISA assay is the selection of a good blocking buffer. Blocking buffers prevent 
the non-specific binding of detection antibody and are applied to the ELISA system 
after the capture antibody has bound to the surface. In commercial kits such as the one 
used in this work the manufacturers offer the kits with all the recommended buffers to 
use in a well plate format. Blocking buffers generally contain some form of protein(s) 
and the effectiveness of blocking buffers will vary depending on the surface 
chemistry of the solid surface they are binding to, consequently as the MCF is made 
of FEP the surface chemistry will be different to polystyrene. Figure 36 shows 4 
different blocking buffers trialled in the IL-8 MCF ELISA assay but without the 
presence of any analyte. 
 
Figure 36: determining optimal blocking buffer to produce the least back ground 
absorbance in the MCF. Data from 5min incubation with OPD (n=3-10) 
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In Figure 36 the highest signal is seen with the milk powder blocking solution which 
has an absorbance above 0.25 and a standard deviation of 0.14. while BSA heated had 
a lower mean absorbance value compared to the milk powder the standard deviation 
was greater at 0.15. BSA had the lowest mean absorbance value of 0.04, FBS had a 
slightly high signal of 0.039 however FBS had a smaller standard deviation of 0.005 
compared to BSA with 0.016. FBS was selected as the best blocking buffer for the 
subsequent MCF ELISA runs.  
In standard colorimetric ELISAs the substrate is incubated with the conjugated 
immobilized enzyme and after a period of time usually optimized by the manufacturer 
a stop solution is added to prevent any further enzymatic reaction. This format is not 
possible with the MCF ELISA as addition of new reagents such as the stop solution 
requires the aspiration of the previous reagents, this would essentially result in the 
substrate (in this case OPD) being washed away and therefore removing the required 
coloured product. In the case of the MCF ELISA the strips must be scanned while the 
enzymatic reaction is occurring, therefore an optimal window of time needs to be 
determined in which an accurate set of data can be obtained. In the development 
phase the MCF strips are continuously scanned with the purpose of capture as many 
time points as possible. 
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Figure 37 A: IL-8 standard curves showing the effect of OPD incubation time on 
sensitivity. The respective observed values (coloured markers) and 4PL (solid line) 
model predicated values are shown. The experimental parameters were 10µg/ml 
capture antibody, 5µg/ml detection antibody, 4µg/ml HRP, 4mg/ml OPD, the 
standards were reconstituted in fresh hMSC cell culture medium. Error bars are 
B 
A 
   128  
 
representative of a minimum of 6 replicates. B: Absorbance values of data in A 
displayed over time. Repeated images were scanned every 2mins (n=3-10) 
Table 9: Summary of LOD and r2 values in Figure 37A. LOD was calculated from the 
absorbance value of the blank plus the 3 times the standard deviation 
Time 
(min) 
LOD 
(pg/ml) r2 
2 132.15 98.3% 
4 38.08 98.4% 
6 43.24 98.8% 
8 40.75 98.9% 
10 44.51 99.0% 
12 143.41 99.0% 
 
Determining the optimal time to measure OPD reduction is a balance between 
obtaining the lowest limit of detection, therefore making the assay more sensitive, and 
having the closest fit to the 4PL model which makes the assay more reliable. The 
scanning time can take between 1-2min which is not ideal in a rapid enzymatic 
reaction. However, in Figure 37A and Table 9 2min post addition of OPD produces a 
high LOD in comparison to the 4 subsequent time points, but the r2 of 98.3% indicates 
a good model fit. The LOD values are between 40pg/ml and 45pg/ml for 6-10min 
OPD incubation times. The LOD at 4min is below that range the r2 value at 4min of 
98.4% which indicates a good fit. After 10mins incubation the LOD steadily increases 
over time. An LOD of around 50pg/ml is further supported by the data in Figure 37B, 
the 12.5pg/ml and 25pg/ml conditions cannot be distinguished from the blank control 
over a 16min time period. The 50pg/ml condition can be distinguished until 
approximately 10mins incubation times were the standard deviation over laps with 
that of the lower values. In terms of establishing an optimal time point, based on the 
data in Figure 37 4mins produced a good curve fit an LOD of 38.06pg/ml and before 
the absorbance values drop in the 50pg/ml standard. One of the challenges of working 
with OPD without a stop solution is that in some capillaries the solution begins to 
fade over time (Figure 38). As shown in Chapter 3 levels of IL-8 and HGF in the T25 
flask format are higher than 100pg/ml for some cell lines and this was at a relatively 
small scale (5ml) compared to the largescale manufacturing environments where 
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concentrations would be expected to be higher. Hence a LOD of ~50pg/ml is 
acceptable for this application, based on the Luminex data in Chapter 3.  
 
 
Figure 38: Example of colour fading within the same capillary. This example shows 
IL-8 50pg/ml with 10mins OPD incubation. 
The reason for the disparity in colour within the same capillaries is unclear. In the 
literature nothing has been found relating this directly to OPD behaviour, though the 
use of OPD in a microfluidic platform with this specific set of conditions has only 
been done a handful of times before (Barbosa et al. 2013; Barbosa et al. 2014; 
Castanheira et al. 2015). Further investigation would need to be done; the possibility 
that the faded sections may not be as well coated with antibody would be an avenue 
that could be explored also. 
The IL-8 MCF ELISA was also tested with samples that had previously been tested 
using the Luminex platform (Figure 39). The samples were from some of the 
conditioned medium used in Chapter 3; two freshly made solutions of Il-8 with a 
concentration of 200pg/ml and 400pg/ml were also run on the same MSA. The 
images were scanned at 4mins, 6mins, 8mins and 10mins, concentrations were 
calculated using the fitted curves in Figure 37A.  
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Figure 39: Comparing Luminex measurements and known standards to the MCF 
ELISA platform using the standard curves formulated in Figure 37. A, B, C and D are 
conditioned medium samples used in Chapter 3; E and F are 400pg/ml and 200pg/ml 
respectively of freshly made standard form recombinant IL-8 protein.  
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4.4.4 MCF HGF ELISA 
 
Figure 40: HGF standard curve at 2, 3, 5, 7 and 8 minutes incubation with OPD. 
Standards are expressed as log values, the pg/ml values are 1000, 500, 250, 125, 62.5, 
31.25, 15.625 and 0. The respective observed values (coloured markers) and 4PL 
(solid line) model predicated values are shown. 
Table 10: Summary of LOD and r2 values based on data in Figure 40 
Time (min) LOD (pg/ml) r2 
2 1.39 56.79% 
3 102.38 95.31% 
5 36.42 99.08% 
7 27.99 97.22% 
8 3.17 97.38% 
 
4.4.5 Improving the measurement process 
In order to obtain meaningful results from the MCF ELISA the images were scanned 
and the processed using ImageJ software. The image processing was done manually 
therefore during some of the stages there is an opportunity to introduce errors or 
operator bias. As with any imaging process ensuring the equipment is clean and free 
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of artefacts is an important step. Artefacts can include liquid droplets on the outside of 
the MCF, dust and debris from the environment or the scanner itself having smudges 
on the scan surface. In plate readers and the Magpix system the optics are in an 
enclosed dust free environment, the flatbed scanner is more open to the environment 
and liquid droplets can form on the imaging surface from the end of the MCF strips. 
Operators must take extra care to ensure the scanning window is clean, however when 
scanning under a time pressure there is the risk of error and accidental spillage. When 
the images of the strips in full colour are split into the blue channels (Figure 41), some 
image quality issues can be seen but these will be discussed later. The operator must 
ensure that the portions of the strips selected for analysis are consistent. Issues arise as 
not all the capillaries may be full or have an equal distribution of colour therefore, the 
operator is deciding what they deem to be the best portion. This introduced variation 
as by nature a human operator will have a different option compared to another 
operator.  
A
 
B
 
Figure 41: Scanned images of MCF ELISA strips held in the MSA of a HGF ELISA 
with 6mins OPD incubation. A) Original full colour scan image B) Blue channel 
image of A  
Once a portion of the strip has been selected a grayscale profile is produced within the 
ImageJ software, the operator must then select a baseline at the top of the peaks and 
measure the height of each peak (Figure 42). Selecting a baseline is guided by the 
peak height, but when the peaks are not level the end placement of the baseline is on 
the operators’ discretion. In Figure 42B it can be seen that not every peak lies directly 
on the selected base line. The peak heights measured are transferred into an excel 
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document and the average absorbance calculated using the absorbance equation in 
Section 4.2.4. 
A  
B  
Figure 42: Analysed section of HGF MCF ELISA 1000pg/ml after 6mins incubation 
with OPD. A) Section of strip analysed as seen in ImageJ B) Grayscale of absorbance 
of image A 
Images in Figure 41 and Figure 42 show one of the challenges of the MCF ELISA 
systems is the improvement of the fluid handling, as seen in the images a number of 
capillaries have failed due to the liquid emptying from the capillary or because of a 
number of air bubbles. This can occur as a result of weakness in the rubber holder 
which connects the MCF strip to the MSA (Figure 27), or the strips were removed 
from the well too quickly when a solution was not fully aspirated into the strips 
therefore introducing air bubbles. The MSA is also in a vertical position when the 
solutions are being aspirated into the strips, but is then moved into a horizontal 
position for measurement which changes the forces exerted on the capillaries and can 
result in geometry induced capillary emptying (Rascón et al. 2016). The total failure 
of a strip would in a manufacturing setting be a negative attribute of this method, with 
the well plate and Luminex platforms liquid handling is straightforward and therefore 
less prone to error. The MCF does contain 10 capillaries that act as repeats which 
provides some tolerance to individual capillary failure. 
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The issue also arises that air bubbles or uneven mixing impact on the accuracy of the 
measurement, while the operator, when analysing the images, should avoid including 
non-uniform capillaries this is not always possible. The first issue encountered was 
that due to the strips being inserted into the connecting rubber seals manually not all 
the strips were perfectly parallel. The strips were also not directly touching the glass 
surface of the scanner due to the MSA which increases the length of the light path 
(Figure 43 A) and therefor the clarity of the image, this is due to light dispersing at 
the source (Myers & Lee 2008). This is demonstrated in Figure 43B and C where the 
image of the MCF scanned in contact with the scanner and therefore has the shortest 
light path has sharper contrast between filled capillaries and the capillary wall.  
  
 
A 
B C 
Figure 43 A) A depiction of the light pathway during imaging of the MCF ELISA 
using a flatbed scanner. B and C two section of MCF strip, B contains fully reduced 
NADP which was scan without the MSA hence the MCF was in direct contact with 
the flatbed scanner, image is representative of 3 scanned strips. C is a section of MCF 
containing 1000pg/ml HGF analyte scanned after 2min incubation with OPD, the 
MCF strip was scanned while being held in the MSA. Image is representative of 10 
scans. 
It can be argued that as long as the image quality is consistent any inherent errors will 
not affect the end result as the standard curve is calculated form the same quality 
image. The fact that the MCF strips are able to have up to 10 replicates per strip also 
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reduced the variability of the assay. The impact of one capillary being measured 
incorrectly will have less impact on the mean than if there were only 3 replicates. 
Usually in the 96 well plate format a standard curve is run on every plate but with the 
MCF the standard curve is not run at the same time as the samples. Other variable 
factors such as the placement of the strips in the rubber seal, and the distance between 
the scanner and the MCF strips must be consistent in order to negate any variation 
between conditions.  
An image analysis software was developed to automate the image processing with the 
aim of removing operator biases and increasing the speed of the image processing 
therefore reducing the time needed to obtain a result. The Luminex platform employs 
a highly calibrated and optimized LED based measurement system. The 96 well- plate 
platform uses a plate reader which is regularly calibrated and designed to obtain 
optimal readings. The MCF system currently uses a standard scanner though the 
scanner is set to the highest resolution the quality of the image selection is not optimal 
as seen in Figure 42B. This presents a number of problems when developing image 
analysis software, as the software processes the image a pixel at a time. A lower 
resolution (therefore less pixels) will have an effect on the end result. 
 
A  
B  
Figure 44: A) MCF strip 0pg/ml HGF 6mins OPD incubation processed using custom 
built software. B) 
The custom built software splits the image into the blue channel, it then realigns the 
capillaries in order to analyse a reliable cross section. It then finds the largest 
consistent section within the strip, this process aims to prevent sections which contain 
bubbles from being analysed, however this is not always possible if no such section 
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exists. When this situation occurs, the software keeps the bubble size included in the 
section to a minimum and will omit the value from that capillary from the end 
analysis. As seen in Figure 44A the quality of the image when interrogated to the 
individual pixel level deteriorates, a grayscale profile can still be obtained but the 
issue with establishing a level baseline is still present.  
A potential reason for the lack of a consistent baseline could be due to the 
10 individual capillaries in each strip not being uniform in terms of diameter. When 
the MCF is filled with 2,3-diaminophenazine (DAP), which is formed when OPD has 
been fully converted by HRP (Hamilton et al. 1999), the baseline becomes, to the 
naked eye, level (Figure 45). It should be note that this image was scanned in direct 
contact with the scanner so any inconstancies introduced by a longer light path will 
not be apparent in the profile. The outer 3 capillaries on both sides of the MCF are 
shorter in height than the middle four peaks. As the profile is an inverse profile this 
would provisionally indicate that the middle four capillaries had a lower concentration 
of analyte.  
 
Figure 45: Grayscale profile of Figure 43B, in which the MCF is filled with fully 
reduced OPD  
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An element which has not been discussed in detail is the selection of the antibodies 
used in the MCF ELISA. The antibodies used for IL-8 and HGF where antibody pairs 
which had be validated by the manufacturer and due to time constraints it was decided 
that further validation was not required. When pre validated antibody pairs are not 
available the specificity of the antibodies and any cross reactivity must be identified 
and validated within the same sample matrix.  
4.5 Conclusions 
Translation of the IL-8 and HGF ELISAs into the MCF ELISA platform has been 
achieved, though the LOD is higher than the Luminex and 96-well platforms in a 
large scale manufacturing setting this would not be an automatic impediment of the 
assay. In a manufacturing setting the aim would be to achieve as high concentrations 
of cytokine as possible therefore a higher LOD would in some instances be 
acceptable. Further optimisation can be carried out to increase the sensitivity of the 
assays, this could include selecting a blocking buffer which reduced the signal to 
noise ratio. The concentration of antibodies could be further optimised, values in the 
HGF and IL-8 assays were based on previous work by (Barbosa et al. 2014; Barbosa 
et al. 2013; Edwards et al. 2011). When considering an immunoassay to be used in a 
near online manufacturing setting more factors need to be considered. One of the 
current weaknesses of the MCF ELISA format is that it is not easy to check for 
sample/standard pipetting errors. With the Lumiex and the 96 well plate format 
samples/standards are pipetted minimally in duplicate the MCF ELISA is currently in 
a 8 strips per device therefore running samples in duplicate would mean only 4 
experimental conditions could be analysed in a single run. This could be overcome 
simply by increasing the capacity of the MSA. The fluid handling would also need to 
be improved, this is very operator dependant; the risk of losing an assay/sample due to 
the capillaries emptying would not be acceptable in a manufacturing setting. An 
automated image processing software would remove the current operator bias that can 
occur with the MCF ELISA image processing method. Though the custom built 
image processing software was not used for the analysis in this work it was shown 
that in order to develop a high quality image processing software, as with any imaging 
processing software the image quality needs to improve. There is a clear benefit to 
using the MCF ELISA over the Luminex and standard 96-well plate platform and that 
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is the reduced in time from sample addition to imaging, automated software would 
also reduce the time to receive a result. 
There is a lot of potential for using the MCF ELISA within a manufacturing setting. 
The rapid sample incubation to assay completion time is a benefit to the production 
environment. This work has taken the first steps into identify the challenges of using 
the MCF platform with a cell therapy manufacturing application as the focus. Il-8 and 
HGF ELISA assays have been shown to work in the MCF platform though more 
refinement is required in improve sensitivity.  
Reducing the amount of manual handling steps currently required would be a great 
improvement for the MCF ELISA. Barbosa et al. (2015) have shown the possibility of 
using fluorescently labelled antibodies, replacing the current OPD colorimetric 
system. This method removes the time pressure of scanning the strips within an 
optimal time frame and as with the Lumiex platform it also reduced the wash steps 
required which in turn saves time. Replacing the aspirating method to fill the 
capillaries with reagents would help reduce the risk of failed capillaries and improve 
the confidence that each capillary contains the same reagents concentration. Exploring 
the possibility of combing the MCF device with micro-needle injection systems 
would overcome a lot of the fluid handling challenges. Each capillary on the same 
strip could be coated with a different antibody which would increase the capacity and 
flexibility of the MCF ELISA. When using different fluorophores in the same strip 
the issue of spectral overlap needs to be taken into consideration and experimental 
set-ups designed with this in mind. The optical clarity of the MCF is a benefit but 
when trying to detect emitted fluorophores to one capillary light can bleed into the 
neighbouring capillaries. 
The ideal system in a manufacturing setting would to be able to integrate the MCF 
ELISA so it would be an at line system that could provide continuous and rapid 
feedback as to the cytokine levels in the culture system. Overall there is a lot of 
promise that the MCF ELISA platform could fulfil a currently unmet need for rapid 
quantification of cytokines within the cell therapy manufacturing setting, supporting 
the hypothesis that translating a plate-based ELISA assay into an MCF based 
microfluidic platform reduces the time between the addition of sample to result 
(Chapter 3). 
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5 Microfluidic cell based analytics 
5.1 Introduction 
Improving efficiency in bioanalytic and bioassays is a major challenge both at the 
research laboratory level to the large-scale manufacturing scale. To be able to 
combine two platforms whereby the bioanalytics occur either concurrently with the 
cell culture or within the same unit would save time, and ideally cost. There would 
also be the added benefit with a closed continuous system as this would reduce the 
need for manual handling steps and therefore operator error, and the ability to 
maintain sterility within the closed system. In Chapter 3 it has been shown that 
hMSCs produce a cytokine secretome that vary between donors and culture 
conditions. There was that added challenge of ensuring the integrity of the cytokines 
between production from the cell and measurement time. Work in Chapter 4 has 
shown that using the microfluidic MCF platform it is possible to detect and analysis 
two of the cytokines which were also measured in Chapter 3 using the Luminex 
platform. The use of the ELISA MCF is of the most benefit during the scale up 
culture environment when it is important to be able to monitor the conditions. It is 
however also important to have the cytokine or protein of interest production data 
during the cell line or clone section phase. There is time and cost saving benefits to 
this within allogenic treatment systems, cell recovery post cryopreservation needs to 
be determined and certain factors can also indicate at an early stage how a specific 
vial will perform. There is also the need for miniaturisation and rapid understanding 
of a cell populations’ behaviour in autologous treatments. Autologous treatments tend 
to have a limited sample size obtained from the patient and a less flexible treatment 
schedule. Looking towards the future of precision medicine individualised treatments 
require a fast turn around and a greater understanding of how the patients tissue will 
respond to a therapy.  
The MCF has the scope to fulfil a need for continuous system analytics, it has already 
been demonstrated that cytokine detection can occur inside the MCF using a 
sandwich ELISA method. The next challenge is to determine if hMSCs can also be 
cultured inside the MCF with the long-term prospect of being able to culture hMSCs 
at one end of the MCF and detecting cytokines as they are being produced by the cells 
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as explained in Chapter 4. Microfluidic cell based assays have been developed using 
other microfluidic platforms previously, primarily with a PDMS-based channel 
system (Eteshola & Leckband 2001; Kim et al. 2007). These systems often require 
isoelectric focusing and are mostly chip-based formats (Huanchun Cui et al. 2005). 
The MCF has the advantage that it is easy to manufacture in long lengths and has 
multiple capillaries in parallel. Like most microfluidic devices which provide a highly 
controlled and sensitive platform it will require refinement with the fluid handling.  
The first step was to determine if it was possible to culture hMSCs inside the MCF 
and what steps were required to improve the environment of the MCF which is made 
from FEP. The surface energy state of FEP has been shown to not facilitate the 
adhesion of cells; this is reflected in the fact cell culture bags are manufactured from 
FEP as cells do not adhere to the surface (Kurlander et al. 2006). Most adherent cells 
are cultured on standard tissue culture plastic which is made from polystyrene and is 
also like FEP, a hydrophobic polymer. The polystyrene surface is usually modified 
using either corona discharge under atmospheric conditions or gas-plasma under 
vacuum which produces a more hydrophilic surface (Ryan 2008). Due to the optical 
clarity of FEP and the use of this polymer for the MCF ELISA it was deemed 
unfeasible to change the polymer the MCF was fabricated from, therefore surface 
modification was the most appropriate step. 
The surface modification of FEP methods need to be compatible with the microfluidic 
dimensions of the MCF. Methods such as gas plasma require the plasma stream to 
have physical interactions with the surface which is not possible as much of the 
surface is internal. Taking into account these constraints and the fact that 
fluoropolymers are highly chemically inert so modifying using chemical reactions 
would be difficult, other avenues were explored. Poly (vinyl- alcohol) (PVA) and 
poly-L-lysine (PLL) have been shown to functionalise the surface of fluoropolymers 
through adsorption and hydrophobic interactions with the surface (Shoichet & 
McCarthy 1991; Coupe & Chen 2001). PVA and PLL are also biocompatible (Shan et 
al. 2009a; Jiang et al. 2011) and can be found in a liquid solution state which can be 
aspirated into the MCF overcoming the physical constraints of other surface 
modification methods. When modifying FEP for cell attachment the surface energy 
must be increased but there must be the correct functional groups that are optimal for 
the adhesion of the cell type or types used. As previously stated in Chapter 2 the ECM 
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is critical for cell function and survival in vivo, therefore these requirements need to 
be well-thought-out when culturing hMSC in vitro. There are multiple elements that 
need to be considered when developing a cell culture based platform made from FEP. 
The desired properties of FEP such as the optical clarity and robustness of the 
fluoropolymer need to be maintained after functionalization. The functionalization 
process must produce a homogenous coating equal or better than current methods 
used to culture the cell type of interest; for hMSCs this is standard tissue culture 
plastic. The function of the cells also needs to be maintain on the modified surface, 
adhesion does not automatically equate to cell viability and secretome expression, 
therefore comparisons need to be made to the most relevant condition the cell type 
has been studied in. It is always desirable for the functionalization process to be as 
inexpensive and as easy to carry out as possible. Options have been presented that can 
satisfy these requirements. Once the FEP surface had been functionalised it needed to 
be further optimised in order for cells to adhere and proliferate but any further steps 
needed to comply as much as possible with these requirements. 
Post-surface chemistry optimisation the MCF was coated with the solution which 
facilities the highest level of hMSC adhesion while maintaining viability and was the 
most consistent across repeats. Either prior or post seeding hMSCs were stained with 
one of three fluorescent stains and imaged in order to present a better understanding 
of the cell morphology and behaviour inside the MCF. Initial development work of 
the hMSCs inside the MCF was carried out.   
5.2 Materials and Methods 
5.2.1 Materials 
Fluorinated ethylene propylene copolymer (FEP-Teflon®) 0.1mm thick films with 
dimensions 150mm x 150mm were purchased from Goodfellow Cambridge Ltd 
(Huntingdon, England). A 2.86 cm diameter little B circle medium punch was sourced 
from Amazon EU (Rue Plaetis, Luxembourg). Low molecular weight PVA powder 
(13,000-23,000 Da 99% hydrolysed), medium molecular weight PVA (37,000-50,000 
Da 99% hydrolysed), high molecular weight PVA (〜130,000 Da 99% hydrolysed), 
2% w/w sterile gelatin, poly-L-lysine hydrobromide molecular weight 70,000-
150,000 0.01% solution, 1g poly-L-lysine hydrobromide molecular weight 70,000-
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150,000 by viscosity and sodium hydroxide 1M (Sigma Aldrich Company 
Sigmacote®, 6 well plate sterile CellCrown™ inserts and Corning® Costar® ultra-
low attachment 6 well plates were sourced from Sigma Aldrich (Dorset, UK). IC 
fixation buffer, IC permeabilisation buffer, ethidium homodimer-1 (EthD-1), 
PrestoBlue, Alexa Fluor 546 phalloidin, LIVE/DEAD viability/cytotoxicity kit for 
mammalian cells, CellTracker™ Green 5-chloromethylfluorescein diacetate 
(CMFDA) dye and trypsin 0.25% (1X) Solution with 0.1% EDTA were purchased 
from ThermoFisher Scientific (Paisley, UK). Bone marrow derived human 
Mesenchymal Stem Cells (hMSCs), Dulbecco's Modified Eagle Medium (DMEM), 
ultra-glutamine 2nM and phosphate buffered saline were supplied by Lonza (Slough, 
UK). Fetal Bovine Serum (FBS) was sourced from Gibco life Technologies (Paisley, 
UK). Ultrapure water was sourced from a Milli-Q purifier (Millipore Corporation, 
Billerica, MA, USA) was used to make up solutions after sterilisation. Standard tissue 
culture plastic 6 well plates were purchased form Fisher Scientific (Loughborough, 
UK). 
5.2.2 Coating of FEP with Poly-L-Lysine 
Circular tokens of FEP were hand cut from a sheet with 0.1mm thickness using a 
standard 6 well tissue culture plate well as a template. The token size was about 
9.6cm2 as per standard 6 well plate wells. The tokens were autoclaved in deionized 
water for sterility and when being used for cell culture were placed in ultra-low 
attachment six well plates, one token per well, and dried under aseptic conditions 
inside a biological safety cabinet overnight. Tokens which were being used for 
surface characterisation were placed in standard 6 well plates and dried inside a 
biological safety cabinet overnight. PLL was reconstituted at room temperature with 
sterile deionised water to a stock concentration of 20mg/ml. The solution was stored 
at 2ºC-4ºC until required. Sodium hydroxide was used to adjust pH to 11 immediately 
before use (Table 11). To each well in a 6 well plate 2mls of solution was added and 
incubated for the required amount of time at room temperature, excess solution was 
aspirated, and the tokens left to dry for a minimum of 2hrss. Live/dead staining of the 
adhered cells was carried out by washing the tokens twice with PBS, 2mls of a 
working solution comprising of 4µM red-fluorescent ethidium homodimer-1and 2µM 
green-fluorescent calcein-AM was added to each well. The plate was wrapped in foil 
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and incubated at 37°C for 40mins; post incubation the plate was imaged using a 
fluorescent microscope.   
Table 11 PLL and NaOH solution rations 
Solution PLL NaOH Final PLL concentration 
(mg/ml) 
1.5PLL0.5pH11 1.5 0.5 15 
1PLL1pH11 1 1 10 
0.5PLL1.5pH11 0.5 1.5 5 
 
When using the PLL 0.01% sterile filter solution formulated by the manufacturer 
2mls of the solution was added per FEP token per well in a 6well in a 6 well plate. 
The adjusting the pH of the PLL for the PLL at pH 11 conditions was carried out by 
adding NaOH to 9mls of PLL, the end total volume was then divided equally between 
three replicate wells (Figure 51). 
5.2.3 Coating of FEP films with PVA and gelatin 
Circular tokens with a surface area of 4.9 cm2 were cut from 0.1mm FEP film sheets 
using a hole puncher (Figure 46A). For cell culture use the tokens we autoclaved in 
deionized water for sterility and then placed in ultra-low attachment six well plates, 
one token per well, and dried under aseptic conditions inside a biological safety 
cabinet. Tokens which were being used for surface characterisation were also 
autoclaved in deionised waster and placed in standard 6 well plates then dried inside a 
biological safety cabinet overnight. Stock solutions of low, medium and high 
molecular weight PVA were prepared at a concentration of 20 mg/ml by adding 10 g 
of PVA powder to 500ml warm sterile water then autoclaved. Post autoclave the 
solution was left in a water bath set at 85oC for approximately 4 hours or until the 
PVA powder had fully entered solution. The PVA and gelatin solutions were then 
mixed aseptically to the required final concentrations (Table 12) and used as indicated 
in the results and discussion section. Well inserts were coated with Sigmacote as per 
manufacturers’ instructions, autoclaved for sterility and used to secure the FEP tokens 
in the wells of the ultra-low attachment plates. Then, 3mls of polymer solution was 
added to each well, and the tokens incubated for the required time. Coating of 
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solutions containing gelatin were incubated at 37oC, all other solutions were 
incubated at room temperature.  
Table 12: PVA gelatin coating mixtures tested; all values shown relate to the mixture 
Sample PVA concentration 
(mg/ml) 
Gelatin concentration 
(mg/ml) 
20PVA0Gel 20 0 
16PVA4Gel 16 4 
12PVA8Gel 12 8 
8PVA12Gel 8 12 
4PVA16Gel 4 16 
0PVA20Gel 0 20 
 
 
Figure 46: Hole punch used to make FEP tokens of equal size (A). The measurement 
grid template; the spots indicate where contact angle measurements were taken on 
each token for the DoE experiment (B). The contact angle measurement set up (C). 
FEP tokens were attached to double side sticky tap on a flat glass slide. 1µl water 
droplets were placed on the red spots (B) and a camera took a photo of the water 
droplet on the surface.  
5.2.4 Surface characterization of modified FEP tokens  
Contact angle measurements (Figure 46B and C) were carried out on dried tokens 
using the automatic DataPhysics OCA 20. Ten 1 µl sessile drop measurements were 
taken per film; the drops were placed either randomly or according to a set grid 
pattern (Figure 46B). Design Expert version 8 from Stat-Ease Inc (Minneapolis, USA) 
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was used to conduct a three-factor general factorial design to investigate the effect of 
molecular weight of PVA, concentration of PVA solution and incubation time on the 
final contact angle. Contact angle measurements could not be conducted on the 
PVA/Gelatin coating mixtures due to the need for the surface to be dry in order for 
the measurements to be carried out. Dried gelatin rapidly absorbs moisture, attempts 
to place a 1 µl resulted in the drop instantly being absorbed. 
Atomic force microscopy (AFM) was undertaken using Veeco Explorer from Veeco 
(Cambridge, UK). On each film an area of 2 µm2 was measured in contactless 
(tapping) mode. 
 
 
Figure 47: Example of an XPS survey scan of FEP 
X-ray photoelectron spectroscopy (XPS) was conducted using K-Alpha X-ray 
photoelectron spectrometer from ThermoFisher Scientific (Paisley, UK). This 
technique was carried out within the Loughborough Materials Characterisation Centre 
at Loughborough university and with support from Pat Cropper. On each token a 
400 µm x 400 µm array was scanned at 16 different spots per array. The tokens were 
scanned for the presence of the elements fluorine (F1s), oxygen (O1s), nitrogen (N1s), 
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organic carbon (C1s) and carbon bound to fluorine (C1s C-F), an example of the 
survey scan can be seen in Figure 47. 
5.2.5 Culturing of hMSCs 
Human MSCs were cultured in Dulbecco's Modified Eagle Medium (DMEM) 
supplemented with 2nM ultra-glutamine and 10v/v Fetal Bovine Serum (FBS). Unless 
otherwise stated cells were cultured for six days with a medium change on day three, 
cell culture incubation occurred at 37°C, 5% carbon dioxide with 95% humidity. In 
normal culturing conditions cell passage was undertaken on day six. Cells were 
detached using trypsin 0.25v/v (1X) solution with 0.1% v/v EDTA. Cells were seeded 
at a density of 5x103 cell/cm2 unless otherwise stated with a culture medium volume 
of 0.2 ml/cm2. Cell counting as conducted using a NucleoCounter® NC-3000™ 
machine and the Via1-Cassette. 
5.2.6 Analysis of hMSCs attachment and growth on modified FEP 
token 
Cells were cultured as per Section 5.2.5. After 6 days of culture cells were passaged 
and seeded on to FEP on day six of cell culture the culture medium was aspirated and 
the tokens washed twice with 3mls PBS cells were then fixed on the tokens in 3mls of 
IC fixation buffer for 10 minutes at 4 ºC. Fixation buffer was aspirated, and cells 
washed three times with PBS and then incubated with IC permeablisation buffer at 
room temperature for 40 min, after which the buffer was aspirated, and tokens washed 
twice with 3msl PBS. The tokens were then incubated with 3mls of a 4 mM ethidium 
homodimer solution at 37 oC for 40 mins. Ethidium homodimer is a nucleic acid stain, 
when bound to DNA it emits fluorescence in the red channel. The ethidium 
homodimer solution was aspirated and 3mls of PBS added to each well. The plates 
were then placed in a Biostation CT (Nikon, Europe), and each well scanned in full 
with phase contrast and with wavelengths excitation 540 nm, emission 600 nm. 
Images were then processed using CL Quant 3.10 software (Nikon, Europe), the 
individual nuclei of each cell were counted. The modified tokens were compared to 
the same number of cells seeded in standard tissue culture plastic 6 well plates as a 
control.  
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PrestoBlue assay was carried out to access the viability of the hMSCs over time. 
PrestoBlue contains resazurin which is reduced by the mitochondria in living cells, 
the reduction results in a colour change the shifts the fluorescent emission spectrum 
(Boncler et al. 2014). Cells were seeded onto FEP tokens in ultra-low attachment 6 
well plates or into standard tissue culture plastic 6 well plates for the control. At time 
intervals stated in the result 300µl of culture medium was removed and replaced with 
300µl of PrestoBlue solution. The plates were wrapped in foil and incubated at 37°C 
for 40mins. After incubation 3x100µl samples were taken from each well and pipetted 
into a 96 well plate. The plate was read on a ELx800 micro plate reader at an 
excitation of 544nm and emission of 590nm; the gains were adjusted based of fully 
reduced PrestoBlue.  
5.2.7 Coating MCF and hMSC analysis in the MCF 
The addition and removal of solutions in the MCF was carried out by inserting the 
ends of the MCF into a rubber connector which was inserted into a piece of rubber 
tubing enabling a seal to form between the tubing and the connector. The set up was 
sterilised by autoclaving and a sterile 1 ml syringe was inserted into the unsealed end 
of the rubber tubing creating a closed and sterile system. 
 
 
Figure 48: Set up of MCF strip to meet the fluid handling and sterility requirements in 
order to fictionalise the surface and seed cells inside the MCF. The MCF was held 
between two rubber connectors which was then inserted into two pieces of rubber 
tubing. Liquid can be added or aspirated using the 1 ml syringes connected to the 
other end of the rubber tubing.  
   148  
 
The MCF was flushed with sterile PBS to remove any debris, and the required coating 
solution added ensuring the capillaries were completely full. After coating for the 
required about of time the MCF was washed with PBS to remove the coating solution. 
The MCF was then seeded with hMSCs at a concentration of 1.5x106 per ml. The 
MCF set up (  
Figure 48) was placed in the incubator and imaged periodically. Imaging was carried 
out either phase contrast or by fluorescently labelling the cells and imaged using the 
Nikon inverted eclipse ti fluorescent microscope. A number of fluorescent cell 
staining methods were investigated; these were alexa fluor 546 phalloidin labelling of 
the actin filaments, a green cell tracker dye and the live/dead cytotoxic staining also 
used in Section 5.2.6. 
5.2.7.1 Alexa Fluor 546 phalloidin labelling 
Post culture the MCF was flushed twice with PBS and filled with fixation buffer for 
15mins at room temperature. The MCF was flushed twice with PBS, filled with 
permeablisation buffer and incubated at room temperature for 40mins. Post incubation 
the MCF was flushed twice with PBS as filled with 5 units per ml solution of Alexa 
Fluor 546 phalloidin. The solution was incubated in the dark for 20mins and then 
imaged using the fluorescent microscope red channel. 
5.2.7.2 Live/Dead viability stain 
Post culture the MCF containing cells was flushed twice with PBS, and was then 
filled with a working solution of 4µM red-fluorescent ethidium homodimer-1and 
2µM green-fluorescent calcein-AM. The MCF was wrapped in foil and incubated at 
37°C for 40mins; post incubation the MCF was imaged using a fluorescent 
microscope. 
5.2.7.3 CellTracker™ green CMFDA dye 
Prior to seeding the MCF hMSCs were stained with green CMFDA dye, the dye us 
able to pass through the cell membrane and is retained in the cytoplasm. The cell 
suspension was incubated with 0.5µM dye for 30mins at 37°C, the cells were 
centrifuged at 220g for 5mins. The working dye solutions was aspirated and the cells 
resuspended in culture medium, the cell culture was then administered into the MCF. 
   149  
 
5.3 Results and Discussion 
As hMSCs are adherent and therefore long term cell survival and function is 
dependent on the cells ability to adhere to a surface it is important to establish the 
level of cell adhesion to FEP in comparisons to standard tissue culture plastic. FEP is 
a known hydrophobic material which is demonstrated by contact angle measurements 
of over 100° when measured using ultra-pure water (Figure 49 A). The surface energy 
and chemistry are thought to be why hMSCs will not adhere to the material as much 
when compared to standard tissue culture plastic, this is clearly demonstrated in 
Figure 49 B and C. After 6 days in culture the hMSCs seeded onto tissue culture 
plastic are more confluent and display morphology consistent with hMCSs in culture, 
a small number of cells can be seen on the FEP surface which have minimal or no 
contact to each other. This establishes the need to modify FEP so it provides a 
functional surface for hMSCs to adhere to. FEP is classed as a super hydrophobic 
material, hydrophobicity or hydrophilicity of a surface is related to the surface energy, 
hydrophobic surfaces have a low surface energy and vice versa (Lampin et al. 1997). 
Understanding the relationship between cell adhesion and functionality to surfaces 
properties including surface energy is one of the big challenges within the field of 
tissue engineering (Dewez et al. 1998).  
 
Figure 49: A) 1µl water droplet on unmodified FEP, the arrow indicates the point of 
water contact with the surface. B) hMSCs seeded on unmodified FEP at a density of 
5000cells/cm2 after 6 days in culture. C) hMSCs on standard tissue culture plastic at a 
density of 5000cells/cm2 after 6 days in culture, image in representative of 3 images 
per condition and three replicates per condition. 
Based on the literature two absorption methods using PVA and PLL were investigated 
to modify the surface of FEP for cell adhesion. Work by Shoichet & McCarthy (1991) 
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explored the use of PLL as a modification substrate of FEP, though the aim of this 
work was not to subsequently adhere cells to the surface. Findings by Shoichet & 
McCarthy (1991) determined that the molecular weight of PLL and the pH of the 
solution were factors in driving adsorption. When using this approach 3 solutions 
(Table 11) of PLL with a molecular weight of 70,000-150,000 mixed with a pH 11 
NaOH based buffer were initially investigated. FEP tokens were incubated with the 
PLL solutions for 72hrss, washed and seeded with hMSCs. The tokens were imaged 
initially after a 24hrss attachment period (Figure 50A-D) and 72hrss (Figure 50 E-H) 
at which point it is expected that hMSCs would have undergone at least 1 population 
doubling as shown in Chapter 3. 
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Figure 50: Attachment of hMSCs seeded at a density of 7.5x105cells/cm2 after 24hrss 
in culture. A) 1.5PLL0.5pH11 B) 1PLL1ph11 C) 0.5PLL1.5pH11 D) hMSC 
attachment control on standard tissue culture plastic. The same tokens were imaged 
after 72hrss in culture, the hMSC attachment control was carried out on standard 
tissue culture plastic Images are representative of 3 images per token or tissue culture 
plastic surface and each modification condition was carried out in duplicate. A 100µm 
scale bar present in each image. 
In Figure 50 after 24hrss in culture hMSCs can be seen in all images, in C the hMSC 
appear sparser and seem to be mostly individual cells compared to A, B and D taken 
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at the same time point. This could be due to a lower concentration of PLL in coating 
solution which results in a limited percentage of the surface being modified, or the 
conditions were not optimal to drive the adsorption of PLL. While more grouped 
areas of hMSC can be seen A and B the cells are more compact in the areas where 
adhesion as occurred as opposed to the tissue culture plastic control. Under standard 
culturing conditions the hMSC have spread and elongated more, forming connections 
between regions. After 72hrss in culture very few cells were observed on the 
0.5PLL1.5pH11 coating condition token, and reduction in cell number compared to 
the 24hrs images was observed on the 1PLL1pH11 and 1.5PLLpH110.5 coatings. Part 
of the challenge with using the method of Shoichet & McCarthy (1991) is that the 
modification was not carried out for the purpose of culturing cells. Subsequently the 
method has not been tested under cell culture conditions such as being in cell culture 
medium at higher temperatures for up to 6 days. Previous work has shown that after 
hMSCs adhere they produce their own cellular matrix within 24hrss which enables 
the cells to spread and grow (Li et al. 2013). What may have been seen in Figure 50 
after 24hrss is the initial focal adhesion of the cells, but the cells may not have been 
functional enough to spread and alter. In the control images, it shows that the hMSC 
should be more spread and do sustain the morphology at 72hrss. 
PLL is a substrate the is used to coat well plates and other tissue culture plastic to 
enable the culturing of cell types which require specific surface properties such as 
neurons (Khademhosseini et al. 2004; Shan et al. 2009a). The previous incubation 
time of 72hrss was been based on literature which indicated that over a longer 
duration (approximately 3 days) more PLL was absorbed onto an FEP surface 
(Shoichet & McCarthy 1991). It should be noted that much of the literature relating to 
the modification of FEP is dated, though still relevant analytical techniques and 
knowledge of material science have developed a lot since these publications. PLL is 
commercially available as a method to coat polystyrene cell culture plastic. To coat 
polystyrene, which is also a hydrophobic polymer, manufactures guidelines state that 
the PLL should be incubated on the surface for 5mins, and includes a drying step after 
washing. This protocol was followed when modifying the FEP surface in Figure 50. 
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Figure 51: Attachment of hMSCs seeded at a density of 5x105cells/cm2 after 24hrss in 
culture to FEP tokens incubated for 5mins in 0.01% PLL (A), 0.01% PLL at pH 11 
for 5mins (B) and 0.01% PLL at pH 11 for 2hrss (C), standard tissue culture plastic 
control (D) as the control condition. Images are representative of 3 images per token 
and two tokens per condition with a 100µm scale bar. 
After 24hrs adhered cells were observed on all 3 FEP coatings (Figure 51) and 
displayed anticipated hMSC morphology that is consistent with the control (Figure 
50). To gain more information regarding cell the viability of the adhered cells the 
coating conditions were repeated and after 6 days of total cell culture time the cells 
were stain using a live dead stain (Figure 52). Cells which produced red fluorescent 
were considered non-viable as the ethidium homodimer-1 was able to bind to DNA 
due to permeability in the cell membrane. Viable cells fluorescent in the green 
channel due to calcine-AM indicating esterase activity in the integral cell membrane. 
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Figure 52: Live/dead imaging of hMSC cultured for 6 days on FEP tokens modified 
with PLL. hMSCs were seeded at a density of 5x105cells/cm2 after 6 days in culture 
to FEP tokens incubated for 5mins in 0.01% PLL (A), 0.01% PLL at pH 11 for 5mins 
(B) and 0.01% PLL at pH 11 for 2hrss. Calcine-AM fluorescence (live stain) can been 
seen on the left with the exact imaging area in the ethidium homodimer-1 red channel 
on the right. Images are representative of 5 images per token and the coating 
conditions were carried out in duplicate. 
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Through using the manufacturers method of PLL coating of FEP improvement in cell 
attachment can be seen (Figure 51), and the cells which do attach are viable after 6 
days in culture (Figure 52). 
One of the challenges when developing a modification method for a cell culture 
application is maintaining sterility. Due to this issue the use of readymade PLL 
solutions with the same molecular weight range that were develop specifically for cell 
culture applications was explored as the manufacturer guarantees sterility. Both PLL 
solutions (the readymade and user reconstituted) used in Figure 50, Figure 51 and 
Figure 52 were added in excess, manufacturer recommendation was 1.0 ml/25 cm2, 
and 2mls was added per 〜9.6cm2 therefore disparity of concentration were not 
considered to be an issue as only a maximum amount of PLL can be absorbed onto 
FEP. Though PLL absorption onto FEP is not fully understood it is thought that 
hydrophobic interactions drive the absorption therefor once a portion of the FEP 
surface has been coated the FEP surface is no longer hydrophobic and more PLL can 
no longer be absorbed (K et al. 2007). The solutions were of the same molecular 
weight which has been reported to be the more critical factor with PLL as the longer 
chains provide more active amino acid binding sights for the cells to adhere to (Shan 
et al. 2009b). As cell attachment also occurs on FEP tokens modified with readymade 
PLL (Figure 51 and Figure 52), this modification method was further investigated 
with contact angle and AFM measurements and compared to FEP surface 
modification using PVA (Figure 53 and Figure 54). 
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A 
B  
C  
D  
 
Figure 53: AFM images A) plain FEP, B) 0.01% PLL incubated for 5min C) 0.01% 
PLL pH incubated for 5mins D) FEP modified with 20mg/ml PVA 130,000 MWt 
incubated for 24hrss. The colour intensity scale ( ) corresponds to the surface 
height with black represented the lowest height through to white indicating the higher 
areas.  Measurements were carried out in duplicate on a single token for each coating 
condition. 
AFM results (Figure 53) shows FEP based on two measurements had a mean surface 
roughness (Ra) of 4.6 ±0.3, the Ra mean value for the 0.01% PLL incubated for 5min  
   157  
 
(Figure 53B) and 0.01% PLL pH11 incubated for 5mins (Figure 53C) coating 
conditions were 4.75±0.8and 4.7±2.1, the lower the RA value the smoother the 
surface. The PVA coating produced the lowest Ra value of 2.2±0.7, which is out of 
the standard deviation range of the uncoated FEP indicating that PVA is present and 
reduced the surface roughness of FEP. The reduction of FEP surface roughness 
through the adsorption of PVA is consistent with work carried out by Kozlov et al. 
(2003). The PLL Ra values cannot be distinguished from the uncoated FEP results, 
this could indicate that PLL has not been absorbed in the regions measured using 
AFM. It could also indicate that PLL absorbed in a thinner layer therefore the contour 
of the FEP surface in maintained. A similar trend is also seen in the contact angle 
measurement results (Figure 54), FEP is shown to have a contact angle of over 100°. 
While the mean contact angle is reduced after token incubation with PLL to between 
80° and 100° error bars place the coating within the plain FEP range. Previous work 
has shown that when plastic is coated with PLL a contact angle of 63.2° was 
measured showing that PLL usually has a lower contact angle when coating plastic 
compared to FEP (Medina Benavente et al. 2014). As with the AFM the large error 
bars could be reflective of PLL not being present on the surface for some of the 
measurements. The PLL coating could be very thin and there for the surface energy of 
the FEP could be influencing the contact angle measurements, or PLL is not as 
hydrophilic as PVA. The standard deviation on the plain FEP within the same token is 
relatively small, however there was a significant difference between token 
measurements in the same condition.  
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Figure 54: Contact angle measurements carried out on modified or unmodified hand 
cut FEP tokens. 10 1µl drops were placed randomly and two contact angles per drop 
were measured (n=20 per token). 3 replicates were made per coating condition; PLL 
coatings were carried out with 0.01% PLL at a total PLL volume of 2mls and 
incubated for 48hrss. A total of 2mls of PVA solution was added per token, 20mg/ml 
PVA solution with molecular weight of 130,000 incubated for 72hrss or 96hrs. 
One of the challenges in surface modification is understanding the level of 
homogeneity of the modified surface. For example, AFM measures 2µm2 area of a 
9.6cm2 token which is 0.02% of the total surface area. Due to the time intensiveness 
and challenges obtaining AFM images and data these measurements were conducted 
in duplicate, it would be an extensive effort to comprehensively characterise such a 
large surface using AFM. Though in Figure 53 difference can be seen particularly in 
the PVA coating condition the small areas tested do not provide insight into the 
homogeneity of the coating over a larger surface area. However valuable insight into 
the surface roughness of the coatings was obtained using AFM as the significant 
difference between coating conditions in Figure 54 merits further consideration, the 
source of the variation needs to be determined or overcome with a more robust 
surface modification method. Consequently, after using the AFM data to focus the 
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coating methods to be investigated further a more detailed approach surface 
characterisation was developed and a consistent coating methodology. The 
methodology was improved by making tokens of the same size using a whole punch 
(Figure 46A) as opposed to manually cutting tokens using a stencil which could 
physically damage the surface. Based on previous data using PVA as the surface 
modification method was explored further, PVA was shown to have a greater impact 
on reducing surface hydrophobicity based on contact angle measurements (Figure 54) 
and surface roughness data (Figure 53). A design of experiment (DoE) approach was 
utilised in order to understand if the level of PVA modification could be controlled 
based on the molecular weight of the PVA, the incubation times and/or the 
concentration of the PVA in solution. Contact angle measurement was used as the 
method to determine the effects of the experimental conditions as it is a simple 
method compatible with a DoE approach and directly relates to the level of 
hydrophobicity/hydrophilicity of a surface (Kwok et al. 1997). 
 
 
Figure 55: DoE investigating factors influencing PVA surface modification of FEP. 
Data shows the effect of PVA molecular weight (13,000-23,000Da, 37,000-50,000Da 
and ~130,000Da), and concentration of PVA at 2mg/ml and 20mg/ml on the contact 
angle of coated FEP. Contact angle values are associated to the surface energy and 
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therefore relate to hydrophilicity or hydrophobicity of the surface. Outliers are 
indicated by dots; 20 measurements were carried out per film with 2 replicates per 
coating condition. 
The result of the DoE experiment shows that the hydrophobicity of FEP can be 
reduced in a controlled manner using different molecular weight of PVA. There is a 
stepwise decrease in the contact angle with increasing molecular weight of PVA, 
reducing the contact angle from ~85-95° to ~45°. The influence of PVA molecular 
weight in  
Figure 55 is consistent at both concentrations of PVA (2mg/ml and 20mg/ml) this is 
in agreement with previous work by Kozlov et al. (2003) in relation to PVA 
behaviour with hydrophobic surfaces. Molecular weight has been determined to be a 
significant factor with a p-value of <0.0001 on modifying FEP. Individually 
concentration and incubation time have been determined to not be a significant factor 
in reducing FEP contact angle with p-values of 0.6705 and 0.6549 respectively. A 
relationship between molecular weight and concentration has been determined to be 
within the boundaries of significance with a p-value of 0.0469.  Work carried out by 
Kozlov & McCarthy (2004) proposed that adsorption of PVA to a hydrophobic 
surface was a two-stage process. Firstly, hydrophobic interactions which reduce the 
interfacial free energy, then secondly crystallization of the PVA which results in 
stability of the layer. The work also proposed that the lower molecular weight 
produced a thicker layer of PVA due to the shorter polymer chains having the ability 
to crystallise more. In the work by Kozlov & McCarthy (2004) 3-5 measurements 
were conducted per surface and the total size of the modified token characterised is 
not stated so it is difficult to obtain insight into the homogeneity of the coatings. 
The ability to control the surface energy of FEP means that it is possible to investigate 
how relevant surface energy is to hMSC attachment and function. In  
Figure 56 20mg/ml PVA was used for each coating condition, though concentration 
was not deemed to have a significant impact on contact angle PVA is an inexpensive 
material so there was no draw back selecting the 20mg/ml concentration.  
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Figure 56: Attachment of hMSCs after 6 days in culture to FEP tokens modified with 
20mg/ml PVA of three different molecular weights. The tokens were incubated for 
24hrs or 96hrss in the respective PVA solutions. Standard deviation is representative 
of 3 replicates per coating condition.  
Though PVA can reduce the hydrophobicity and surface roughness of FEP it is not 
able to effectively facilitate adhesion of hMSCs (  
Figure 56). Even by producing a range of surface energies hMSCs did not adhere to 
the extent seen on standard tissue culture plastic.  
Cell attachment data implies that surface energy and roughness are not the main 
reason why hMSCs do not attach to FEP. Functional groups that relate to the ECM  to 
which the cells can attach to have been a focus of many surface modification methods 
(Rosso et al. 2004; Guilak et al. 2009), though PLL has previously shown to meet this 
requirement the coating cannot be as well controlled as PVA. Consequently, the 
approach of using a mixture of PVA and a protein which is commonly used for 
promoting cell attachment was adopted. PLL was not deemed a suitable substrate for 
this method as its functionality is strongly related to its physical structure and 
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orientation, hence using PLL in a mixture would add an extra element of  unneeded 
complexity (Davidson & Fasman 1967; Shoichet & McCarthy 1991). Other 
commonly used proteins such as collagen and Matrigel (a protein mixture) were not 
compatible with the FEP coating method as they are temperature and time sensitive. 
Gelatin is a commonly used substrate for cell attachment and is denatured protein, 
therefore its function is not thought to be so strongly related to its structure so the 
functionality of gelatin is unlikely to be impeded by the presence of PVA. Gelatin has 
also previously been used in the hydrogel field with PVA to facilitate cell adhesion 
(Miao et al. 2015). 
By modifying FEP with PVA and gelatin mixtures an improvement in hMSC 
numbers after 6 days in culture (Figure 57) compared to no gelatin (  
Figure 56) being present. Though the cell number was not equal to that seen on tissue 
culture plastic after 6 days in culture. As expected the coating containing no gelatin in 
Figure 57 had the lowest number of cells attached, the coating with only gelatin 
performed better but did not have the highest number of cells.  
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Figure 57: Cell attachment numbers to surfaces modified with PVA, gelatin or a 
mixture of PVA and gelatin. FEP tokens were incubated in the respective solutions 
for 96hrss, tissue culture plastic was used as the control surface condition. Cell count 
were carried on day 6 of culture, error bars are representative of 3 repeats. 
Based on the standard deviation in the cell attachment data (Figure 57) 8PVA12Gel 
and 20PVA0Gel produced the most consistent surface for cell attachment though 
4PVA16Gel had a higher percentage over all. To establish a reason behind this the 
coating methods were analysed using XPS. Due to the hydroscopic nature of dried 
gelatin contact angle analysis could not be carried out.  
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Figure 58: XPS data of FEP tokens modified with PVA, gelatin or a mixture of PVA 
and gelatin, incubation times of 24hrss (A) and 96hrss (B) were investigated. The 
surface was analysed for fluorine (F1s), oxygen (O1s), nitrogen (N1s), organic carbon 
(C1s) and carbon bound to fluorine (C1s C-F). Error bars are representative of mean 
values of 16 measurements from three replicates.  
Based on the XPS data (Figure 58) for the PVA only coating in both the 24hrs coating 
condition (A) and the 96hrss coating (B) fluorine can still be detected. This indicates 
that either the coating is less than ~5 µm in thickness, and the F1s electron can be 
targeted or that the coating is heterogenous and regions of unmodified FEP are 
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exposed. With a longer incubation time in all conditions containing gelatin the F1s 
and C1s C-F (atoms found in FEP) atoms are barely detectable compared to the 24hrs 
coating. This implies that a longer coating time results in a more homogenous coating 
and/or a thicker coating. The 8PVA12Gel coating and the 4PVA16Gel coating show 
the least level of exposed fluorine after 24hrss and 96hrss incubation. In 16PVA4Gel 
after 96hrss F1s and C1s C-F are also not detected. Based on the cell attachment data 
in Figure 57 and the XPS data in Figure 58 8PVA12Gel would appear to perform 
more consistently as a coating and facilitating cell attachment. Gelatin does enhance 
cell attachment though with PVA after 24hrss the coating is more homogenous. The 
incubation time is an important factor from a device manufacturing perspective, being 
able to functionalise a surface more quickly saves time and therefore money.  
Platter images of AFM data are able to show the physical location of identified atoms, 
this gives a greater level of insight into where specific elements were detected. Platter 
images of the coatings in Figure 59 concur with the XPS data (Figure 58) where FEP 
is (F1s) very low or undetectable components of gelatin or PVA are present (Cs1). 
Plain FEP (a) has the greatest amount of fluorine detected, though some organic 
carbon (Csl) can been seen this could be attributed to atmospheric carbon which can 
be difficult to eliminate in XPS machine.  
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Figure 59: XPS Platter images of a) uncoated FEP, b) FEP coated with 8PVA12Gel 
for 96hrs and c) FEP coated with 0PVA20Gel for 96hrs. The colour represents spatial 
distribution of F1s (blue - left hand side images) and Cs1 organic (red – right hand 
side images). Images are representative of three experimental replicas. 
a)
b)
c)
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Figure 60: PrestoBlue assay during six days of incubation (n=3) of hMSCs seeded on 
FEP tokens coated for 96 hrs.  As a control 50,000 cells on tissue culture plastic were 
also assayed. Error bars are representative of 3 measurements per replicate well. 
While previous data has shown the number of hMSCs attached to FEP tokens after 
culture, attachment does not automatically equate to functional cells therefore a 
PrestoBlue assay was conducted to determine the level of cellular metabolic activity. 
PrestoBlue data shows an interesting and consistent pattern across the 3 coating 
conditions (0PVA20Gel, 8PVA12Gel and 20PVA0Gel). On day one all conditions 
had less metabolic activity compared to the tissue culture plastic control over time the 
level increased indicating cell growth. The 20PVA0Gel had the lowest overall level of 
activity indicating that the cells attached did not grow and proliferate, or that cells 
were detached and lost during culture. Detachment could be due to a lack of coating 
in the area and therefore the cells we only able to focally adhere and not able to 
maintain the adhesion over time. 8PVA12Gel produced the highest fluorescent 
intensity on day 6 of culture although initial levels were lower that the 0PVA20Gel 
coating on days 1,2,3 and 5. The cell line used in this experiment was the M2 cell 
line, it was determined in Chapter 3 that this cell line had a population doubling time 
of 1.5 to 2 days. The growth cycle of the cells needs to be considered when looking at 
   168  
 
the data in Figure 60 in order to hypothesis why in all conditions the values on day 3 
remain similar to day 2 and why there is a drop-in intensity in day 5. PrestoBlue is 
reduced in the cells mitochondria which are responsible for generating the energy for 
the cell to undertake all cellular functions. When a cell is proliferating, the 
mitochondria are more active, when the cell is at rest a lower level of activity is 
occurring and therefore the intensity of PrestoBlue will be less (Sonnaert et al. 2015). 
Based on the consistent PrestoBlue activity in the 20PVA0Gel coating the cells 
attached are alive but not proliferating. 
The next stage was to transfer the coating work into the MCF platform and identify 
the challenges of seeding the MCF with hMSCs. The 8PVA12Gel coating mixture 
was used when coating the MCF and a higher concentration of cells equal to 
50000cells/cm2 were seeded. Dead space such as the tube between the MCF and the 
syringe (  
Figure 48) were taken into consideration when making the decision to administer cells 
in excess. Three methods of cell staining were used, as each stain provided different 
elements of information regarding the cell. Actin staining provides more detailed 
morphology of the cells. The stain can help show the level of contact or spread the 
cells are having inside the MCF, for example if they are adhering with direct full 
contact or is portions of the cell are adhered. The live/dead stain would be able to 
determine how viable the cells were. Initially the green cell tacker was not thought to 
be an appropriate stain due to auto fluorescence from the MCF. However, as cell 
tracker was the only stain to be administered before the cells were seeded it was 
unaffected by the many wash steps and administering of solutions to the MCF.  
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Figure 61: Fluorescent staining of hMSC inside the MCF coated with 8PVA12Gel. 
Green cell tracker shows cells in the MCF 2hrss post seeding (A) and after 24hrss in 
culture (B), cells are present in both images. Actin staining of hMSC using a 
phalloidin conjugated stain can be in D and F, the corresponding phase contrast image 
can be seen in C and E respectively. Live/dead staining of hMSCs inside the MCF 
was conducted 24hrss after seeding, merged images of the stains can be seen in H and 
J with the corresponding phase contrast images in G and I respectively. Actin of 
hMSCs grown on standard tissue culture plastic after 6 days in culture stained with 
phalloidin conjugated (K). Images are representative of a minimum of 3 MCFs. 
The green cell tracker (Figure 61A and B) shows that cells are present 2hrss post 
seed, the cells can still be seen at 24hrss post seed however the morphology is 
showing the cells to be rounded rather than the hMSC elongated morphology 
previously seen. Actin staining was carried out inside the MCF 24hrss after cells were 
seeded (Figure 61 D and F) though fluorescence was detected it is difficult to 
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ascertain morphological information of the hMSC, image D and the corresponding 
phase contrast image C show a cylindrical structure which is not indicative of hMSCs 
but was also seen in the green cell tracker images (A and B). A region of stained actin 
was seen in image F however as hMSC adhered inside a transparent capillary is not a 
well-documented concept it is difficult to determine what adhered cells should look 
like within a cylinder compared to a flat surface. The image (F) shows a striated form 
which is consistent with the elongation of hMSC, the same stain carried out on 
hMSCs cultured on tissue culture plastic can be seem in image K for comparison. 
Imaging in a capillary also presents focusing issues and impairs image quality which 
compounds the identification issue, hence image K provides a higher level of 
morphological information and understanding into hMSC interaction. Similar 
striations can be seen in Image J, but this was an ethidium homodimer-1 stain which 
fluoresces when bound to the nucleus of the cell. Both the phase contrast images for 
the actin stain (E) and the ethidium homodimer-1(I) display the striations which adds 
to the evidence that within the capillaries cells are cells in the foreground or back 
ground will always be a challenge as seen in Figure 61 A and B green out of focus 
cells ac also been seen. Another challenging of imaging in capillaries is knowing what 
or were present. Ethidium homodimer-1 stains DNA which is found in the nucleus 
and does not have a striated form. If the cells have lysed ethidium homodimer-1 could 
be staining DNS debris which has attached to the capillary wall. As both staining 
methods require washing, fixation of the cells and addition of the staining solution to 
the MCF there is a possibility that hMSCs did adhere but were subsequently removed 
or damaged during these steps as indicated by the ethidium homodimer-1 stain. 
Therefore, the actin of residual cell wall could be what is stained in image F, and the 
cells in Image J may have had their membranes ruptured consequently only the 
ethidium homodimer-1 (the dead part of the live/dead stain) was positive. In images F 
and I the clarity of the FEP is reduced which could be due to cell presence. Imaging 
fluorescent stains at high resolutions in a 3D environment and parallel capillaries 
presents some significant challenges. Bleeding of fluoresce between capillaries is a 
challenge particularly as FEP is highly transparent. Being able to focus without 
interference from other stained morphology to look for in the hMSCs, while 2D 
morphology has been well documented a hMSC adhered to the side of a capillary is 
less well known. The actin staining seen on standard tissue culture plastic (Figure 
61K) shows a high level of structural detail while the MCF actin stain (Figure 61F) it 
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is difficult to distinguish structural detail, though as previous mentioned this staining 
could be of the remanence of actin as whole hMSCs could have been removed during 
the staining protocol. When imaging in 3D it is common to encounter such issues and 
often a balance has to be found between phototoxicity, spatial resolution and when 
applicable temporal resolution (Gao et al. 2012). With the use of more advanced 
imaging equipment improvements to imaging technology can and is continuously 
being made which could be applicable in the future for MCF imaging (Appel et al. 
2013; Jungmann et al. 2014). 
The administration of solutions including the cell seeding was carried out manually 
therefore there was little control over the flow rates and pressure within the MCF. 
Other microfluidic hollow fibre cell culture platforms use more controlled flow 
systems, such as Huang et al. (2016) who used a flow rate of 10µl/min. Based on the 
evidence provided it is possible to administer hMSCs into the MCF but further work 
needs to be carried out on refining the administration process. Through a poorly 
controlled fluid handling process there is also the possibility that the PVA/gelatin 
coating was removed, there for fluid handling also needs to be improved for the 
coating process. 
5.4 Conclusions  
This work identifies the importance of surface homogeneity and functionality within 
the remit of cell based assays. Though not the primary focus this work as contributed 
to the understanding of critical surface characteristics for hMSC adhesion 
highlighting that surface energy is not the most significant factor for hMSC surface 
adhesion. While previous work by Shoichet & McCarthy (1991) has shown PLL to 
absorb onto the surface of FEP this work has progressed to show that hMSCs will 
subsequently adhere to the modified surface. Though morphologically differences 
between hMSCs on tissue culture plastic and on the PLL modified surfaces could be 
seen. The live/dead imaging also indicated that a high proportion of the hMSCs were 
dead, though this method was qualitative it did not add to the confidence in the 
coating method. Much of the previous literature discusses the importance of surface 
proteins ex vivo as they are in vivo adherent cells require an ECM for adhesion and 
structure, this work supports that understanding with hMSC attachment (Badylak et 
al. 2009; Guilak et al. 2009; Brown et al. 2010). 
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Through using PVA only as a coating method it was established that surface energy is 
not the critical factor for hMSCs adhesion. However, using different coating 
parameters most notably the molecular weight of PVA the surface energy, determined 
by contact angle measurements, could be controlled. Controlling the level of 
hydrophobicity is also relevant to other potential uses of the FEP and MCF for 
example achieving a controlled level of capillary rise in the MCF for “lab on a stick” 
format applications (Reis et al. 2016). While PVA alone did not facilitate cell 
attachment as well as tissue culture plastic, with the addition of gelatin to PVA FEP 
cell attachment after 6 days was improved. Based on AFM data gelatin or PVA alone 
indicated a heterogenic coating particularly after 24hrss coating time however as a 
mixture FEP was coated more homogenously and/or thicker which provided a more 
consistent cell attachment number. The addition of gelatin to PVA has been done 
before in the area of hydrogel cell scaffolds (Miao et al. 2015) however no literature 
has been found documenting this method for modifying the surface of FEP.  
When transferring, the knowledge gained when coating flat 2D FEP tokens into the 
MCF format many challenges were encountered. The work on hMSC attachment in 
the 2D format was carried out using robust and reproducible methods, refinement of 
the cell seeding method (Section 5.2.7) used in Figure 61 is required for the MCF 
format. Using a manual injection method results in an uncontrolled and inconsistent 
force to which the cells inside the MCF are subjected to. Particularly when 
fluorescent visualisation of the cells us required it cannot be determined if the cells 
may have been removed or detached during the wash steps or the addition of the 
fluorescent stain. Improvement in the fluid handling to enable this microfluidic 
method to achieve the level of control seen in many commercialised microfluid 
platforms needs to be made (Haber 2006). In order for hMSC to attach the system 
would need to be static for a period of time, when seeding microcarriers for bioreactor 
culture hMSC are seeded to the microcarriers and the culture is static for 18hrss to 
allow cells to attach (Rafiq et al. 2013). Flow would then need to be introduced for 
the removal of waste products and the addition of fresh nutrients for the cells. 
Overall it has been shown that it is viable for hMSC to attach to modified FEP 
proving that it is possible that the surface of FEP can be modified to improve the 
culture of viable hMCS (Chapter 2, Section 3.2). While there are indications this work 
can be translated to the MCF surface, to be able to study attachment of hMSC and 
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assaying of hMSC inside the MCF requires further improvements to the system as 
detailed in Chapter 6. 
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6 Conclusions 
The overall objectives of this research were to identify the analytical challenges of 
manufacturing an hMSC based cell therapy. As a proof of concept the effect of 
culture conditions on the ability for hMSC to promote angiogenesis was analysed. 
The analytics and bioassays used to assess hMSC functionality were also evaluated 
from a ‘use in the manufacturing environment’ perspective. 
By using an approach to identify the levels of 5 cytokines produced by hMSCs from 
four donors in three different culture environments with different oxygen levels along 
with secretome analysis it was determined that it was not possible to predict 
secretome behaviour based solely on the donor. Cytokine analysis showed that levels 
did vary between donor and culture environment, and the response to lower oxygen 
environments cannot be predicted based on the behaviour of one cell population. 
Consequently, this disproves hypothesis 1 (Chapter 2, Section 3.2) that hMSCs 
secretome profiles of VEGF-A, bFGF, HGF, PDGF-BB IL-8 /CXCL8 exhibit the 
same trends under three different atmospheric oxygen concentrations independent of 
the cell donor. While a clear trend could not be determined between the branch 
formation assay and analysed cytokine levels in the conditioned medium, differences 
could be seen between samples in the branch formation assay. In conclusion, this 
work indicates that the number of angiogenesis influencing factors investigated needs 
to be expanded to gain a more complete picture of the levels secreted by hMSCs and 
the influence on the branch formation assay. as noted in Chapter 2, over 120 different 
cytokines are produced by hMSCs (Park et al. 2009), it would be an extensive study 
to investigate all of these.  
Based on the cytokine data in Chapter 3 IL-8 and HGF cytokines were selected for 
testing the feasibility of using the MCF ELISA platform for with a view to use the 
analytical technique away from the research bench and closer to the manufacturing 
floor (Chapter 4). While some improvements were suggested regarding the detection 
and analysis method overall it was possible to carryout HFG and IL-8 ELISAs using 
the MCF platform. The platform greatly reduced the assay time from addition of the 
sample to scanning the result, this is a great advantage in a time pressured 
manufacturing environment. Thus, proving hypothesis 2 (Chapter 2, Section 3.2) that 
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translating a plate-based ELISA assay into an MCF based microfluidic platform 
reduces the time between the addition of sample to result. 
As a result of this the feasibility work carried out on the MCF ELISA platform to 
detect IL-8 and HGF the it was then determined if it was possible to develop a 
combine microfluidic system with a view to having both the sandwich ELISA and 
hMSC culture within the same microfluidic platform, the MCF. The application of the 
combination device was to detected cytokines relevant to the MOA of hMSC directly 
as the cells are secreting them. Many microfluidic devices incorporated the cell 
culture and analytics within one device (Toriello et al. 2008; Kamei et al. 2013), this 
provides more rapid results and also less error incorporated through operator 
handling. The most significant out come from this section of work was the successful 
functionalisation of FEP to improve hMSC adhesion using a PVA gelatin coating 
under optimised conditions. Proving hypothesis 3 that the surface of FEP can be 
modified to improve the culture of viable hMCS (Chapter 2, Section 3.2). This has 
laid the ground work and overcome a significant hurdle for the further development of 
an all in one microfluidic device using the MCF. 
Rapid and precise analytics are much needed within many therapeutic areas not just 
cell therapies and manufacturing. Most notably in the area of precision medicine, 
where the classic “one size fits all” approach to medicine is being rejected due to the 
limited effectiveness of this approach (Roda et al. 2018). This work further supports 
the needs for precision medicine in relation to hMSC based cell therapies and 
demonstrates that the current criteria for defining hMSCs (Dominici et al. 2006) is 
limited. As discussed in Chapter 2 Section 2.6.1 applying limited characterisation 
criteria which doesn’t fully demonstrated hMSC function for a specific therapeutic 
application is damaging the field. Combining cost effective cell culture (i.e. small 
scale) and rapid ELISA analytics is a realistic option to address these issues. It would 
be a powerful tool within the manufacturing setting from process development to 
defined production parameters and is applicable to the precision medicine field. The 
relationship between small-scale cell culture and large-scale cell culture would need 
to be determined to ensure that, functionality such as secreting factors are independent 
of culture scale. Should that be the case combined platforms would reduce the risk 
and associated cost of manufacturing cell therapies through providing more in-depth 
information in a timely manner without increasing the labour or finical burden. 
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6.1 Future works 
It was shown in Chapter 3 that predicting hMSC secretome profiles under different 
culture conditions between donors was not possible. While this was mostly attributed 
to donor variation differences between the M2 and M3 controls indicating processing 
of the cell cultures also impacts secretome profiles. While improving process control 
may improve consistency within the same donor cell population, overcoming donor 
variation is not possible. This demonstrates the need for rapid bioanalytics when using 
hMSCs as a cell therapy treatment, though these lessons can be applied to any cell 
type. 
The cell culture method used for obtaining samples analysed in Chapter 3 was the 
T-flask, which is the culture method used to expand hMSC populations for some 
clinical trials (Pérez-Simon et al. 2011) In order to provide cell numbers in the 
quantities required for sustainable cell therapies scale up as opposed to scale out of 
the cell culture needs to be carries out, and hence investigating the behaviour of 
hMSC in a bioreactor environment would be a future stage of this work. For 
allogeneic therapies where there is a selection of starting material a manufacturer 
needs to be able to determine which lot will perform to the required level during the 
scale up process. For autologous treatments gaining a fundamental understanding of 
the underlying causes for the variation between donors is important. Therefore, gene 
expression profiling would be useful in determining if the variation is genetic or if it 
occurs during the transcription of mRNA into proteins. 
The branch formation assay analyses method used in this work is more highly 
automated from an imaging perspective in terms of removing operator bias when 
selecting the imaging area and improving the regularity of imaging. The assay 
produces a large volume of data per 24 well plate and with more detailed data more 
events need to be explained such as the behaviour of branches merging together and 
how that is seen within the data.  
Overall the most critical part of the branch formation assay is to determine if the 
events seen in vitro are truly reflective of those events in vivo. This is usually carried 
out with animal studies, alternatively in tandem with an on-going clinical trial in order 
to gain more relevant data. The flatness of the Geltrex used for the branch formation 
assay needs to be more consistent between wells and assays, manual spreading of the 
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matrix introduces variation. In the assays for this work the HUVECs were from 
pooled donors to reduce the donor bias, there is scope to personalise the assay using 
the patients’ own endothelial cells which would be more pertinent to determine the 
individual response of the treatment.  
With respect to the MCF ELISA platform fluid handling an issue; prior to full assay 
validation in the context of cell therapy manufacturing the robustness of the assay 
needs to be improved. This includes removing operator bias from the imaging 
processing system and assembling of the MSD needs to become more dependable to 
prevent capillary failures. Future work should also include moving toward the use of 
fluorescent labelled antibodies to avoid the restrictions encountered using OPD 
without a stop solution. 
Within an industry setting a more automated process which can be integrated into 
current manufacturing processes is the goal for bioanalytics (Scheper et al. 1999). 
Image processing software can be easily developed (Russ 2011), however the quality 
of the image determines the quality of the data output. Moving away from the flatbed 
scanner towards a more physically stable and therefore more consistent imaging 
platform would be a future step in improving assay robustness. Barbosa et al. (2015) 
have already begun to use fluorescent based assays in the MCF ELISA platform this 
would overcome some of the mixing issues seen in Chapter 4 which resulted in non-
uniformed colour being analysed. Also using the OPD detection method means results 
need to be read in a defined window, and once measured cannot be re-measured. In 
contrast, fluorescence based assays, providing there is no photo bleaching can be re-
measured. The challenge of using antibodies conjugated to fluorophores would 
potentially be fluorescent spectral overlap between capillaries. In the microtiter plate 
the well walls are black to prevent this; therefore, the MCF may require interposed 
optical blockers in every other capillary to overcome this.  
In Chapter 5 it was shown that the surface chemistry of the MCF would need to be 
modified in order to facilitate the adhesion of hMSC with a view to produce an all in 
one device similar to Figure 62.  
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Figure 62: Schematic of an MCF microfluidic combination device for cell culture and 
serial detection of cytokines secreted by the cells. 
The use of gelatine and PVA mixture to modify the surface of FEP proved successful 
and repeatable on a flat surface. It was also easily administered to the internal surface 
of the MCF which was a recognised limitation of other FEP surface modification 
methods. As with the MCF ELISA some of the challenges in adapting the MCF for a 
combination platform related to the fluid handling. While aspirating the PVA/gelatine 
coating mixture into the MCF was straightforward, using equipment which 
maintained sterility, enabled replacement of fluids inside the MCF and control of fluid 
speed and pressure were not achieved within the time frame of this work. Other 
microfluidic platforms utilise micro pumps to deliver fluids with precision to the 
device (Haeberle & Zengerle 2007). The use of pumps has not previously been a 
requirement for the MCF as the uses have included a dip stick style test (Reis et al. 
2016), and syringe based aspiration (Barbosa et al. 2014; Barbosa et al. 2015) which 
did not require the level of control at low rates needed in human cell work. Being able 
to provide an appropriate and consistent flow rate inside the MCF is the next step for 
the combination device development work, mechanical stresses such as shear stress 
needs to be at an acceptable level for the cell type being used, in this incidence 
hMSCs (Shah et al. 2014). As the device would also be detecting proteins, shear stress 
in also an important factor to prevent unwanted protein aggregation which would 
result in inaccurate lower levels of analyte being detected (Cromwell et al. 2006). 
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Designing a controlled automated fluid handling system would also overcome some 
of the limitations of other microfluidic devices which rely on multiple inlet and ports 
that reduces the through put of the device and makes using the device more complex 
(Haeberle & Zengerle 2007; Gupta et al. 2010). Some lab on a chip devices also 
require cell seeding and culture prior to assembly of the analytical devices, over 
handling of the devices can risk damage to the cells (Fernandes et al. 2009). An all in 
one, fully controlled microfluidic cell culture and analysis system would be the end 
goal for this platform. 
The behaviour of the cells, in this work hMSCs, will need to be compared to other 
culture platforms, and determine if the culture of cells at this scale causes adverse 
effects. It is a common concern when studying cell behaviour in vitro that it is not 
truly reflective of in vivo cell behaviour (Huh et al. 2011). Microfluidic devices are 
thought to be able to mimic the in vivo cellular microenvironment which would make 
the platform more relevant than standard tissue culture plastic. Therefore, culturing 
cells inside the MCF has the potential to be an improvement on current methods.  
Overall this work has identified challenges in manufacturing hMSCs and has made 
progress in addressing some of these challenges. Using hMSC as a mainstream 
treatment for many conditions is becoming a realisation. However, in the pressure to 
fulfil the potential of these applications a need to for rapid bioanalytics has grown 
rapidly.  
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